



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Growth And The Growth Hormone-Insulin Like Growth Factor 1 Axis In Children With Chronic Inflammation

**Citation for published version:**

Wong, SC, Dobie, R, Altowati, MA, Werther, GA, Farquharson, C & Ahmed, SF 2016, 'Growth And The Growth Hormone-Insulin Like Growth Factor 1 Axis In Children With Chronic Inflammation: Current Evidence, Gaps In Knowledge And Future Directions', *Endocrine Reviews*, vol. 37, no. 1, er20151026, pp. 62-110. <https://doi.org/10.1210/er.2015-1026>

**Digital Object Identifier (DOI):**

[10.1210/er.2015-1026](https://doi.org/10.1210/er.2015-1026)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Endocrine Reviews

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.





THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# Growth And The Growth Hormone-Insulin Like Growth Factor 1 Axis In Children With Chronic Inflammation

### Citation for published version:

Wong, SC, Dobie, R, Altowati, MA, Werther, GA, Farquharson, C & Ahmed, SF 2015, 'Growth And The Growth Hormone-Insulin Like Growth Factor 1 Axis In Children With Chronic Inflammation: Current Evidence, Gaps In Knowledge And Future Directions' *Endocrine Reviews.*, 10.1210/er.2015-1026

### Digital Object Identifier (DOI):

[10.1210/er.2015-1026](https://doi.org/10.1210/er.2015-1026)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

Endocrine Reviews

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



**Growth And The Growth Hormone-Insulin Like Growth Factor 1 Axis In Children  
With Chronic Inflammation: Current Evidence, Gaps In Knowledge And Future  
Directions**

SC Wong <sup>1</sup>, R Dobie <sup>2</sup>, MA Altowati <sup>1</sup>, GA Werther <sup>3</sup>, C Farquharson <sup>2</sup>, SF Ahmed <sup>1</sup>

<sup>1</sup> Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for  
Children, Glasgow, United Kingdom

<sup>2</sup> Division of Developmental Biology, Roslin Institute, University of Edinburgh, United  
Kingdom

<sup>3</sup> Hormone Research, Murdoch Childrens Research Institute, Melbourne, Australia

**Abbreviated title:** Growth and GH-IGF axis in children with chronic inflammation

**Key words:** Growth hormone, insulin like growth factor-1, insulin growth factor binding  
proteins, growth failure, cytokines, inflammation, glucocorticoid, juvenile idiopathic arthritis,  
inflammatory bowel disease, crohn's disease, ulcerative colitis, cystic fibrosis

Address for correspondence

Dr Sze Choong, Wong

Developmental Endocrinology Research Group

Royal Hospital for Children,

Glasgow, G51 4TF

United Kingdom

Tel: 00 44 141 451 5885

Email: [jarod.wong@glasgow.ac.uk](mailto:jarod.wong@glasgow.ac.uk)

**Abstract**

Growth failure is frequently encountered in children with chronic inflammatory conditions like juvenile idiopathic arthritis, inflammatory bowel disease and cystic fibrosis. Delayed puberty and attenuated pubertal growth spurt is often seen during adolescence. The underlying inflammatory state mediated by pro-inflammatory cytokines, prolonged use of glucocorticoid and suboptimal nutrition contribute to growth failure and pubertal abnormalities. These factors can impair growth by their effects on the growth hormone-insulin like growth factor axis and also directly at the level of the growth plate via alterations in chondrogenesis and local growth factor signaling. Recent studies on the impact of cytokines and glucocorticoid on the growth plate studies further advanced our understanding of growth failure in chronic disease and provided a biological rationale of growth promotion. Targeting cytokines using biologic therapy may lead to improvement of growth in some of these children but approximately one third continue to grow slowly. There is increasing evidence that the use of relatively high dose recombinant human growth hormone may lead to partial catch up growth in chronic inflammatory conditions, although long term follow-up data is currently limited. In this review, we comprehensively review the growth abnormalities in children with juvenile idiopathic arthritis, inflammatory bowel disease and cystic fibrosis, systemic abnormalities of the growth hormone-insulin like growth factor axis and growth plate perturbations. We also systematically reviewed all the current published studies of recombinant human growth hormone in these conditions and discuss the role of recombinant human insulin like growth factor-1.

## **1. Introduction**

## **2. Background physiology of normal linear growth**

58	2.1	Systemic regulation of linear growth
59	2.2	Growth plate
60	2.2.1	Local growth plate regulation
61	<b>3.</b>	<b>Inflammation and growth plate abnormalities</b>
62	3.1	Effects of inflammatory cytokines on the growth plate
63	3.2	Effects of glucocorticoid on the growth plate
64	3.3	Effects of malnutrition on the growth plate
65	<b>4.</b>	<b>Animal models of chronic disease and growth disorders</b>
66	<b>5.</b>	<b>Juvenile idiopathic arthritis (JIA)</b>
67	5.1	Disease and management
68	5.1.1	Oligoarticular JIA
69	5.1.2	Polyarticular JIA
70	5.1.3	Systemic JIA
71	5.2	Clinical evidence of growth failure in JIA
72	5.3	Systemic abnormalities in GH/IGF-1 axis in JIA
73	5.4	Efficacy of rhGH on linear growth in JIA
74	5.5	Factors affecting the growth response to rhGH in JIA
75	5.5.1	Disease status and glucocorticoid
76	5.5.2	Systemic IGF-1 levels
77	5.6	Efficacy of rhGH on disease process in JIA
78	<b>6.</b>	<b>Inflammatory bowel disease (IBD)</b>
79	6.1	Disease and management
80	6.1.1	Ulcerative colitis
81	6.1.2	Crohn's disease
82	6.1.3	Inflammatory bowel disease unclassified
83	6.2	Clinical evidence of growth failure in IBD
84	6.3	Systemic abnormalities in GH/IGF-1 axis in IBD
85	6.4	Efficacy of rhGH on linear growth in IBD

86	6.5	Factors affecting the growth response to rhGH in IBD
87	6.5.1	Disease status and glucocorticoid
88	6.5.2	Systemic IGF-1 levels
89	6.6	Efficacy of rhGH on disease process in IBD
90	<b>7.</b>	<b>Cystic fibrosis (CF)</b>
91	7.1	Disease and management
92	7.2	Clinical evidence of growth failure in CF
93	7.3	Systemic abnormalities in GH/IGF-1 axis in CF
94	7.4	Efficacy of rhGH on linear growth in CF
95	7.5	Factors affecting the growth response to rhGH in CF
96	7.5.1	Disease status and glucocorticoid
97	7.5.2	Systemic IGF-1 levels
98	7.6	Efficacy of rhGH on disease process in CF
99	<b>8.</b>	<b>Side effects of rhGH therapy in chronic disease</b>
100	8.1	Glucose tolerance and insulin sensitivity
101	8.2	Skeletal complications
102	8.3	Disease complications
103	8.4	IGF-1 levels and cancer
104	<b>9.</b>	<b>IGF-1 and combined GH/IGF-1 in chronic disease</b>
105	<b>10.</b>	<b>Summary and perspective</b>
106	10.1	Clinical studies of growth and pubertal disorders
107	10.2	Systemic abnormalities of GH/IGF-1 in chronic disease
108	10.3	Growth plate regulation in chronic disease
109	10.4	Endocrine growth promoting therapies in chronic disease
110	<b>11.</b>	<b>Conclusion</b>
111	<b>12.</b>	<b>References</b>
112		
113		

| 114  
| 115  
| 116  
| 117  
| 118  
| 119  
| 120  
| 121  
| 122  
| 123  
| 124  
| 125  
| 126  
| 127  
| 128  
| 129  
| 130  
| 131  
| 132  
| 133  
| 134  
| 135  
| 136

| 137     **1.       Introduction**

| 138     Impaired linear growth is commonly encountered in children with chronic inflammatory  
| 139     conditions such as juvenile idiopathic arthritis (JIA) (1) inflammatory bowel disease (IBD),  
| 140     especially those with Crohn’s disease (CD) (2,3) and cystic fibrosis (CF) (4,5). This may be  
| 141     associated with delayed onset of puberty and attenuated pubertal growth spurt (6), especially

in those with IBD as these children tend to present in late childhood and adolescence [Figure 1]. Poor growth may lead to short stature and a reduction in adult height is seen in a sub set of these patients despite contemporary medical therapy (7-9) which may have an impact on their quality of life (10).

Sub-optimal nutrition, prolonged use of glucocorticoid (GC) and chronic inflammation itself contribute to the underlying pathophysiology of growth failure (11,12). This may be through effects on the systemic growth hormone (GH) axis that regulates linear growth or through direct effects at the level of the growth plate (13) [Figure 2]. Chronic inflammation may lead to a continuum of abnormalities in the systemic GH/ insulin like growth factor-1 (IGF-1) axis including relative GH insufficiency, GH/IGF-1 resistance due to impairment of IGF binding proteins, down regulation of GH/IGF receptors and / or impairment of local GH and IGF-1 signaling pathways [Figure 3].

Determining the prevalence of growth failure from current published studies in children with JIA, IBD and CF is very challenging due to the different definitions used. Studies defining growth failure based on stature are not helpful, as this may underestimate the prevalence of faltering growth, given that a child with relatively normal height may have been growing very poorly over a period of time. Stature also needs to be interpreted in the context of the child's mid-parental height.

Evaluating growth rate (height velocity) maybe a better method to determine the prevalence of growth failure but in a group of children where a degree of delayed puberty maybe relatively common, comparing height velocity (HV) purely based on age and gender may be misleading. Due to the unpredictability of the inflammatory process, HV is also likely to vary depending on the disease status rather than time course from diagnosis compared to other conditions where treatment protocols may be fixed (eg childhood cancers). HV needs to be interpreted in the context of pubertal staging or bone age as it varies according to gender and pubertal status (14). In healthy girls, peak HV is attained at the age of approximately 12 years, corresponding to early breast stage (stage 2) whereas in healthy boys this is usually at the age of 13.5 years corresponding to later stages of puberty (genital stage 4, 10-12 ml testes)



(15,16). There is no consensus regarding the most appropriate method to interpret HV in these children. In addition, normative data for HV are from small groups of children evaluated in the 70s.

Consideration must be given to bone age assessment in children with chronic disease. Interpretation of bone age may be inaccurate if performed in the hand affected by arthritis (17). The use of change in height (Ht) SDS maybe a better method of defining growth problems in longitudinal growth studies in children with chronic disease as recently suggested as a way to report response to growth promoting therapy (18) but may also need to be interpreted in the context of puberty and/or skeletal maturation for adolescents.

Targeting the inflammatory process aggressively using immunomodulators (eg azathioprine, methotrexate) and anti-cytokine therapy (eg infliximab, etanercept, adalimumab), minimizing the use of systemic GC to achieve adequate control of inflammation and optimizing nutrition may be associated with improvement in markers of the GH-IGF axis and are paramount for ensuring normal growth and pubertal development (19,20). However, almost one third of children with JIA and CD treated with contemporary regimens continue to grow slowly (18) and improvement in disease activity does not seem to normalize linear growth in these children (21,22). In adolescents with CF, faltering growth often precedes the diagnosis of CF related diabetes (23). Whilst treatment with insulin may improve lung function and body mass index (BMI) in children with CF related diabetes (24,25), the impact of insulin on improving growth and pubertal development is still unclear (23). In an individual with CF and faltering growth, assessment of glucose homeostasis should be performed to exclude CF diabetes. Optimization of metabolic control with insulin should be performed in those already with established CF related diabetes and poor growth.

Pubertal induction with sex steroid may be considered in those individuals who are growing slowly in association with delayed puberty despite optimization of disease status and nutrition, although the timing, route of administration, dose of sex steroid and duration of treatment is unclear. Abnormal bone development is also seen in these adolescents (26-28) and in these individuals with chronic disease, decisions regarding pubertal induction will also

need to include careful assessment of bone mass and the potential benefit of sex steroid on bone acquisition. It is beyond the scope of this current review to address issues of pubertal induction in chronic disease which we feel is an area of research often neglected.

The availability of recombinant human growth hormone (rhGH) in the past 30 years has led to its use in non-growth hormone deficient conditions (29) such as Turner Syndrome (30-32), small for gestational age (33,34), idiopathic short stature (35) , short stature homeobox (SHOX) deficiency (36), Prader Willi Syndrome (37) and chronic renal insufficiency (38). In younger pre-pubertal children with chronic disease and in those with pubertal delay who continue to grow slowly despite pubertal induction, rhGH may be a therapeutic option. Emerging therapeutic clinical trials of rhGH in pediatric JIA, IBD and CF suggest that short term linear growth may improve with rhGH therapy. These studies demonstrate that rhGH, especially at a higher dose, may be able to overcome the relative GH resistant state seen in chronic disease (39).

The review aims to provide the most up to date summary of growth failure, systemic abnormalities in the GH/IGF-1 axis and local growth plate disturbances observed in children with JIA, IBD and CF. In addition, we will summarize and critically evaluate the published literature on the role of rhGH and rhIGF-1 as growth promoting therapies in these children.

This review is timely given that management of chronic disease has changed significantly over the last 15 years. Modern therapies have opened up the therapeutic options of management of these childhood chronic disease but a subset are still non responders to these treatment and in some instances the occurrence of significant adverse effects preclude the use of these modern therapies. It is for these reasons that poor growth and abnormalities of pubertal development may still be encountered and the management of these children and adolescents can be particularly complex. The full PubMed database was searched with no time restriction in July 2015 using the following keywords: inflammatory bowel disease, crohn's disease, crohn disease, ulcerative colitis, cystic fibrosis, juvenile idiopathic arthritis, juvenile arthritis, juvenile rheumatoid arthritis in combination with growth hormone, insulin

like growth factor-1 and IGF-1. Non-English articles were excluded. Relevant articles were obtained and information synthesized into this literature review by the authors.

## **2. Background physiology of normal linear growth**

In this section, we will review the normal regulation of linear growth via systemic and local factors. The reader is however referred to other recent thorough and excellent reviews on this area (40-42). It is generally accepted that the GH/IGF-1 axis is a main regulator of linear growth via its endocrine effects at a systemic level and also via local autocrine/paracrine mechanisms. Understanding of the systemic and local regulation of normal linear growth has advanced significantly over recent years. Information on how the systemic GH/IGF-1 axis interacts with local paracrine factors in the regulation of normal linear growth is still unknown. Chronic disease via chronic inflammation, glucocorticoid and poor nutrition can impact growth at multiple levels via their effects on the GH/IGF-1 axis systemically and at the level of target organ.

### **2.1 Systemic regulation of linear growth**

The endocrine regulation of normal linear growth involves pituitary derived GH and the IGF system. It was initially thought that GH itself did not exert its effects directly on target organs but did so via IGF-1, produced in the liver. It is now known that both GH and IGF-1 exert separate and independent effects on growth. GH can act to induce the expression and action of local IGF-1 at the level of the growth plate to lead to increase bone growth (43).

Local injection of GH directly into cartilage growth plates of the hind limbs of hypophysectomised rats produced significant increase in lengths of the injected limb compared with the non injected contra lateral limb, pointing to the direct effect of GH on regulating growth (44). In addition, if all the growth promoting actions of GH are mediated by IGF-1, then the GH receptor and IGF-1 null mice should be similar to the double GH receptor and IGF-1 receptor mutant mice (45). Lupu et al showed that post natal mice with combined GH receptor gene and IGF-1 gene deletion had the smallest size, whereas mice with GH

receptor gene deletion only were larger in size than those with IGF-I gene deletion (45). Several other groups also found that body size and tibial growth rate of mice with GH gene deletion were lower than those with IGF-I gene deletion (46-48). Numerous studies have produced conflicting results and are unable to pinpoint to the precise mechanism of the action of GH and IGF-I on the epiphyseal growth plate (49,50).

The relative contribution of hepatic generated IGF-1 to epiphyseal bone growth is currently unclear (51). In the liver IGF-I deficient (LID) mice, deletion of the liver gene of IGF-I reduced circulating IGF-I to 25% of the wild type mice. Bone length and body size of the LID mice were not different from the wild type mice. IGF-I mRNA expression in a variety of tissues including heart, muscle, fat, spleen and kidney were similar between the LID mice and the wild type mice, suggesting that there is no compensation from IGF-I derived from other tissues accounting for the preservation of linear growth in the LID mice (52). A combined knock out of LID, acid labile subunit knock-out (ALSKO), IGF binding protein 3 knock-out (BP3KO) had significantly reduced systemic levels of IGF-1 but only a modest degree of growth retardation, pointing to the possibility of the importance of local factors regulating bone growth (53).

Mice with targeted deletion of IGF-I in chondrocytes had normal systemic levels of IGF-I but 40% reduction in local IGF-I. Body length was however reduced by 27% (54). On the other hand, elevated systemic levels of IGF-1 were able to rescue the growth impairment in IGF-1 null mice pointing to the role of systemic IGF-1 on autocrine/paracrine effects (55). The IGF-1 null mice also have compensatory increase in local IGF-2 locally which may explain the modest growth impairment in that model. GH promote growth plate chondrogenesis independent of local IGF-1 and IGF-2 levels (56) and addition of rhIGF-1 to rhGH treatment in healthy female mice did not lead to improvement in bone growth (57). A study in a knock in mouse model of mutated IGF-1 with markedly low total IGF-1 and formation with IGFBPs but high levels of unbound IGF-1 showed significantly increased body size pointing to the role of free bioavailable IGF-1 on regulation of growth (58)

It has been suggested that an element of redundancy may exist between local and endocrine growth factors like IGF-1, where the absence of one source (systemic vs. local) may be compensated by the other. The regulation of GH and IGF-1 systemically and at local level may differ in health and in chronic disease (41).

## **2.2 Growth plate**

The process of bone growth relies upon chondrocytes produced at the epiphyseal growth plate, which are progressively synthesized and replaced by bone with accompanying longitudinal (endochondral) bone growth. Growth plate (epiphyseal plate) is a layer of hyaline cartilage in growing bone located in the metaphysis between the epiphysis and diaphysis. It is left over cartilage from the endochondral ossification. The epiphyseal plate consists of four zones (59)

The zone of resting cartilage is near the epiphyses and consists of a small, scattered chondrocytes. These cells do not function in bone growth therefore; these are termed as “resting”. Resting zone chondrocytes replicate at a slow rate (60) and act as stem cells that replenish the pool of proliferative chondrocytes (61).

The zone of proliferating cartilage consists of slightly larger chondrocytes arranged like stack of coins. Chondrocytes divide to replace those that die at the diaphyseal surface of the epiphyseal plate. Proliferative zone chondrocytes replicate at a high rate and the cells line up along the long axis of the bone (60,62)

The zone of hypertrophic cartilage consists of even larger chondrocytes that are also arranged in columns. The lengthwise expansion of the epiphyseal plate is the result of cell division in the zone of proliferating cartilage and maturation of the cells in the zone of hypertrophic cartilage. During the hypertrophic phase, chondrocytes increase their height about 6-10 fold. Hypertrophic differentiation makes a significant contribution to longitudinal growth (63). These chondrocytes calcify the surrounding extracellular matrix and produce factors that attract the invading bone cells and blood vessels (64). Prior to blood vessels invading the chondrocytes lacuna, they undergo apoptosis (65)

### **2.2.1 Local growth plate regulation**

GH acts locally to recruit resting chondrocytes into the proliferative state as well as stimulate local production of IGF- which in turn stimulates proliferation of proliferative chondrocytes. Infusion of IGF-1 to hypophysectomized rats stimulate chondrocytes at all the stages of differentiation, including the hypertrophic zone, clearly pointing to a role of IGF-1 at the local level (66,67).

At a local level, GH action may be regulated by suppressor of cytokine signalling 2 (SOCS2) (68). The SOCS2 knockout mice exhibit an overgrowth phenotype associated with increased GH/IGF-1 signalling leading to wider proliferative and hypertrophic zones of the growth plate (69). Studies using chondrocytes and metatarsals from the SOCS2 knockout mice showed increased GH signalling locally and maybe independent of local IGF-1 (70).

The local regulation of growth also involves several other paracrine signalling like fibroblast growth factors, Indian hedgehog, parathyroid hormone-related protein, bone morphogenetic proteins and vascular endothelial growth factor (40). How these systems interact with GH/IGF-1 regulation in health and disease is currently still unknown.

## **3. Inflammation and growth plate abnormalities**

### **3.1 Effects of inflammatory cytokines on the growth plate**

Various cell and organ culture approaches have borne evidence demonstrating the adverse effects of proinflammatory cytokines on growth plate chondrogenesis (71) [Figure 4]. IL-1- $\beta$  and TNF $\alpha$  decrease both the width of the proliferating zone and the rate of endochondral bone growth; a possible consequence of altered chondrocyte proliferation, differentiation and apoptosis rates (71-74). Furthermore, IL-1 $\beta$  and TNF $\alpha$  reduce chondrocyte expression of cartilage matrix proteins including aggrecan and collagen types-II and -X (71,75,76). The addition of IL-6 alone appears to have little effect on growth plate chondrocytes although it may be able to inhibit the early differentiation steps of chondrocyte precursors (71,73,77-79). It is possible that IL-6 needs to be added in combination with

soluble IL-6R to have an effect on chondrocyte proliferation, differentiation and bone growth (73,80,81). Importantly both IL-1 $\beta$  and TNF- $\alpha$  are also produced locally by growth plate chondrocytes to regulate physiological bone growth and that the inhibition of endogenous levels leads to improved longitudinal bone growth (82,83). The growth and long bone length of the IL-1 receptor type 1 knock-out mouse were however normal despite a narrower growth plates due to a smaller hypertrophic zone (84).

The direct analysis of proinflammatory cytokines on linear bone growth has been aided by the study of cultured fetal metatarsal bones. IL1- $\beta$ , IL-6 and TNF- $\alpha$  inhibit linear growth and in combination they have an additive growth inhibitory effect (71,73,81). Furthermore, TNF- $\alpha$  and IL1- $\beta$  also act in synergy to induce IL-6 production in fetal metatarsals (81). There is also restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following prolonged exposure to pro-inflammatory cytokines (71) [Figure 5]. This mirrors the clinical impression of greater degree of growth impairment in those children with longer periods of symptoms prior to diagnosis (85). Addition of antibodies to TNF- $\alpha$  and IL1- $\beta$  lead to partial rescue of bone growth in the metatarsal model (73) [Figure 6a].

In addition to analyzing the effects of recombinant cytokines on metatarsal growth, approaches using biological fluids from children with JIA have also been informative. These preliminary studies disclosed that serum from affected children disturbed chondrogenesis and linear bone growth. The results with synovial fluid were less consistent, emphasizing the interindividual variation of the observed effects (86) . As opposed to the partial rescue of bone growth in metatarsals exposed to cytokines (TNF- $\alpha$  and IL1- $\beta$ ), addition of antibodies to TNF- $\alpha$ , IL1- $\beta$  and IL-6 failed to show any improvement in metatarsal growth when exposed to biological fluid from a child with systemic JIA where a whole range of inflammatory cytokines may be detected other than TNF- $\alpha$ , IL1- $\beta$  and IL-6 (86) [Figure 6b].

Inflammatory cytokines may disrupt growth plate function by inhibiting IGF-1 intracellular signaling (87,88) . Evidence for this is however limited as neither TNF- $\alpha$ , IL-6 nor IL-1 $\beta$  appear to affect IGF-1 receptor expression (71,74,89-91). Alternatively,

proinflammatory cytokines may disrupt signaling downstream of the IGF-1R. TNF- $\alpha$ , IL-6 and IL-1 $\beta$  can attenuate IGF-1-induced activation of both the MAPK/ERK 1/2 and the PI-3K pathways in chondrocytes (74,92). In myoblasts, IL-1 $\beta$  can inhibit the ability of IGF-1 to phosphorylate tyrosine residues on both of its downstream docking proteins, IRS-1 and IRS-2 but it is as yet unknown if this also occurs in chondrocytes (87). Proinflammatory cytokines may also disrupt chondrocyte GH signaling. IL-6 and oncostatin M can activate JAK/STAT signaling leading to down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocyte (80,93). Likewise, IL-1 $\beta$  can antagonize GH signaling through STAT5 in hepatocytes whilst activating STAT3 in mouse kidney tumor cells (94,95). Whilst the mechanisms by which JAK/STAT signaling is blunted in inflammatory conditions are unclear, there is an emerging body of evidence implicating a role for the SOCS family of proteins which can inhibit JAK2 and STAT activation in a negative feedback loop, and whose expression is stimulated pro-inflammatory cytokines (96-101).

### **3.2 Effects of glucocorticoid on the growth plate**

The growth-suppressing effects of GC appear multifactorial with some GC actions modifying skeletal responses to the GH/IGF-I axis whereas other evidence indicates a direct effect of GH on growth plate chondrocytes. Common to both mechanisms is the interaction of GC with its cytosolic receptor (GR) which results in the modulation of gene transcription. This is accomplished via several different mechanisms. First, GCs bind to a cytosolic GC receptor attached to a heat-shock protein (HSP). The HSP dissociates, and the GR dimerizes and translocate to the nucleus and binds to promoters on the target gene known as GC response elements (GRE), resulting in the activation or repression of a specific set of transcription factors (102,103). It has also been shown that the GR is capable of binding directly to specific transcription factors such as nuclear factor- $\kappa$ B (NF $\kappa$ B) and activator protein-1 (AP-1) which are involved in the up-regulation of inflammatory genes. This



mechanism is ligand-independent and does not require receptor dimerization, therefore rendering it genetically separable from transcriptional activation (104).

GCs block the activation of the GH-receptor (GHR) and the IGF-1 receptor (IGF-IR) in chondrocytes, inhibit pulsatile GH release and reduce IGF-1R and GHR expression by chondrocytes. GCs also impair IGF-1 signaling, predominantly via the PI3K pathway at the growth plate (92,105-110). Studies of linear bone growth have shown that dexamethasone (Dex) and IGF-1 have opposite effects, with Dex decreasing and IGF-1 increasing cell proliferation. Furthermore, IGF-1 is able to ameliorate Dex-induced growth impairment suggesting that IGF-1 may protect the growth plate against the adverse effects of GC (111).

Evidence for a direct effect of GC on the growth plate comes from a study in which pharmacological levels of local Dex infusion significantly decreased tibial growth compared with the contralateral limb (112). The GR has since been localized to proliferating and hypertrophic chondrocytes in the rat (113) as well as hypertrophic chondrocytes in the human growth plate (114). GC inhibit chondrocyte proliferation and differentiation whilst stimulating chondrocyte apoptosis and autophagy (105,110,111,115-117). The inhibitory effects of GCs on chondrocyte proliferation are consistent with GCs disrupting cell cycle progression and promoting cell cycle exit (118,119). Whilst chondrocyte p21 expression is increased by Dex this increase does not contribute to GC-induced growth retardation (120,121). The role of other cyclin dependent kinase inhibitors such as p27 in mediating GC inhibition of chondrocyte proliferation has also been questioned (122).

GCs may stimulate apoptosis by altering the relative amounts of pro-apoptotic members of the Bcl-2 family such as Bax and Bid and thereby promote mitochondrial apoptosis (123,124). The Bax deficient mice display resistance to GC induced growth failure, confirming that increased apoptosis as a crucial factor in GC induced growth impairment. (123) The global effects of pharmacological GC doses on chondrocyte gene expression have been investigated using microarray technologies. Both down-regulated genes such as secreted frizzled-related protein and IGF-I, and upregulated genes including serum/GC-regulated kinase, connective-tissue growth factor and lipocalin 2 have been identified (125,126).

Novel GCs that have the anti-inflammatory properties of conventional steroids without one or more of the side-effects have been described (127,128). One of these compounds AL-438 acts through the GR and whilst retaining full anti-inflammatory efficacy it has a GC sparing effect on chondrocyte proliferation and longitudinal bone growth (115,129). This, and similar compounds, could prove important in the search for new anti-inflammatory treatments for children. GC excess and GH deficiency impair longitudinal bone growth. After remission, growth often accelerates beyond the normal growth rate for that particular age, a phenomenon called catch-up growth (130,131). This has also been observed in many growth-retarding conditions such as Cushing's syndrome (132), hypothyroidism (133), celiac disease (134) and anorexia nervosa/malnutrition (132). However catch-up growth in children with chronic inflammation may not be complete even after discontinuation of GC treatment if the inflammatory insult is ongoing, which is often the case.

Studies in rabbits in which Dex was infused directly in the tibial growth plate resulted in slow bone growth of the treated bone but not of the contralateral vehicle-treated bone (135). After cessation of Dex infusion, tibial bone growth rate was increased compared with the contralateral leg, thereby demonstrating catch-up growth (136). Based on these findings, Gafni and Baron (137) proposed that the underlying mechanism for catch-up growth was intrinsic to the growth plate. Specifically, the decrease in chondrocyte proliferation noted during GC treatment conserves the proliferative capacity of chondrocytes and delays chondrocyte senescence. Therefore, after discontinuation of GC treatment, the growth plate chondrocytes are less senescent *i.e.* have greater proliferating potential and thereby explaining the increased growth rate. *In vitro* studies have also shown that Dex-treated cells retain the capacity to re-enter chondrogenesis following the withdrawal of GC (119). This implies that, although Dex arrests growth and differentiation of chondrocytes, the capacity for cells to undergo chondrogenesis is maintained in the presence of GC despite the fact that progenitor cells are quiescent.

### 3.3 Effects of malnutrition on the growth plate

There is no doubt that undernutrition impairs skeletal growth and contributes to the growth failure in children with chronic disease. In a rat model of colitis, inflammation itself, independent of poor nutrition, explains 40% of the growth impairment (138). Aggressive nutritional therapies are often considered in children with IBD and CF, including the use of supplemental feeds and gastrostomy feeding. In the last few decades, in CD, the use of exclusive enteral nutritional (EEN) during acute relapse is generally used in place of oral GC as first line, except in those with severe disease, in most countries (139).

Rat studies show that undernutrition lead to reduction in GH production (140) but also reduction in hepatic GH sensitivity due to decreased GH receptor mRNA in the liver and resultant low systemic IGF-1 (141,142). In humans, malnutrition is associated with hepatic GH resistance but associated with elevated systemic GH levels (143,144). Short periods of fasting (2-3 days) in animal studies report reduction in linear growth by 30% compared with control animals, associated with reduction in all zones of the growth plate and decrease in chondrocyte number. In addition, GH receptor and IGF-1 expression is reduced in growth plates of mice with food restriction (145).

GH resistance during fasting maybe a metabolic adaptation and fibroblast growth factor 21 (FGF21) has been identified as a key regulating factor inducing gluconeogenesis, fatty acid oxidation and ketogenesis. Short periods of fasting can lead to elevation of FGF21 (146,147). The link between FGF21 and growth is demonstrated by the fact that transgenic mice over expressing FGF21 have reduced bone growth and hepatic GH resistance (148). On the other hand, FGF21 knockout mice subjected to 4 weeks of food restriction did not exhibit reduction in linear growth and did not show GH resistance (145). Increased FGF21 during periods of undernutrition affect GH sensitivity by directly inhibiting GH binding in growth plate chondrocytes with no impact on the number of GH receptors locally. This may be an indirect effect via the effects of two transmembrane proteins, LEPROT and LEPROTL1, which are increased during fasting, leading to reduction in GH binding and action at the growth plate (149). Recently it has been shown that fasting is associated with significant

increase in microRNA-140 specifically at the level of chondrocytes, although its precise mechanism on malnutrition growth failure is still unclear (150).

#### 4. Animal models of chronic disease and growth disorders

Animal models of arthritis and colitis confirm the direct effects of chronic inflammation on growth, the GH/IGF axis systemically and at a local level. In addition, they have also provided evidence of the direct role of inflammation on delayed puberty and poor pubertal growth.

The IL-6 transgenic mice have an adult size that is 50-70% smaller compared to non-transgenic littermates, even after controlling for food intake (151). This was associated with normal systemic GH but low IGF-1 and low IGFBP-3. ALS levels on the other hand remained normal (151,152). The low IGF-1 was seen to be due to increased renal clearance whilst the low IGFBP-3 was due to increased proteolysis (152). Blocking IL-6 reversed the growth phenotype and normalized IGF-1 levels, pointing to the role of IL-6 on growth failure in chronic inflammation (153).

In a study of rats with *Mycobacterium butyricum* induced arthritis, weight gain was three fold lower than controls. This was associated with low IGF-1 but increased IGFBP-3 due to decrease in proteolysis (154-156). Pituitary GH and liver IGF-1 gene expression were reduced (157). In a study using a mouse model of systemic arthritis, C-natriuretic peptide overexpression in chondrocytes prevented endochondral growth retardation and reduced articular cartilage damage (158). This is thought to be mediated via an increase in chondrocyte proliferation, differentiation, hypertrophy, matrix production and local resistance to the effects of pro-inflammatory cytokines (158).

Following trinitrobenzenesulphonic acid (TNBS) induced colitis, rats demonstrate growth retardation independent of under-nutrition, leading to only 30% of the growth rate of healthy rats (159,160), associated with normal systemic GH levels but low IGF-1 (159). The IL-6 colitis rat also has 30% of the growth rate of controls, associated with low IGF1 levels (161).

Studies in TNBS colitis rats and dextran sodium sulphate (DSS) colitis demonstrated that inflammation causes delayed puberty inconsistent with changes in food intake, body weight, leptin and corticosterone levels (162-164). Plasma levels of 17 $\beta$ -estradiol in females and testosterone in male rats with colitis were significantly lower, although basal gonadotropin levels were similar (162). In females DSS mice with colitis, estradiol and gonadotropin levels were not lower (164). In males DSS mice with colitis, there was no difference in testosterone levels but stimulated LH, basal and stimulated FSH levels were lower in those male mice (163). In our opinion, these animal data suggest that cytokines may affect the secretion or sensitivity of gonadotropins, or act at the level of the gonadotropin releasing hormone which may differ depending on gender. Administration of inflammatory cytokines (165,166) via intracerebroventricular injection and peripheral injection of lipopolysaccharide (167) have been shown to decrease levels of LH and FSH. Although TNF- $\alpha$  and IL1- $\beta$  can inhibit steroidogenesis in leydig cells (168), the animal models of colitis do not support an effect of cytokines on the gonads causing primary gonadal failure as the etiology of delayed puberty.

CF mice with a null mutation in the CFTR were significantly lighter and shorter compared with wild type mice associated with significantly lower systemic IGF-1 levels. Marginal reduction in GH levels were seen only in the female mice (169). CF mice have mild pancreatic pathology with little or no exocrine pancreatic dysfunction. They however exhibit growth failure suggesting that pancreatic exocrine status may not play a significant role in poor growth in this animal model (170). A study in pigs with CF demonstrated growth deficits at birth with associated lower IGF-1 levels which is due to the lack of CFTR impairing GH secretion (171).

Adjuvant induced arthritis in rats treated with rhGH showed increased body weight (156,172) associated with increase levels of systemic IGF-1 and IGFBP-3 (156,172), with reduction in IGFBP-1 and IGFBP-2 (156). Also, transgenic mice overexpressing GH with induced colitis had similar weight trajectory as controls. Compared with wild type mice with induced colitis, transgenic mice with induced colitis had higher systemic IGF-1 levels (173).

In contrast, rhGH treatment in interleukin 10-null mice with colitis improved weight gain but did not raise systemic IGF-1 levels (174). Whilst systemic IGF-1 levels were higher in rhGH treated rats with colitis, they were still lower than levels in control rats (175). In response to rhGH therapy, animal models of colitis have reduced hepatic activated tyrosine phosphorylated STAT5 (176,177). Currently, there are no studies evaluating the growth plate phenotype in animal models of chronic inflammation treated with rhGH. rhGH in rodent models may also activate the prolactin receptor. To the best of our knowledge, there are no animal studies of rhGH in chronic disease specifically targeting the GH receptor.

## **5. Juvenile idiopathic arthritis (JIA)**

### **5.1 Disease and management**

Juvenile idiopathic arthritis comprises a heterogeneous group of disease subtypes involving inflammatory arthritis's beginning before the age of 16 years with symptoms presenting for greater than 6 weeks (178). The pathogenesis is currently unknown although it is thought to be due to a combination of environmental triggers and specific immunogenic factors (179,180). There are currently seven subtypes of JIA according to the International League of Associations for Rheumatology (ILAR) classification (178,181,182). In currently published literature regarding growth and pubertal development, distinction is generally only made between those patients with oligoarticular, polyarticular and systemic JIA.

Management of JIA differs depending on the subtype. There is currently no cure for JIA and treatment is focused on achieving optimal function of joints, preserving or ensuring normal mobility for day to day activity, ensuring normal growth development and minimizing negative impact on the child and family (183). Pain relief is achieved with the use of non-steroidal anti-inflammatory drugs (NSAID).

In those with more severe joint involvement that do not respond to NSAID, intra-articular GC injection is used as second line treatment. Response is usually seen within days

of injection and a response rate of 60-70% is maintained for several months (184-186). Early use of intra-articular GC injections, may result in fewer local long term consequences like contractures, muscle atrophy and leg length discrepancy (187,188). Reports of children treated with intra-articular GC and development of Cushingoid features exist in the published literature (189-191). The effect of intra-articular GC injections on linear growth in JIA is unclear. One study of 21 patients showed no adverse effects on linear growth (192). In a report of 2 patients with JIA (193), leg growth of the contralateral leg was reduced using knemometry after intra-articular GC injection. This could reflect local overgrowth of the affected inflamed limb which can occur in these children (194).

For those with severe arthritis, oral GC may be needed. In some instances, intravenous GC (methylprednisolone) for a short period may also be required especially awaiting the therapeutic effects of background immunomodulator(eg methotrexate) (195). Other aspects of disease management in subtypes of JIA will be summarized in the next subsections.

#### **5.1.1 Oligoarticular JIA**

This is the commonest subtype of JIA accounting for almost 50% of all children with JIA (196). These children have 4 joints or less affected. The arthritis is generally asymmetrical and predominantly involves the large joints of the lower extremities excluding the hips. The most commonly affected joints in decreasing order are the knees, ankles, elbows and the wrists (196,197). A subgroup of patients with oligoarticular JIA have extension of joint involvement such that there is > 4 inflamed joints after the first six months of disease, termed extended oligoarticular JIA. Approximately 50% of those who present with  $\leq 4$  inflamed joints at diagnosis show subsequent extension of involved joints (198,199). It is unclear if this is a separate entity or if these patients in fact have polyarticular JIA.

#### **5.1.2 Polyarticular JIA**

585           This group of children with JIA have 5 or more joints inflamed. All children with  
586 polyarticular JIA generally are likely to require a disease modifying anti-rheumatic drug  
587 (DMARD) such as methotrexate, sulphasalazine or leflunomide; anti-TNF therapy eg  
588 etanercept - or both classes of drugs. It is not uncommon, especially in those with severe  
589 disease, for a short bridging course of oral GC to be used. Current data suggests that  
590 methotrexate is the DMARD of choice in polyarticular JIA with approximately 86%  
591 responders at 2 years (200). Sixty three percent of children with polyarticular JIA will  
592 respond to treatment with methotrexate (201).

593           In those with recalcitrant disease, anti- (tumor necrosis factor) TNF therapy offers the  
594 possibility of improving inflammation in these children. Etanercept (Enbrel) is the anti-TNF  
595 of choice in JIA. Etanercept is a soluble, dimeric fusion protein consisting of the human p75  
596 TNF receptor fused to the Fc region of the human IgG1. Approximately 74% of children with  
597 methotrexate resistant JIA will respond to treatment with etanercept (202,203). Adalimumab  
598 (Humira), a humanized monoclonal antibody against TNF- $\alpha$ , has also been shown to be  
599 effective in methotrexate resistant polyarticular JIA (204). Several studies have demonstrated  
600 the efficacy of etanercept in improving linear growth in children with JIA, mostly children  
601 with polyarticular JIA (22,205,206). Improvement in growth is greatest in those with lower Ht  
602 SDS at baseline and those not treated with GC. Growth response is modest, with a recent  
603 study from a large group of 191 children demonstrating that change in Ht SDS was only 0.29  
604 SD after two years of therapy (22).

### 605 606           **5.1.3 Systemic JIA**

607           The initial description of children with systemic JIA involves the observation of the  
608 classical triad of remittent fever, typical macular, salmon colored rash and arthritis. The  
609 arthritis could be oligoarticular initially but often progress to polyarthritis with resulting  
610 significant deformity leading to disability. The systemic signs of fever and rash can precede  
611 arthritis up to several months. Growth failure is frequently seen in children with systemic JIA,  
612 especially during acute flare (207). Predictors of poor prognosis in systemic JIA include age



of onset < 6 years, disease duration > 5 years or persistent systemic features at 6 months of disease including fever, need for GC and thrombocytosis (208). Whilst anti-TNF therapy is often used as first line biologic agent in systemic JIA, it is generally less effective compared to polyarticular JIA. 54% of patients with systemic JIA show poor response to etanercept (209)

Evidence suggests that systemic JIA is in fact more driven by IL1- $\beta$  and IL-6 (210,211). Anakinra (Kineret) is a recombinant human (rh) IL-1 receptor antagonist shown to be effective in several preliminary open label and retrospective studies of children with GC dependent systemic JIA (211-213). Two recent randomized trials of Anakinra in children with systemic JIA have documented its efficacy in reduction of inflammation (214,215). Only about 45% of these children are IL-1 blocker responders and responders are those with lower number of active inflamed joints, higher absolute neutrophil count (212), suggesting that IL-1 may not be the only driving cytokine in some children with systemic JIA.

In systemic JIA, elevated levels of IL-6 have also been seen and appear to correlate with arthritis, fever and thrombocytosis (216). Tocilizumab (Actemra) is a humanized monoclonal antibody against the IL-6 receptor (217) and has been shown to be effective in early phase III trials of children with systemic JIA despite DMARD and anti TNF therapy (218). A recent study in a group of children with systemic JIA treated with Tocilizumab showed that growth rate improve significantly following 2 years of therapy with resultant normalization of IGF-1. These children however remained relatively short as Ht SDS only improved by +0.3 SD after 2 years. Ht SDS at baseline was approximately -2.0 SD (219).

## **5.2 Clinical evidence of growth failure in JIA**

Localized growth impairment is not uncommon even in those with oligoarticular JIA and may result in significant leg length discrepancy as knees are commonly affected (194). The temporomandibular joint can also be affected in those with systemic and poly-articular JIA and may result in relative micrognathia, irregular growth of the jaw (220,221). Recent 3D facial asymmetry quantification confirms unilateral destruction of cartilage of the mandibular

condyle (222) in JIA. All these clinical observations point to the role of local bone growth impairment associated with chronic inflammation.

In JIA, poor growth is more common in children with poly-articular (especially those with rheumatoid factor positive) and systemic JIA (207,223,224) although approximately 12% of children with oligoarticular JIA have recently been shown to have > 1SD reduction in Ht SDS at adult height (AH) compared with Ht SDS at diagnosis (225). Evaluation of the clinically unaffected knee with MRI in a group of children with oligoarticular JIA revealed abnormalities in 40% (226). It is possible that clinical evaluation may not be sensitive enough to detect the more widespread joint involvement in some of these children classified as oligoarticular JIA (227). Children with very early onset of systemic JIA ( $\leq 18$  months) have a more severe disease phenotype and unsurprisingly poor growth is more frequent (228).

Onset of puberty maybe delayed in JIA by about 0.4 to 2.2 years compared to healthy children (229,230). Progression through puberty can be compromised in JIA. None of the adolescents with JIA reached breast and genital stage 5 at 16 years despite the onset of puberty between 12-13 years in one study (230). A few studies have reported that onset of puberty may be earlier in children with systemic JIA in comparison with the other subtypes of JIA (229,231). These preliminary data need to be interpreted with care as the onset of puberty was defined by genitalia stage from patient self-assessment rather than clinical examination of testicular volume. Menarche in girls with JIA is delayed by one year compared to healthy girls and also to maternal age of menarche. Age of menarche was significantly later in those with systemic JIA in this study (232). Other studies found no difference for age at menarche for girls with JIA (233,234).

Pubertal growth spurt in JIA may be attenuated and is often poorest in those with systemic JIA (231). In one study, actual HVs for children with oligoarticular and polyarticular JIA were approximately 1.5 cm/ year for those children aged 12-16 years whilst HV was only approximately 0.5 cm/ year for those with systemic JIA. A substantially compromised magnitude of peak height velocity (2.8 cm/year) was reported in this study. Peak height velocity was 3.6 cm/year for oligo-articular JIA, 4.9 cm/year for polyarticular JIA and 1.7

cm/year for systemic JIA (231). HV for healthy children in puberty ranges from about 4-8 cm/year on average.

Current published studies report significant reduction in adult height (AH) in JIA (198,207,235-239) [Table 1]. However, these studies were published over a decade ago which would have included children treated in the 1980s. The use of immunomodulators and anti-cytokine have only been incorporated into routine clinical practice in the last 10-15 years. Current studies of AH in JIA include different numbers of the various subtypes of JIA. The study by Simon et al from 2002 which reported a mean AH of -2.0 SD only included children with systemic JIA who were treated for approximately 7 years with continuous oral GC, a practice that is less common these days even in children with severe systemic JIA (207). AH of individuals with JIA treated with contemporary immunomodulators and anti-cytokine therapy is currently unknown. In addition, there is increasing use of intra-articular injection of GC instead of prolonged use of oral GC which may be beneficial for controlling joint inflammation but has less systemic side effects. It is possible that there may be growth suppressive effects of intra-articular GC especially for those children who require multiple repeated injections.

Growth and pubertal development in other less common inflammatory rheumatologic conditions such as systemic lupus erythematosus (SLE), dermatomyositis, and systemic sclerosis are not well studied. In a 2 year follow up study of 331 children with SLE, short stature was uncommon at baseline of study visit (median Ht SDS -0.4, median parent adjusted Ht SDS -0.3). However, Ht SDS continued to deteriorate despite institution of therapy, particularly pronounced in boys. Parents adjusted Ht SDS < -1.5 was seen in 25% and 15% of males and females at end of study, respectively (240). In SLE, delayed onset of puberty was seen in 15.3% of girls (breast stage 2) and 24% of boys (testes  $\geq$  4ml). Over twenty per cent of adolescent girls with SLE had delayed menarche (>15 years) or absent menarche. Irregular menses and secondary amenorrhea was seen in fewer than fifty per cent. In the group of older adolescent girls, delay onset of puberty, pubertal tempo or menarche was seen in over one

third of girls whereas in older boys, delay onset of puberty and pubertal tempo was seen in almost fifty per cent (241).

Some studies have reported an association between GC and growth failure in JIA (236,242) whilst others have not (227,237,243). One study evaluated the relationship between inflammatory cytokines and linear growth in 79 children JIA. HV Z score was associated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and IL-6. IL-6 was the only significant factor (independent of other disease markers and GC dose) influencing growth rate on regression analysis in this study, highlighting once again the importance of disease itself on growth failure (244). Although it is often difficult to separate the impact of GC and inflammation on growth impairment, judicious use of oral GC may have less impact on growth than uncontrolled inflammatory status. However, undoubtedly, prolonged high dose of systemic GC will have a negative effect on growth.

To summarize this section, significant growth impairment leading to short stature is often seen in children with severe poly-articular JIA and systemic JIA. The recent report of long term growth problems in children with oligo-articular JIA needs to be confirmed in further studies. The extent of long term growth failure and short stature at AH in a cohort of individuals with JIA managed with modern therapies is currently unknown.

### **5.3 Systemic abnormalities in GH/IGF-1 axis in JIA**

Chronic inflammation in JIA is associated with a state of relative GH resistance. A biochemical picture of GH resistance was seen in six slowly growing children with systemic JIA who had normal GH secretion from overnight GH sampling, normal GH response to two provocative tests (clonidine and ITT) but low IGF-1 and IGFBP-3 levels (245). Nine out of ten children with JIA underwent overnight GH sampling had normal GH secretion (246). Following 4 days treatment with rhGH (0.23 mg/kg/wk), IGF-1 and IGFBP-3 only increased by 31% and 14% respectively in JIA, whilst IGF-1 and IGFBP-3 rose by 85% and 73% in 8 children with constitutional delay in puberty (247). The resistance to GH in JIA is due to a reduction in GH receptor gene expression. Following a 2 year follow up period, GH receptor

mRNA in lymphocytes of JIA increased, paralleled by improvement in disease activity, reduction in IL-6 levels and increase in IGF-1 levels (248)

Impairment of GH secretion is also seen in children with JIA. Twenty three out of 63 children with JIA who had been treated with GC for a mean of approximately 4 years at mean 0.2 mg/kg/day Prednisolone at evaluation had evidence of GH deficiency by clonidine and/or arginine stimulation test (249). In a group of children with JIA not on oral GC, abnormal GH secretion was diagnosed in 50% based on results of overnight GH sampling and L-Dopa stimulation test, suggesting that inflammation itself may also impair GH secretion. The cut off for GH sufficiency was taken at the level equivalent to 10 mcg/L (250). The recommended peak GH of < 10 mcg/L has not been validated and this arbitrary cut off may need to be altered with the availability of newer monoclonal GH assays (251,252). These may vary depending on the provocative agent used. However, the clinical studies in JIA mirrors results experimental studies in animal models of chronic inflammation induced by lipopolysaccharide and endotoxin demonstrating that pituitary derived GH production can be reduced (154,253). The impact of intra-articular GC injections on GH secretion in children with JIA is unknown.

Impairment of IGF binding proteins have also been reported in children with JIA. In 26 children with systemic JIA, normal levels of ALS, low IGF-1 and markedly low IGFBP-3 due to increase proteolysis of IGFBP-3 were reported (152). In another study of 17 children with JIA (majority oligo-articular JIA) and mild growth failure, normal IGF-1, marginally low IGFBP-3 but disproportionately low ALS was reported (254).

Whilst low levels of IGF-1 are generally seen in most studies of childhood arthritis, some studies suggest that poorly growing children with inflammatory rheumatic conditions may have IGF-1 in the normal ranges, which suggest that a functional state of relative IGF-1 resistance may exist (246,255,256). In 23 children with JIA, mean IGF-1 SDS adjusted for age was -0.84. Five of those individuals had relatively “high” IGF-1 SDS > +1 SD (216). It is possible GC treatment in the presence of inflammation reduces IGF-1 sensitivity. A study of 32 adults with rheumatoid arthritis (16 on Prednisolone) showed that IGF-1 was significantly

higher in the group on Prednisolone (mean 221 microgram/L vs. 122 microgram/L). Twelve weeks treatment with anti-TNF therapy (adalimumab) led to normalization of the raised IGF-1 in the group on Prednisolone such that the levels were similar in both groups. (256).

To summarize this section, studies of the systemic GH-IGF axis in children with JIA point to a state of GH resistance in the majority of the cases. Abnormalities in GH secretion may also exist in non-GC treated children, although this could be due to the impact of intra-articular GC. Abnormalities of IGF binding proteins are reported in children with JIA but comprehensive studies of the ternary complex are still currently unavailable. IGF-1 resistance especially in those treated with high dose GC may also occur. Whilst GH/IGF-1 resistance occurs in JIA, there is insufficient scientific evidence to determine the contribution of systemic hormone resistance on growth impairment in children with JIA.

#### **5.4 Efficacy of rhGH on linear growth in JIA**

Earlier non-randomized studies that included children with JIA who were relatively older reported that HV can improve by over 100% with rhGH (247,257-264) [Table 2]. Subsequent randomized controlled trials including one with a placebo arm have confirmed these findings and suggest a modest effect on short to medium term catch-up growth [Table 3] (39,250,265-268)

Two studies that compared different doses of rhGH suggested better growth response with the “higher” dose compared with the “lower dose” (0.16 mg/kg/wk vs. 0.33 mg/kg/wk and 0.15 mg/kg/wk vs. 0.30 mg/kg/wk) (247,260). A recent trial in JIA has investigated even higher doses of rhGH (0.47mg/kg/week) (268). The growth response appears to be better in this study but the subjects in this trial had shorter duration of disease and GC exposure.

The only randomized study with AH data in chronic inflammatory disease was conducted as an RCT using rhGH 0.33 mg/kg/wk for a mean duration of 8.4 years and it reported a mean difference of 14.3 cm at AH between the two groups. Treatment led to a net gain of Ht SDS of +2.3 SD as the control group lost 0.7 SD from baseline to AH. At AH, rhGH treated patients were still relatively short with mean AH of -1.6 SDS. However,

untreated children had a mean AH of -3.4 SDS (39) [Fig 8]. The efficacy of rhGH on AH in JIA is similar to gains seen in children with chronic renal insufficiency (CRI) treated with rhGH (269,270).

In a non-randomized study using rhGH 0.33 mg/kg/week, using data from some of the children previously included in a randomized trial and patients clinically treated with rhGH off label, mean total pubertal height gain was 7.3 cm better with rhGH treatment. Similarly, mean AH in the rhGH group was - 1.7 SD whilst the AH of the matched controls was -3.2 SD (249). Total pubertal growth with rhGH in JIA is comparable to children with idiopathic GH deficiency treated with rhGH and healthy children during puberty (249,271,272).

To evaluate the role of “early” use of rhGH before significant short stature is present, Simon et al conducted an RCT using rhGH 0.47 mg/kg/wk in a group of prepubertal children with JIA who were growing at less than 3cm/year and had a mean Ht SDS of about -1.0. These children had a relatively short duration of disease of approximately 2 years at baseline. After 3 years of rhGH, the relative Ht gain was +1.5 SD (268). These data suggest that early introduction of rhGH in the course of JIA before the onset of severe growth impairment may normalize growth rate. The benefit of “early” treatment with rhGH before the onset of severe growth failure needs further evaluation particularly in light of newer therapeutic development in JIA disease management, although we know that catch-up growth following anti-cytokine therapy may only be modest (22).

There is now sufficient evidence to show that the use of relatively high dose rhGH leads to improvement of linear growth in children with JIA. Only one study with information on AH using rhGH dose similar to those used in conditions like TS and CRI report fairly similar AH outcome. Larger, adequately powered trials of rhGH in JIA are now needed to confirm long term AH outcome and address issues like optimal dose of rhGH and timing of starting rhGH. The impact of rhGH in those with systemic JIA, often the ones most severely affected, is still unclear, as current trials have included only a small number of such children. Future rhGH studies will also need to stratify for JIA subtypes at inclusion.

## **5.5 Factors affecting the growth response to rhGH in JIA**

### **5.5.1 Disease status and glucocorticoid**

Studies of rhGH in JIA have demonstrated that the growth response to rhGH is negatively associated with inflammatory markers such as CRP (39,260) and ESR (39). Some studies also found a negative association between cumulative prednisolone dose and growth rate during rhGH therapy (255,261,265,266). The association between prednisolone dose and growth rate was not statistically significant when the analysis was performed in a regression model, suggesting that inflammation plays a greater role in modulating growth response (39). One study showed that children with polyarticular JIA grew better on rhGH than those with systemic JIA although the number of children with systemic JIA was relatively small (263)

### **5.5.2 Systemic IGF-1 levels**

A modest positive association has been reported between growth rate with IGF-1 and IGFBP-3 in response to rhGH. AH of the rhGH and control patients in the study by Bechtold et al showed a modest association with average IGF-1 and IGFBP-3 in JIA ( $r=0.61$  for IGF-1 and IGFBP-3) over the treatment period (39).

## **5.6 Efficacy of rhGH on disease process in JIA**

There are no published studies of rhGH on its effects on experimental arthritis, but there is currently no evidence to suggest any specific concerns about worsening of inflammatory arthritis.

## **6. Inflammatory bowel disease (IBD)**

### **6.1 Disease and management**

Inflammatory bowel disease is a group of inflammatory disorders of the gastrointestinal tract characterized by chronic inflammation. IBD has a relapsing and



remitting nature, which is often unpredictable. IBD has classically been categorized into ulcerative colitis (UC) and Crohn's disease (CD) on the basis of combinations of clinical presentation, radiological and endoscopic and histopathological features. Recent evidence suggests that the underlying etiology of IBD is due to the interaction of three factors: genetic susceptibility, environment abnormal immune host response and commensal gut microbiota (273). It is believed that the pathogenesis of IBD occurs from errors in the interpretation or regulation of immune perception and responsiveness to endogenous microbiota and thus disruption in mucosal homeostasis. This results in the initiation of immune responses in genetically predisposed individuals (274). Familial aggregation of IBD has long been recognized (275-278), but in the last twenty years detailed mapping of a region on chromosome 16 resulted in the identification of the NOD2/CARD15 gene. This gene encodes a cytoplasmic protein designated NOD2 or CARD15, which serves as a pattern recognition receptor for bacterial lipopolysaccharide and regulates activation of nuclear factor- $\kappa$ B and secretion of  $\alpha$ -defensins by ileal paneth cells (279-281). Numerous other candidate genes have subsequently been identified but only accounts for a small proportion of pediatric IBD (282-284).

Focusing specifically on growth and genetic influences in pediatric IBD, studies have shown that patients with an OCTN1/2 haplotype (285) and those with the IL6-174 GG genotype had lower height at diagnosis (161). Another study revealed that patients with TNF- $\alpha$  promoter polymorphism had higher Ht SDS at diagnosis (286). A much more recent study reported significant association between growth impairment in CD and a stature related polymorphism in the dymeclin gene (287). To date, it is unclear if these associations with genetic factors are independent of the severity of inflammation

### **6.1.1 Ulcerative colitis**

UC is a condition where the inflammatory response and morphologic changes remain confined to the large intestine, with rectal involvement in about 95% of cases. In UC, inflammation is limited to the mucosa and consists of continuous involvement of variable severity, with ulceration, edema and hemorrhage along the length of the colon. Characteristic

histopathological findings are chronic mucosal inflammation with extensive polymorph nuclear leukocytes, mononuclear cells, crypt abscesses, and distortion of mucosal goblet glands and goblet cells. Induction of remission at diagnosis and subsequent acute relapse is with oral GC. Maintenance of remission in UC is with background therapies like amino salicylates (mild disease) or immunomodulators (eg azathioprine, methotrexate) and anti-cytokine disease. In UC, major surgery with total colectomy and ileal pouch anal anastomosis is curative (288). The efficacy of anti-cytokine therapy in UC is unclear and as such not used as frequently (289).

### **6.1.2 Crohn's disease**

In contrast, CD is inflammation that can involve any part of the gastrointestinal tract from the oropharynx to the perianal area. Diseased and inflamed segments are separated by normal healthy bowel otherwise known as “skip lesions”. Inflammation can be transmural, often extending to the serosa, resulting in sinus tracts or fistula formation. Typical histopathological findings include small superficial ulcerations over a Peyer's patch and focal chronic inflammation extending to the submucosa and sometimes accompanied by non caseating granuloma formation. Common sites involved are the ileocecal region, terminal ileum, small bowel and isolated colonic involvement.

In CD, induction of remission of mild to moderate disease is often with exclusive enteral nutrition (EEN) (290). This is the provision of an exclusive liquid diet for a duration of 8-12 weeks which has been shown to be just as effective as GC for reduction of inflammation and but has no adverse effects on growth and bone metabolism (291). EEN is commonly used in Europe and is gaining popularity in the United States and the rest of the world. Background maintenance therapy using amino salicylates or immunomodulators with azathioprine are often used in moderate to severe disease close to the time of diagnosis. Methotrexate can be used as a second line immunomodulatory (292).

Escalation to anti-cytokine therapy like infliximab and adalimumab will be considered in those children with severe disease who are not responsive to GC and those with

chronic low grade inflammation but who are GC dependent. In the real world setting, the use of anti-TNF therapy in paediatric CD is associated with modest response with 56% achieving remission after 12 months (293). Safety issues like significant acute reactions and long term safety concerns including lethal forms of lymphoma preclude its use over extended periods of time (294,295). There is no doubt that the use of anti-TNF therapy in CD is associated with improvement in linear growth (296-298). Similar to the experience in children with JIA, this improvement is only modest with studies reporting increased in Ht SDS of between 0.2 to 0.3 SD over 12 months of therapy (299).

### **6.1.3 Inflammatory bowel disease unclassified**

CD involving the colon only is commoner in children than in adults which makes it challenging to distinguish CD and UC for some individuals. In these instances, the term IBD unspecified (IBDU) is used (previously known as indeterminate colitis). Observational studies suggest that children with IBDU could be considered a distinct subtype of IBD as the disease often takes an aggressive and progressive course (300)(REF).

## **6.2 Growth failure in children with IBD**

In IBD, growth impairment appears to be more frequent and severe in children with CD than those with UC (18,301,302).(303,304) A UK IBD register that collected data for new cases presenting between 1997 and 2003, reported that, at diagnosis, mean Ht SDS was -0.3 for both boys and girls with CD whereas it was -0.1 and +0.22 for boys and girls with UC, respectively (305). Ht SDS < -2.0 is present in approximately 10% of children with CD at diagnosis (18,306,307). In another recent study, mean Ht SDS for 102 children with CD (mean age 11.9 years) was -0.2, but those with *Saccharomyces cerevisiae* antibody (ASCA) had significantly lower height than those without (308). Whilst height reduction at diagnosis as a group appears to be mild, deteriorating height velocity is known to occur before the diagnosis of CD and can occur in the absence of gastrointestinal symptoms (309). A retrospective study of 116 children with CD provided further evidence for this as these

children were shorter than their genetic potential at diagnosis with mean Ht SDS of -0.5 compared with mid-parental Ht SDS +0.2 (18).

Several contemporary studies show that despite modern therapies, growth failure and short stature is still seen in a subset of children and adolescents with IBD (18,307,310). A study in a cohort of contemporary children and adolescents with IBD showed that Ht SDS showed a negative association with the body image domain of the pediatric IBD specific quality of life score IMPACT III, with higher scores indicating poorer quality of life (10) [Fig 8]. Further research on the impact of abnormal growth and pubertal development and the impact on quality of life in children with IBD and other groups of chronic disease are needed. This is a challenging area to acquire meaningful information as there needs to be distinction between the impact of poor growth and the impact of the disease itself on quality of life.

Delayed onset of puberty has been previously reported to be common in CD (6,311-313), although careful evaluation of pubertal status by clinician examination is currently limited (10,311). Other current published studies have used age of menarche, bone age delay and age at initiation of growth spurt as assessment of pubertal delay (6,312-314). A report from the mid-90s showed that onset of breast development was delayed by 1.5 years in children with CD and UC. Boys in that study had 0.8 years delay in onset of testicular enlargement consistent with early puberty. This report is from a time when immunomodulators and certainly biologic therapy would not been used in clinical practice with heavy reliance on long term oral GC therapy.

Although the treatment of children with IBD has changed considerably, a study from a contemporary cohort of children who analyzed retrospective pubertal growth data reported persisting evidence of delayed puberty as judged by the age at peak height velocity in those with CD. This delay was more likely in those with a higher ESR or lower BMI. Peak HV SDS adjusted for pubertal age was also reduced, suggesting that the pubertal growth spurt may be attenuated. This study however, excluded children who were treated clinically with growth promoting therapy like sex steroid and / or rhGH, who by default are likely to be those with significant short stature or severe growth retardation (6). Therefore it is possible that there is

greater impact on puberty and pubertal growth spurt despite modern therapy. A recent prospective study of a cohort of children and adolescents with IBD suggests that pubertal delay was uncommon with only 0.3 years of bone age delay. Adolescent boys had attenuated growth rate during puberty whereas marginally delayed onset of puberty was seen in adolescent girls with IBD in this contemporary cohort (10).

Two studies demonstrated bone age delay of approximately one year in children with CD (312,313,315), which is within acceptable limits, including one study from patients managed between 2007-2009 with 60% of patients on immunomodulators and 20% on infliximab (315). In girls, age at menarche occurred after 16 years in 73% with CD in a cohort managed between 1968 and 1983 (314). In a cohort managed between 2007-2009, girls with CD reached menarche at median age of 13.9 years (313) compared with healthy controls of 12 years.

Several contemporary studies of growth in children with IBD show lack of adequate catch up growth despite advances in primary disease therapy. In a study of 176 children with CD, Ht SDS at diagnosis, 1 and 2 years remain unchanged at approximately -0.5 SD. The percentage of children with Ht SDS < -2.0 however was slightly less frequent by 2 years: 10% at diagnosis, 8% 1 year, 6.5% 2 year. This cohort was largely managed with oral GC (Prednisolone) for induction of remission as only 4% had primary enteral nutrition therapy within 3 months of diagnosis. (306). Another study of 116 children with CD where enteral nutrition was more commonly used for induction of remission (63% of cases from diagnosis), Ht SDS (approximately -0.5 SD) remained the same from diagnosis to a mean final follow-up of 4.6 years after diagnosis (18).

In contrast to JIA, only a modest reduction in AH has been reported by most studies in adults with childhood-onset IBD (3,8,9,303,314,316-319) [Table 4]. AH is significantly lower in childhood onset CD with onset before puberty, although definition of puberty in this study was unclear (320). In a relatively contemporary cohort of 123 patients with CD, AH was only 2.4 cm lower than target height. However almost twenty per cent achieved a AH that was more than 8cm below their mid-parental height suggesting that a small sub-group of

adults with childhood onset CD may have significant long term growth impairment leading to short stature. Longer duration of symptoms prior to diagnosis and jejunal disease were related to AH in that study but these factors require further study (9). Conventional assessments with endoscopy and barium studies often do not identify jejunal disease adequately, questioning the relationship with AH in that study. Parents' heights were also obtained from patient estimation. In another study of AH in IBD where 108 patients had AH and parental height measurements performed by researchers, 28 out of 108 (26%) who had more than one Ht SDS  $< -1.6$  during growth (defined as growth impaired group) had AH of 0.9 SD lower than mid-parental Ht SDS. In those with no evidence of growth impairment, defined as those who did not have Ht SDS  $< -1.6$  more than once during growth, AH was only 0.1 SD lower than mid-parental Ht SDS. (319).

Published evidence suggests that short term linear growth may be better in those children managed with enteral nutrition during acute relapse compared with oral GC (321,322), although the effects of EEN practice on long term growth outcome is less convincing. AH in CD (-0.4 SD) did not differ between an American study (319) and a United Kingdom study (-0.3 SD) (9) where the agent of induction of remission differed: oral GC in the American study and EEN in the United Kingdom study. Similarly, in a group of children with CD managed with EEN at initial diagnosis and who were encouraged to continue to take supplemental enteral nutrition, weight and BMI SDS increased up to 2 years follow-up, whereas Ht SDS remained unchanged (323).

Numerous studies of anti-cytokine therapy using infliximab and adalimumab in CD show significant improvement in growth rate (296-298), although some did not demonstrate any improvement in linear growth (324,325). The improvement in growth in these children may be independent of progression in puberty, reduction in GC, and maybe better in those who are concurrently treated with methotrexate. However approximately 30% of these children may still have poor growth following biologic therapy (296).

Clinical studies in children with IBD have largely shown no relationship between GC and linear growth (304,326). Saha et al, reported no difference in Ht and HV SDS in

prepubertal children with CD and UC treated with GC versus those who did not receive GC. (243). A more recent study of a cohort of 102 children with CD treated with long term low dose oral GC in the form of Prednisolone (mean dose of 0.2 mg/kg/day for mean 14.4 months) showed that almost twenty per cent of the cohort showed growth failure, although HV was not adjusted for delayed puberty. Of those with growth failure, only one third showed catch up growth after discontinuation of GC (327).

Several studies have evaluated the association between cytokines with linear growth and markers of the GH-IGF axis in children with IBD. In 37 children with IBD (17 CD), IGF-1 levels were lower whilst IGFBP-2 was higher compared with controls during relapse. IL1- $\beta$  levels were related to negatively with IGF-1 and positively with IGFBP-2 (328). Levels of lipopolysaccharide was significantly higher in children with CD lower height at diagnosis and follow-up (329). Several studies of genetic polymorphism in genes regulating cytokine production have shown a relationship with growth impairment in pediatric IBD. Children with CD with the -174 GG promoter polymorphism which affects IL-6 transcription had significantly lower Ht SDS at diagnosis (161). The presence of 238G/A and 863C/A polymorphism on the TNF- $\alpha$  promoter gene has been shown to be associated with better height and linear growth in children with CD and appears to be independent of disease activity (286).

Current studies suggest that a sub-group of children with IBD especially those with CD have significant growth failure leading to short stature at AH. Despite the introduction of modern GC sparing therapies including anti-cytokine therapies, poor growth is still encountered, although significantly delay in onset of puberty is perhaps less common. The authors believe that the persistence of poor growth in a small group of these children reflect the fact that some children with CD still do not achieve disease remission with current therapies or adverse effects preclude the use of aggressive modern therapies. Given the short window for growth in CD, as the age of presentation is often in the adolescent years, adjuvant growth promoting therapies may still need to be explored in this small subset. Finally, the

growth outcome of children with IBDU who may have a more severe disease course is still currently unclear.

### **6.3 Systemic abnormalities in the GH/IGF-1 axis in children with IBD**

Similar to children with JIA, growth failure in IBD is associated with a state of GH resistance. Early evaluation of the GH axis in 10 children with IBD showed excessive rather than impaired response, using overnight GH profile, propranolol-glucagon and ITT, supporting the notion that these children may be GH resistant (330). IGF-1 levels have been shown to be low in these children, although again delayed maturation may contribute to these result (331). Similarly, in 14 children with CD and growth failure who were not on oral GC, normal GH response to ITT was seen in most of the children. Four out of 14 (29%) of these children had peak GH levels < 6 mcg/L suggesting abnormalities in GH secretion (332). In a study of 5 children with CD with poor growth and delayed puberty (median age 15 years, median bone age 11 years and all except one patient was in Tanner I and II), three out of the 5 had inadequate five hour mean GH levels and peak GH during sleep-further evidence that subtle abnormalities in GH secretion may exist. However, only one child had low GH peak to ITT and none of these 5 children were on oral GC (333).

Abnormalities in the GH axis may be present at diagnosis of children with IBD (330). In addition, abnormalities in the GH-IGF axis in children with chronic inflammation are not permanent as they have been shown to be responsive to primary disease therapeutic intervention using Prednisolone (334), enteral nutrition (335,336), infliximab (337) and surgical resection (336).

It is now recognized that a range of abnormalities in GH and IGF-1 secretion and sensitivity exists in children with IBD and growth failure (338) [Fig 9]. In 28 children with IBD (25 CD) evaluated with an ITT, 11 (39%) had peak GH > 6 mcg/L and IGF-1 SDS < 0 (biochemical functional GH resistance). Biochemical functional GH deficiency defined as peak GH < 3 mcg/L and IGF-1 SDS < 0 was seen in 4 (14%). Biochemical functional GH insufficiency defined as peak GH < 6 mcg/L but  $\geq$  3 mcg/L and IGF-1 SDS < 0 was seen in



11 (39%). Two children had normal GH levels and IGF-1 SDS  $\geq 0$  suggestive of biochemical functional IGF-1 resistance.

Comprehensive studies of the IGF binding protein and ternary complex in children with IBD are currently not available. In a contemporary group of children and adolescents with IBD, pubertal onset was not delayed but abnormal pubertal growth was observed. This was associated with reduction in IGF-1 levels but marginally elevated IGFBP-3, which was postulated to lead to reduction in bioavailability of free IGF-1 (10). A recent study reported gender differences in IGF-1 and IGFBP-3 levels in children with CD such that boys had significantly lower levels even after adjusting for bone age delay, although Ht SDS was similar in both groups (315). A previous study suggested that females with CD had a more severe disease course, although males were more likely to exhibit growth failure (339). One study previously reported that IGFBP-2 is significantly higher in children with CD at relapse and that this was associated with IL-6 (328). The role of IGFBP-2 and regulation of linear growth is unclear but it is thought that it may lead to reduction of the formation of ternary complex and may have a direct inhibitory role at the level of the growth plate (340,341).

In summary, growth failure in children with IBD is associated with a range in defects in secretion and sensitivity of the GH-IGF1 axis. The relative contribution of inflammation, use of GC and nutrition on these systemic abnormalities is difficult to tease out from current studies. Indeed, the contribution of these systemic abnormalities on the growth phenotype of these children is unclear. Studies with comprehensive evaluation of IGF binding proteins are limited in children with IBD. IGFBP-2 may be a marker of disease in children with IBD but whether IGFBP-2 plays an inhibitory role on linear growth in childhood IBD is still unknown.

#### **6.4 Efficacy of rhGH on linear growth in IBD**

Compared to studies in JIA, there is a paucity of data of rhGH in children with IBD [Table 5 (342-348) and Table 6 (349-351)]. A non-randomized study of rhGH (0.35 mg/kg/wk) in 10 children (Mean age 11.9 yrs, Ht SDS of -1.8) reported an 85% increase in HV at 6 months rising from 4.0 cm/yr. to 7.4 cm/yr. This improvement was maintained in a

subgroup of seven children who continued treatment for a further 6 months (344). The only RCT of rhGH at 0.45 mg/kg/wk, for improving linear growth in children with IBD, conducted by Wong et al reported that HV increased by a median of 140% in the rhGH group compared with an 8% reduction in the control group at six months [Fig 10]. Therapy over the six months period was associated with a median difference of 3.3 cm of height gain between the rhGH and control group; equivalent to a median relative gain in height SDS of +0.4SD (351). rhGH therapy in this trial was associated with significantly higher levels of total IGF1, but no significant changes in IGFBP-3, ALS, free IGF-1 and IGFBP-2 (352). Another RCT of rhGH (0.53 mg/kg/wk) in children with CD designed to evaluate the role of rhGH in improving disease process, showed that HV improved by 60% in the rhGH group at 12 weeks. Eighteen of the 20 children who showed disease clinical remission at 12 weeks continued rhGH for a total of 52 weeks. Ht SDS of this group improved from -1.1 to -0.4 (350).

Given the results of the preliminary studies of rhGH in children with IBD, there now needs to be larger definitive trials of rhGH in slowly growing children. Challenges include interpretation of growth rate during puberty and evaluation of disease activity. It is possible that the growth response to rhGH may be more favorable in those with shorter duration of disease and where nutrition is optimized. In that regard, future clinical trials of rhGH in IBD should target those with shorter duration of disease since diagnosis and explore the benefit of concurrent supplemental feeding.

## **6.5 Factors affecting the growth response to rhGH in IBD**

### **6.5.1 Disease and glucocorticoid**

In IBD, HV was inversely related to pediatric crohn's disease activity index (PCDAI) and ESR. However, in individuals on rhGH but not the control group, HV showed a positive association with hemoglobin, negative associations with ESR and PCDAI. Cumulative prednisolone dose was not associated with growth response but the dose of prednisolone used in that cohort was negligible (351).

### 6.5.2 Systemic IGF-1

In children with IBD treated with rhGH, IGF-1 showed a modest but weak statistically significant association with growth rate during the period of treatment (351).

## 6.6 Efficacy of rhGH in on disease process in IBD

Several animal models of colitis suggest a direct effect of rhGH on chronic inflammation via a reduction of both mucosal apoptosis and IL-6 dependent signal transducer and activator of transcription3 (STAT3) activation (173,174,353). rhGH can also directly alter systemic markers of inflammation. rhGH in children with growth hormone deficiency (GHD) may lead to reduction in systemic pro-inflammatory cytokines although the data of rhGH in children with non-GHD states are conflicting (354-358). In a study by Slonim et al with the primary aim of assessing the effects of rhGH treatment on reduction of inflammation, 32 adults with CD were randomized to rhGH (17 rhGH) or placebo injections for four months. rhGH treatment was administered at 5mg daily for one week followed by 1.5 mg daily thereafter. Reduction in Crohn's disease activity index (CDAI) was significantly greater at 4 months with rhGH: -143 points in the rhGH group and -19 in the placebo group. There was however no significant change in Hb, hematocrit (HCT), ESR, prealbumin, ferritin or iron levels after 4 months (347).

To explore the role of rhGH on disease activity in pediatric CD, Denson et al conducted an RCT in 20 children (19 rhGH) with CD (10 rhGH-0.53 mg/kg/wk). The authors' concluded that rhGH may be an adjunct for treatment of inflammatory disease based on improvement in PCDAI (350). In the rhGH group, PCDAI was 32 and 8 points at baseline and 12 weeks. In the control group, PCDAI was 33 and 22 at baseline and 12 weeks. The percentage of GC usage in the rhGH group was lower at 12 weeks, although the dose of prednisolone was similar in both groups. Other markers of disease activity including endoscopic severity, fecal calprotectin and ESR were also similar.

Whilst generally accepted and validated as a disease index, there is a potential pitfall in the use of PCDAI (359) in rhGH studies. PCDAI is made up of three domains:

(1) Subjective patient recall of symptoms

(2) Laboratory parameters and clinical examination

(3) Auxology: weight and HV SDS. HV SDS accounts for 10 points if HV SDS < -2.0 SD, 5 points if < -1.0 SD but > -2.0 SD and 0 points if HV SDS > -1.0.

In the study by Denson et al, HV SDS was -1.0 and -1.8 at baseline in the rhGH and control group. At 12 weeks, HV SDS was +2.0 and -2.1 in the rhGH and control group (350). We believe that the lower PCDAI in the rhGH group in that study merely reflects improvement in linear growth independent of reduction of inflammation. The possibility that rhGH may improve inflammation directly in pediatric CD remains an open question but need to be explored in future studies using other disease end points other than the PCDAI.

In the study by Wong et al. PCDAI was lower after 6 months therapy with rhGH which could be interpreted as improvement in disease activity. However, when data was analyzed using the abbreviated PCDAI which omits the laboratory, physical examination and auxology domains, there was no difference in disease activity over the 6 months in both groups. ESR, CRP, Hb, HCT, albumin, TNF, IL-1 and IL-6 were similar in both groups and after the 6 months period (351). Extensive evaluation of 28 cytokines, chemokines and inflammatory growth factor using the Multiplex assay in that clinical trial showed no differences over the six months period in rhGH or control group and they also did not differ between the two groups (352). Careful disease evaluation including the use of fecal calprotectin, endoscopy or new imaging techniques like MRI should be considered in future rhGH trials in IBD.

## **7. Cystic fibrosis (CF)**

### **7.1 Summary of disease and management**

Cystic fibrosis (CF) is an autosomal recessive genetic condition, primarily affecting the lungs but also the pancreas, liver, intestine and other organs. The defect is on the CF transmembrane conductance regulator (CFTR) gene (7q31.2) on the long arm of chromosome 7 which leads to absence of normal CFTR protein which is a c-AMP activated ion channel.

As a result of this, decreased chloride secretion and increased sodium absorption across epithelial surface is seen. In the airways, this causes depletion of the airway surface liquid and impaired mucociliary clearance which leads to pulmonary infection and inflammation of the airways. This starts early in life and progresses to chronic infection and pulmonary inflammation. Proteases, inflammatory cells and cytokines like IL-8, IL-6, TNF- $\alpha$  in CF(360,361) may lead to ongoing airway wall inflammation, remodeling and eventually bronchiectasis. Inflammatory mediators like neutrophil elastase and bacterial lipopolysaccharide in turn mediate the inflammatory effects by activating the transcription factor nuclear factor- $\kappa$ B which regulates pathways that induce production of cytokines. Pathogens such as *Pseudomonas aeruginosa*, *Burkholderia cepacia*, *Staphylococcus aureus* and *Haemophilus influenza* eventually colonize the airway secretions of CF individuals.

Recent studies show that TNF gene polymorphism is associated with disease progression and severity of pulmonary function (362,363), whilst another study found an association with gene polymorphism in IL-1 $\beta$ , IL-8 and IL-10 to be associated with more severe lung disease in CF (364). Cytokines in CF may also impact on the GH-IGF axis as demonstrated in studies relating inflammatory cytokines to systemic markers of the GH axis. In a group of young adults with CF, IL-6 was positively associated with IGFBP-2 (365). Similarly, in a group of prepubertal children with CF, change in IL-6 was positively associated with change in IGFBP-2 (366).

In CF, gastrointestinal symptoms and signs including failure to pass meconium in a new born infant is seen. In severe instances this could be associated with meconium ileus in a small proportion of infants. Exocrine pancreatic insufficiency occurs in the majority of individuals and requires pancreatic enzyme supplementation. In CF with pancreatic insufficiency, mucosal inflammation is often seen with raised fecal calprotectin. Fecal calprotectin in CF is also associated with height SDS (367). Endocrine defects involving damage to islet cells of the pancreas may lead to CF related diabetes. CF related diabetes with features of both type 1 and type 2 diabetes mellitus is increasingly recognized especially in

late adolescents. This is often parallels deterioration in lung function, growth and abnormal bone development.

Current management of CF requires early treatment and prevention of pulmonary infections with antibiotics, physiotherapy and nutritional support. Allergic bronchopulmonary aspergillosis is an exaggerated immune response to *Aspergillus fumigatus* which is seen in about 4-11% of individuals with CF, which will lead to worsening of lung function(368,369). Oral GC is often used for prolonged periods as inhaled GC is not effective in this condition(370).

Structured CF multidisciplinary services and easy access to health carers cognizant to the issues in CF have improved clinical outcome in CF over the last few decades (371). With increasing survival of people with CF, issues relating to growth and pubertal development have become a greater concern.

## **7.2 Growth failure in children with CF**

Growth failure and short stature in CF may not have been given as much attention but with the increasing age of survival of these individuals, they may become more important issues to consider. Severe short stature in CF may not be a common occurrence. In a recent study of 169 children with CF in the Netherlands, prevalence of short stature was 8%. However, when target height was taken into account, this was only 5%. When both delayed maturation and target height were taken into account (height for bone age adjusted for target height), this was only 1% (372). Similar to children with JIA and IBD, severe short stature in contemporary groups of children with CF is uncommon although poor growth is still seen (372).

Improved clinical care through multidisciplinary teams and the introduction of neonatal screening for CF has been shown to be associated with improvement in growth. Studies have shown that ongoing clinical care in specialist centers all throughout the life cycle leads to improvement in growth parameters, although it is unclear which aspects of clinical care is associated with improvement in growth. Interestingly, improvement in growth in those

managed in specialist centers was not associated with improvement in pulmonary function (373,374). Most current published studies report some association between height and pulmonary/pancreatic function (375-377) although other studies show no association of growth with colonization with *Pseudomonas aeruginosa* (378) and respiratory function as assessed by FEV1 (379), highlighting the multifactorial nature of poor growth in CF.

Addressing nutrition in CF is paramount and may improve linear growth in CF but this needs to be assessed on an individual basis. Long term supplemental enteral feeding in children with CF using gastrostomy feeding show improvement in height although height often improves at least after 18 months of gastrostomy feeding (380-383). In a contemporary group of children with CF, the prevalence of malnutrition was only 7%, whereas 15% were overweight and 8% were obese (384) and therefore overzealous nutritional management should be avoided.

Evidence suggest that children with CF identified from screening exhibit better linear growth compared with those diagnosed due to clinical symptoms (385). In a study of 89 CF children identified from neonatal screening, one third of that cohort had height below the 3<sup>rd</sup> centile and half of that cohort had height below the 10<sup>th</sup> centile (386) whereas in an older study of children diagnosed from clinical symptoms, 40% had height below the 5<sup>th</sup> centile at diagnosis (387).

With the introduction of neonatal screening, it is now recognized that infants with CF are lighter, shorter and have smaller head circumference at birth (388-391), associated with reduction in systemic IGF-1 levels from analysis of blood spot screening (171). CF genotype itself may have an impact on growth and this is still poorly documented in current growth studies in children and adolescents with CF. Children homozygous for  $\Delta F508$  mutation had Ht SDS approximately 1 SD below the mean from infancy to early adolescence (392). Thus, the condition itself via mechanism still unknown can predispose to growth failure and this deserves further research.

Poor growth often precede the onset of CF related diabetes (23), and can impact on pubertal growth and adult height (393). Poor growth associated with CF related diabetes may

not be normalized with insulin treatment even when started early (393), although currently studies of insulin treatment in CF diabetes with linear growth outcomes are limited. CF diabetes is often diagnosed in mid to late adolescents, although with increased awareness and screening, diagnosis in childhood is not uncommon.

Short stature in CF may have an impact on disease severity as short stature in CF is an independent predictor of mortality, which may reflect a sub- group with poorer nutrition or low grade chronic inflammation and ongoing pulmonary exacerbations (394). A poorly growing child with CF and short stature may also have lower lung reserve. The possible benefit of rhGH therapy on pulmonary function in CF will be discussed in a later section.

Similar to children with IBD and JIA, pubertal abnormalities are also seen in children with CF. Delay in skeletal maturation, onset of puberty, attenuated pubertal growth spurt has been reported in adolescents with CF. Bone age was reported to be delayed by more than 24 months in 25% of adolescents and compared to healthy children, age of peak height velocity as a marker of onset of puberty was delayed by 9-10 months in boys and 10-14 months in girls. Girls with CF reach menarche 2 years later than their healthy peers (395). Older studies show that delayed puberty is present especially in girls with CF despite good clinical status, with an association of delayed pubertal onset especially in those with the  $\Delta F508$  mutation (396). However, a recent retrospective study including 729 contemporary children with CF, showed that delayed onset of puberty was not a common occurrence (379)

Adolescents with CF may have lower peak HV compared with healthy adolescents with constitutional delay in growth and puberty (397). Those individuals with CF with delayed puberty appear to also have poorer HV during pubertal progression (4,379). One study reporting body proportions in a group of younger adolescents with CF showed that their legs were shorter than trunks, although pubertal assessment was not reported (5). Delayed puberty and short stature in CF correlated with less participation in social activities, which may be related to the degree of pulmonary function and disease state. Delayed puberty in CF was associated with poorer degree of ideal formation and less positive body attitude (398).



Table 7 summarizes studies with information on AH in CF (4,379,388,399-403). Interpretation of AH prognosis in CF from published studies is difficult given the fact that it is possible that mortality in some of the more severely affected individuals in adolescence may lead to more favorable AH of those studies with measurements conducted in adulthood. On the other hand, survival and treatment have also improved over the last few decades.

The existing literature of growth in CF suggests that nutritional issues and pulmonary exacerbations are not sufficient to explain the growth abnormalities in these children. There is now sufficient evidence to suggest that poor growth in CF is already seen in the neonatal period and that CF genotype ( $\Delta F508$ ) plays a contributing role. Whether this is due to underlying chronic inflammation or other unknown factors is yet to be determined. In adolescence, further worsening of growth and pubertal disorders may herald the onset of CF related diabetes and this requires early diagnosis and treatment, even though growth may not fully normalize with insulin therapy. The complex interplay between CF genotype, inflammation, nutritional and endocrine perturbations on growth requires further investigation. The impact of CF neonatal screening on improvement in long term growth outcome needs clarification.

### **7.3 Systemic abnormalities in GH/IGF-1 axis in children with CF**

In CF, it is generally accepted that GH resistance also exists although studies of GH secretion is limited. Using arginine and clonidine as pharmacological stimulant of the GH axis in a small group of adolescents with CF, approximately 50% had peak GH levels  $< 6$  mcg/L and IGF-1 SDS -0.5, suggesting that relative GH resistance and GH insufficiency can occur. It was unclear if sex steroid priming was used in this group of children with delayed puberty as bone age was delayed at least by 2.5 years (404).

Low IGF-1 and IGFBP-3 have been previously reported in studies in children with CF and show associations with pulmonary outcomes. In a study of a group of prepubertal and pubertal children, IGF-1 SDS was -1.2 SD and IGFBP-3 SD was -0.7 during acute pulmonary exacerbation, although another study reported low IGF-1 with normal IGFBP-3 (365). IGF-1

correlated with forced expiratory volume 1 (FEV1) and forced vital capacity (FVC); whereas IGFBP-3 correlated with FVC. (405). In a group of prepubertal children with CF, systemic IGF-1 and bioavailability of IGF-1 correlated with serum TNF- $\alpha$ , providing further evidence to the role of inflammation on the GH-IGF axis in these children. Systemic IGF-1 showed an association with height in children with CF although the relationship is modest at best (366,406-408). In addition, systemic IGF-1 in CF may also be associated with weight, protein catabolism (408), lean body mass (409) and pulmonary function (405,410).

Other studies report abnormalities in IGF binding proteins with normal systemic IGF-1 in CF in particular significantly lower IGFBP-3 and higher IGFBP-1 (406). Reduction in bioavailability of IGF-1 due to abnormalities in IGF binding proteins could account for the growth failure in CF (366,411) or alternatively “normal” IGF-1 in the face of growth failure in CF could also point to IGF-1 resistance. The direct role of IGFBP-1 on growth is unclear, although it shows an association with insulin secretion in CF, suggesting that IGFBP-1 may have a role in growth impairment via its effects on glucose homeostasis in CF (237). Changes in IGF-1 and bioavailability of IGF-1 also correlated with progressive insulin deficiency (412,413). Finally, IGFBP-2 has also been reported to be higher in CF compared to healthy controls. Change in IGFBP-2 was associated with changes in IL-6 over a 12 months period (366).

In summary, systemic evaluation of the GH-IGF axis in CF have produced mixed results. Low IGF-1 may be present in infants with CF within the first few weeks of life. The interlink of IGFBP-1 with insulin secretion and IGFBP-2 with inflammation may provide further insight into growth failure in CF, but comprehensive studies of the IGF axis and the contribution to linear growth are needed.

#### **7.4 Efficacy of rhGH in CF**

Clinical trials of the use of rhGH in CF have recently been evaluated in two systematic reviews including meta-analysis of published studies (414,415). Both reviews have included studies where height or growth rate were not reported as some of the published

studies have been powered to assess the effects of rhGH on metabolic consequences, body composition and disease parameters.

For this review, we have focused on studies of rhGH in CF with growth outcomes: Table 8 (416-421) and Table 9 (422-427). To date, there are 6 RCT of rhGH therapy on linear growth in children with CF. The longest duration of rhGH clinical trials in CF currently in the literature is 12 months. Change in Ht SDS with rhGH treatment over 12 months in CF range from +0.2 to +0.6. The majority of published trials in CF have used rhGH at a dose of 0.3 mg/kg/wk. One RCT consisted of two treatment groups; a lower dose rhGH at 0.273mg/kg/wk and a higher dose rhGH at 0.49 mg/kg/wk in comparison to a untreated group of controls (425). Both doses of rhGH in that study led to significantly better growth rate over a short term period of 6 months but there appears to be a dose dependency of rhGH dose on linear growth. It is worth noting that current clinical studies have excluded individuals with CF who have abnormalities of glucose homeostasis/ CF related diabetes and those who are colonized with *Burkholderia cepacia*. These reflect a sub-group of individuals who may be more severely affected who may be more likely to present with growth failure in the clinical practice to pediatric endocrinologists. It is therefore possible that rhGH may be less effective in these individuals and care must be taken in extrapolating results of current clinical trials of rhGH in CF when faced with clinical decisions of the role of rhGH in such individuals.

The three largest RCT of rhGH in CF all show that HV is approximately 150% higher in the rhGH treated group compared with control/placebo (422,424,425). In the study by Schnabel et al including two doses of rhGH, the “lower” dose of rhGH was comparable to the dose used by Hardin et al (424) and Stavley et al (422). In that study, height velocity in the group treated with the “higher” dose of rhGH of 0.49 mg/kg/week was approximately 180% higher than the control group; whereas height velocity in the group treated with the “lower” dose of 0.273 mg/kg/wk was approximately 150% higher than the control group (425)

The individuals included in the RCT by Schnabel et al (425) were in mid adolescents as the inclusion criteria was bone age of 8-18 years, whereas the studies by Hardin et al (424) and Stavley et al (422) were younger, pre pubertal at baseline. Pubertal progression was

reported by Stalvey et al (422) and did not differ between the rhGH and control group. Hardin et al (424) and Schnabel et al (425) reported no progression in bone age over the treatment period. No individual trial has reported response to rhGH depending on pubertal staging. In the meta-analysis of pooled data by Phung OJ et al (414), prepubertal children appeared to have greater increase in HV compared to pubertal children, whereas pubertal children appear to have better weight gain than prepubertal children with CF treated with rhGH. In the trial by Hardin et al a sub-analysis of change in Ht SDS was similar in those with Ht SDS < -2.2 and those with Ht SDS > -1.2 (424).

Short term studies of up to 12 months in children and adolescents with CF, show improvement in Ht SDS of +0.2 to +0.6 SD. However, none of the clinical trials have included older adolescents with CF related diabetes and therefore the efficacy of rhGH in these adolescents is unknown. Given the information that suggests that children with CF are already shorter at birth and in infancy with low IGF-1 levels, there is a case to consider future clinical trials of rhGH in younger children. Children with the  $\Delta F508$  genotype should also be targeted for future rhGH studies given the strong link with growth failure in those with the genotype. Compared with JIA and IBD, published trials of rhGH in CF have included relatively large number of subjects but duration of follow-up is only 6-12 months. Conducting clinical trials in these individuals can be challenging given the rest of the burden of clinical care of CF and quality of life measures should be evaluated in future studies.

## **7.5 Factors affecting growth response to rhGH in CF**

### **7.5.1 Disease and glucocorticoid**

Clinical studies of rhGH in CF have not related clinical outcome, pulmonary function or GC use with responsiveness to rhGH therapy.

### **7.5.2 Systemic IGF-1**

In CF, pooled data from subjects previously enrolled in clinical trials of rhGH revealed that IGF-1 was significantly correlated with height and growth rate (408).

## **7.6 Efficacy of rhGH on disease process in CF**

A role of rhGH in improvement of pulmonary disease in CF has been postulated to be due to increase in absolute lung volume as a result of increased growth. Another mechanism could be due to improvement in lean body mass via the potential anabolic effect of rhGH. In individuals with CF, the ability of alveolar macrophages to kill *Pseudomonas aeruginosa* was reduced compared with healthy controls and this was associated with reduction in lower IGF-1 levels from broncho-alveolar lavage. Exposure of the macrophages to IGF-1 enhanced their ability to kill *Pseudomonas* suggesting that the GH-IGF axis may have a role in regulation of the immune system in CF (428). Preliminary evidence also suggest that IGF-1 may increase cystic fibrosis transmembrane conductance regulator which is defective in individuals with CF, leading to altered airway composition and therefore pulmonary infections (429).

In CF, several rhGH studies have shown a reduction in number of days of hospitalization and the use of intravenous antibiotics (424,427). These are from studies which did not include a placebo group. Current rhGH studies in CF have shown differing results on objective measures of pulmonary function. One study noted significant improvement in exercise tolerance measured by peak power output and VO<sub>2</sub> max on cycle ergometer in the rhGH treated children (426). Another rhGH study in a group of children and young adults with CF (10-23 years) showed that maximal work load and VO<sub>2</sub> max increased significantly with rhGH therapy over 12 months (430). In randomized studies in CF, FVC and percentage predicted FVC increased significantly in the rhGH group. FEV<sub>1</sub> on the other hand increased significantly in rhGH treated children but not percentage predicted FEV<sub>1</sub>.

It is generally accepted that pulmonary function should be reported as percentage predicted (normalized to height). It is possible that improvement in pulmonary function may not parallel improvement in height in the short term and that objective improvement in lung function may happen later. In addition, a very short child with poor lung function may have a relatively “normal” percentage predicted values as his/her lung function has been matched to a younger shorter child, making interpretation of changes in pulmonary status in growth

promoting studies difficult. Future studies should include newer methods of assessing pulmonary disease in CF which are more sensitive to short term changes in respiratory status and may not be related to body size.

## **8. Side effects of rhGH therapy in chronic disease**

### **8.1 Glucose tolerance and insulin sensitivity**

rhGH treatment has been reported to be associated with a decrease in insulin sensitivity in some of the studies in children Turner syndrome (431,432), Prader Willi Syndrome (433,434), small for gestational age (435) and idiopathic short stature (436). It may also be associated with an increased risk of type 2 diabetes mellitus in children with risk factors such as Turner Syndrome, Prader Willi Syndrome (437). Some of these conditions themselves have an increased risk of reduction insulin sensitivity.

Children with inflammatory conditions may also be at risk of developing insulin resistance as a result of the inflammatory process (438) as well as the use of concurrent GC therapy (439). Approximately 50% of children with chronic rheumatic conditions on GC had impaired glucose tolerance on oral glucose tolerance test (OGTT) (255). In JIA, rhGH is associated with reduction in insulin sensitivity, reflected by increased fasting and stimulated insulin levels (261,263,268). In 43 children with JIA who had previously been treated with rhGH, impaired glucose tolerance was observed in 37% and transient diabetes mellitus in 5%. There was a higher incidence of impaired glucose tolerance in those who were treated late possibly reflecting a longer duration of disease and greater exposure to exogenous glucocorticoid. The two cases that developed frank diabetes were also overweight (440).

In children with IBD, therapy with rhGH over a six months period led to increase in fasting insulin with no abnormalities of glucose homeostasis. This cohort consisted of the majority of individuals who have not been previously treated with GC. Despite the fact that fasting insulin levels increased following rhGH therapy in IBD, the clinical significance of this is still unclear. The highest level of fasting insulin was 16 mU/L in a group of individuals in mid and late adolescence (351). A recent consensus suggests that the threshold of fasting

insulin for diagnosis of insulin resistance should be a level of  $\geq 30$  mU/L for those in tanner stage 3 and 4; and  $\geq 20$  mU/L for those individuals in tanner stage 5 (441).

As mentioned previously, current clinical trials in CF have included individuals with no abnormalities in glucose homeostasis and/or CF related diabetes. The impact of rhGH treatment on glucose homeostasis in a child with CF and established diabetes is unknown. In current clinical trials in CF, rhGH increases fasting glucose but there were no changes in post prandial or peak glucose with OGTT. Increased fasting glucose was not seen in shorter term rhGH studies (6 months). OGTT results were only available from short term 6 months studies. HbA1C also did not change with rhGH therapy (414). However, given the glucose variability in CF related diabetes, future studies should evaluate glucose homeostasis using continuous glucose monitoring, which is increasingly recommended for diagnosis of CF related diabetes (25,442).

To summarize this section, studies of the use of rhGH in children with chronic disease treated with GC (JIA studies) show that its use may lead to impaired glucose tolerance and type 2 diabetes in approximately 50% and 5% of treated individuals, respectively. In published rhGH trials in IBD and CF, where use of GC is low, reduction in insulin sensitivity is seen but no diabetes mellitus have been reported, although duration of rhGH treatment in those studies are relatively short. The clinical significance of raised insulin especially in the prepubertal child during rhGH treatment on long term metabolic outcome in these children is unclear. The extent by which rhGH therapy can affect glucose homeostasis in individuals with CF and established diabetes needs further exploration.

## **8.2 Skeletal complications**

Skeletal complications such as scoliosis (443), Legg-Calve-Perthes disease (444,445), slipped capital femoral epiphysis (446,447) and osteochondritis (448) have been described in children following commencement of rhGH therapy but systematic surveillance of the spine especially in rhGH trials in children with chronic inflammatory disease has not taken place. In one study, lumbar lordosis and scoliosis developed in similar numbers of rhGH and control

subjects (5 in each group) with JIA (39). Only one patient with JIA treated with rhGH developed hip osteochondritis (263); whereas there are no reports of Legg-Calve-Perthes disease in JIA or IBD. Slipped upper femoral epiphyses have never been reported in this group of patients.

There is a concern that the use of higher doses of rhGH may advance bone age and accelerate pubertal progression but this has not been observed in children with JIA and IBD (39,351). Age of onset of puberty in children with JIA with follow-up data at final adult height did not differ between the rhGH and control group (39)

### **8.3 Disease complications**

The current published trials in children with chronic disease do not raise concerns about rhGH worsening disease process. Previous studies in GHD and non GHD children following rhGH injections suggest that the immune system may be activated although it is unclear if the net effect is an up regulation or down regulation of inflammatory cytokines (354-358). Six months therapy with rhGH was not associated with any significant changes in a range of pro- and anti-inflammatory cytokines in children with IBD (Ref).

Intestinal fibrosis leading to strictures is a complication of CD, due to an excessive, irreversible healing response to chronic inflammation. This is associated with overgrowth of the muscularis mucosa, muscularis propria, excessive collagen deposition (449) and mesenchymal cell hyperplasia (450). In a rat model of colitis, rhGH was reported to stimulate collagen accumulation in intestinal myofibroblasts (451) but rhGH has also been reported to reduce the severity of fibrosis via the induction of suppressor of cytokine signaling proteins (452). There is a need to study this further especially when rhGH is administered in IBD.

### **8.4 IGF-1 levels and cancer**

The use of replacement rhGH therapy for GH deficiency in children previously treated for childhood cancer has not been shown to be associated with tumor recurrence or development of new tumors. The Childhood Cancer Survival Study (CCSS) identified an



increased risk of meningioma in children treated with rhGH (453,454), although most of those children had also received radiation to the brain which by itself could be associated with the development of meningioma (453,454). In addition, the CCSS did not match rhGH treated patients with rhGH naive patients matched for potential confounders for development of second tumors. A recent study that matched for age, site of primary diagnosis, date of radiotherapy, radiation dose and fractionation found no increased risk of tumor recurrence or development of second tumors in rhGH treated patients (455).

An association between increased risks of malignancies has been reported in children with JIA (456-458) and IBD (459,460) which may seem to be unrelated to treatment with immunomodulators and biologic therapy. Currently there are no reported associations between cancer in children with JIA and IBD treated with rhGH. Patients with acromegaly with excessively high GH and IGF-1 levels have an increased risk for thyroid, breast and colorectal carcinoma (461-463). Preliminary evidence also suggests that patients with IGF-1 deficiency due to genetic mutations in the GH receptor with very low/undetectable IGF-1 levels appear to be protected from cancer development (464).

In JIA and IBD, rhGH leads to an increase in IGF-1 and IGFBP-3 levels. Bechtold et al's RCT of rhGH (0.33 mg/kg/wk) in JIA showed, reassuringly, that IGF-1 and IGFBP-3 remained within the normal reference ranges. Average IGF-1 SDS and average IGFBP-3 SDS during rhGH were -0.93 and -0.24, respectively (39). Following rhGH (0.53 mg/kg/wk) for active CD, IGF-1 SDS increased from -0.4 at baseline to +1.8 SD at 12 weeks and + 3.3 SD at 24 weeks. IGF-1 SDS was as high as +5SD at 24 weeks which is an issue to be of concern (350).

Even if systemic IGF-1 levels may not be excessively raised with relatively "high" dose rhGH in children with chronic disease, there is the concern that systemic IGF-1 levels may not reflect local expression of IGF-1 (465). Animal models of colitis treated with rhGH do not show increased expression of local IGF-1 (173,175). Suppressor of cytokine signaling 2 (SOCS2) which may be altered in chronic inflammation and which negatively regulates GH action, has been reported to limit intestinal GH action (466,467). It is possible that this may

be a protective mechanism against high systemic IGF-1 (68,468). However, in the mouse model, the protective effect of SOCS2 on the intestines was only seen in older animals. Clearly, long term surveillance of rhGH treated patients with JIA, IBD and CF is crucial.

## **9. IGF-1 and combined GH / IGF-1 in chronic inflammatory disease**

As discussed, GH mediates its effects on target tissues via direct and indirect effects (41). The direct effects of GH are those mediated via the GH receptor; indirect effects are mediated largely via GH related peptides like IGF-1 but also IGF binding proteins. Whilst systemic factors (GH and IGF-1) have independent effects on target organs like the growth plate, local IGF-1 levels may play a more important role in regulation of longitudinal growth.

Given the possibility of a state of functional GH resistance with resultant secondary IGF-1 insufficiency in chronic inflammation, rhIGF-1 maybe a therapeutic option for these children (469). The use of rhIGF1 in children with primary IGF-1 deficiency due to mutations in the GH receptor is effective in improving linear growth. As opposed to complete catch up growth that is seen in children with GH deficiency treated with rhGH, children with primary IGF-1 deficiency due to mutations in the GH receptor treated with long term rhIGF-1 still remain significantly short (470,471).

Whilst there are currently no studies of rhIGF-1 in children with JIA or IBD, one small randomized trial of rhIGF-1 (80 mcg/kg twice daily) compared with placebo, in 7 children with CF failed to show an effect on linear growth despite normalization of serum IGF-1. The study showed a reduction in insulin sensitivity with rhIGF-1 treatment. The dose of rhIGF-1 used in the study is within the recommended starting dose for children with primary IGF-1 deficiency. Doses up to 120 mcg/kg twice daily, can be used in those children (472). The lack of improvement of linear growth with conventional dose of rhIGF-1 in the study with CF may point to a degree of functional IGF-1 resistance. Therefore, higher doses of rhIGF-1 may be needed to be evaluated in future studies. The potential adverse effect of hypoglycemia, may preclude the use of higher dose of rhIGF-1.

Interestingly, systemic IGFBP-3 did not increase with rhIGF-1 in the study of children with CF. On the other hand, some but not all studies of rhGH in chronic inflammatory conditions have shown that IGFBP-3 can increase with rhGH treatment. rhIGF-1 may in fact reduce the level of IGFBP-3 and IGF-2 in children with idiopathic short stature (473). IGFBP-2 did increase with rhIGF-1 treatment in those children. There is also the theoretical possibility that rhIGF-1 administration may suppress endogenous GH secretion. In TNBS rats with colitis treated with rhIGF-1, there was a rise in IGF1 levels and improved linear growth, although growth rate was only 50% of those of control rats (138).

A trial of rhIGF1 in children with idiopathic short stature and “low” IGF1 who were approximately 7 years at baseline, also raised the concern that rhIGF-1 may accelerate skeletal maturation, which would be disadvantageous for adult height prognosis. Twelve children (14.1%) in the two rhIGF-1 arms (80 mcg/kg and 120 mcg/kg twice daily) as opposed to one (4.4%) in the control arm entered into puberty during the one year (473). This is in contrast to the use of higher dose of rhGH in idiopathic short stature which does not lead to increase in skeletal maturation and advancement of pubertal progression (474).

A pilot pharmacokinetic study of rh-IGF-1 at 120 mcg/kg/day in eight children with severe CD lead to significant increase in systemic IGF-1 with almost half the cohort reaching IGF-1 SDS > +2.0 (475). The authors developed a mathematical model that allows prediction of a dose of rhIGF1 that could be used to maintain systemic IGF-1 below +2.5 SD of the mean accounting for age, weight and PCDAI. Whether this mathematical model is valid over a longer period of time where changes like growth and puberty may play a greater role is unclear. In addition, given the fluctuating nature of CD, it is unclear how well the PCDAI may reflect disease activity in this model. A randomized trial of dose titration of rhGH based on systemic IGF-1 in children born small for gestational age show less favorable growth response, although IGF-1 levels remained in the physiological ranges in the dose titrated group (476) .

Given the importance of GH and IGF-1 in longitudinal growth, combined treatment with rhGH and rhIGF-1 may be more physiological and beneficial for growth. Reports of

combined use in humans show a higher serum concentration of IGF-1 in those who had combined therapy versus those who had IGF-1 alone, possibly related to the negative feedback effect of IGF-1 on pituitary GH secretion. A recent study in female rats, however showed that combined rhGH and rhIGF1 therapy did not lead to further improvement in linear growth despite an improvement in cortical bone mass (57). On the other hand, in an experimental rat model of uremia, combination therapy appears to be more effective than rhIGF-1 or rhGH alone as growth promoting therapy (477). The addition of rhGH to rhIGF-1 may reverse the insulin suppressive effects of the latter and may have anti-catabolic effects on protein synthesis and muscle mass in seven calorie restricted adults (478). Given the uncertainties of the efficacy of high dose rhGH in improving muscle mass in children with chronic inflammation thus far, combination therapy may confer advantages in that respect. Combining rhGH with rhIGF-1 may prevent the glucose lowering effect of IGF-1 (478). Up to 20% of children with idiopathic short stature treated with rhIGF1 120 mc/kg twice daily were hypoglycemic (478). The use of IGF-1 may itself counter the insulin-resistant state that may be induced by the use of high dose rhGH therapy in a group of children who may be insulin resistant due to their state of chronic inflammation as well as the use of GC.

Given the evidence of relative GH resistance in children with chronic inflammation, there is good biological rationale to explore the use of rhIGF1 on its own or in combination with rhGH in future well designed collaborative RCTs.

## **10. Summary and perspective**

### **10.1 Clinical studies of growth and pubertal disorders**

It is clear that clinical outcome studies on growth, pubertal development and AH in JIA, IBD and CF treated with contemporary treatment regimens are needed. Height, especially AH, needs to be interpreted in the context of the child's midparental height. As degrees of delayed puberty can occur in these children, interpreting HV needs to be in the context of bone age or pubertal staging. The use of change in Ht SDS may be a better method of defining poor growth given the paucity of normative longitudinal data for HV. Ideally,

newer studies should consider reporting growth problems in these children by describing Ht SDS and change in Ht SDS or HV adjusted for bone age/puberty (372). Undoubtedly, studies of AH are needed from contemporary groups of children with chronic disease, due to the constantly changing landscape of therapies of chronic disease. Published data on AH may never be reflective of current cohort of individuals managed in the clinic, given the time it takes to acquire information on long term growth outcome and the possibility of new therapies.

Outstanding questions in the clinical aspect of growth and pubertal disorders include:

- (1) What are the clinical predictors of persistent growth failure in children with chronic disease? Are there informative biomarkers eg disease parameters, inflammatory cytokines, genetic factors or novel biomarkers early on in the course of the disease?
- (2) What are early predictors for catch-up growth following anti-cytokine therapy in JIA and IBD? What is the utility of systemic vs local markers of inflammation for prediction of growth response? Can composite assessment of systemic inflammation and systemic markers of the GH/IGF axis increase the prediction?
- (3) How much does poor growth and pubertal disorders contribute to abnormal bone accrual and muscle development in children with chronic disease?
- (4) What is the impact of poor growth, short stature and delayed puberty on the quality of life of adolescents with chronic disease and do they differ from children with no underlying chronic condition? Are adolescents with chronic disease more bothered about short stature/poor growth than delayed puberty?

## **10.2 Systemic abnormalities of GH/IGF-1 in chronic disease**

This review identified a number of heterogenous studies of the GH/IGF-1 axis suggesting multiple defect in the secretion and sensitivity of the GH/IGF-1 axis. Studies have evaluated IGF-1 and IGFBP-3, although ALS have not been extensively studied in these conditions.

Important questions to be answered in this area include:

- (1) How does inflammation impact on formation of the ternary complex and how does this change following therapy of chronic disease especially anti-cytokine?
- (2) What is the link between inflammation and comprehensive studies of the ternary complex?
- (3) The direct role of IGF binding proteins on long bone growth in chronic disease is unclear. We have touched on the possible role of IGFBP-1 and -2 which requires further clarification. A consideration of the differential effects of all the binding proteins in chronic disease is needed. For instance, is there compensatory changes in IGF binding proteins with chronic inflammation and what is the impact on regulation of growth in chronic disease?
- (4) What is the IGF-1 response to rhGH injections as part of the IGF- generation test and how does this GH sensitivity change with disease factors?

### **10.3 Growth plate regulation in chronic disease**

Recent growth plate studies have demonstrated that pro-inflammatory cytokines have a direct effect at the level of the growth plate. GC treatment and malnutrition can lead to impairment at the level of the growth plate.

Critical research questions to be answered in this area which may impact on clinical management and research include:

- (1) How does cytokine, GC and malnutrition impact on local GH and IGF-1 signalling?
- (2) How do intrinsic growth plate factors interact with extrinsic systemic factors in the regulation of growth in chronic disease?
- (3) What is the role of IGF binding proteins at the local level in chronic disease?
- (4) What is the interaction between FGF21 and cytokines and how may that impact on local bone growth/local growth factor signalling?

### **10.4 Endocrine growth promoting therapies in chronic disease**

There is a need to perform larger, more conclusive studies of rhGH therapy which explore the issues raised in this review. Close collaboration with pediatric rheumatologists, gastroenterologists and respiratory clinicians would ensure that appropriate assessment of disease status is performed. Given the complexity of the management of children with chronic disease and ongoing burden of the disease, the opinion of the young person and their families should be sought in the design of future therapeutic trials of growth promoting therapies.

Disease activity should be assessed using a range of methods. For CD, caution is needed if the PCDAI is used. Data should be presented for the different domains of the PCDAI, if that is to be used as a disease marker. In CF, more objective assessment of disease should be evaluated in future studies other than hospitalizations. Evaluation of inflammatory state using inflammatory cytokines should include assessment of more than 1 cytokine and in addition measurements of cytokines at local organs (eg gastrointestinal tract, synovial fluid) may be more accurate but more challenging to obtain in research studies.

Research agenda to be considered include:

(1) A definitive trial of rhGH on improving growth in children with chronic disease especially in children with IBD is needed. This would require collaboration at a national level at the least.

(2) It is clear that a degree of functional GH insensitivity exists in chronic disease and a higher dose of rhGH may be needed. A study on dose comparison addressing longer term growth outcome and potential adverse events (abnormalities in glucose homeostasis) in these groups of children are needed. Preliminary evidence from the dose comparison trial of rhGH in CF suggest that the percentage increase in growth rate with the “higher” dose of rhGH leads to marginal improvement in growth velocity (425) .

(3) It is unclear whether the dose of rhGH should be titrated by systemic IGF-1 or growth response and this requires further research.

(4) It is possible that in most children a short course of therapy for 12 months or during periods of poor growth may be sufficient for improving growth and

prolonged therapy may not be necessary. Intermittent therapy with rhGH during periods of relatively poor growth may also be more cost effective. This method of using rhGH as opposed to continued use until final height needs further exploration.

(5) Future rhGH studies should also examine the effect of therapy on disease, bone health, body composition, cardiovascular health and quality of life in these children with chronic disease. It is also unclear if long term outcome of addition of rhGH to sex steroid confers better height prognosis in those groups of children who are growing slowly with delayed puberty.

(6) Given that some children with chronic disease continue to grow slowly with anti-cytokine therapy (18) and that improvement in height with anti-cytokine maybe marginal (21,219), the role of rhGH in addition to anti-cytokine therapy should also be explored in future studies

(7) The impact of pubertal induction on growth in chronic disease deserves higher research priority. There are numerous unanswered questions on the dose, duration, route of administration and timing of introduction of sex steroid in chronic disease.

(8) Given the relative GH resistant state in chronic inflammation, the role of combination therapy of rhIGF-1 with rhGH or rhIGF-1 on its own may need to be explored in future well designed trials.

(9) Given the range in deficits in systemic levels of GH/IGF-1 in chronic disease, can these be used to determine choice of growth promoting therapies ie rhGH, rhIGF-1 or combination therapies and therefore growth response?

## **11. Recommendations for clinical practise**

In the absence of extensive data, the off label use of rhGH in chronic disease in countries where rhGH may be available needs to be considered very carefully and discussed thoroughly with the young person and the family. rhGH therapy should only be considered



after the primary disease has been treated as aggressively as possible, GC use has been minimized and the nutritional status has been optimized. In patients with delayed puberty, this should be addressed before the consideration of rhGH, although data on pubertal induction in these children is limited (479,480). If rhGH is used, the definition of response in children with chronic disease is unclear but may be better defined as change in Ht SDS ( $> +0.5$  SD over twelve months).

It is our opinion that fasting glucose and HbA1C should be considered in all children with chronic disease prior to commencement of rhGH therapy. Ideally, an OGTT should be performed at baseline as well. Given the challenges in interpretation of insulin levels in groups of children who are in puberty, there is a case to omit its measurement in the clinical monitoring of children with chronic disease treated with rhGH therapy. It is our opinion that results from an OGTT may be more useful for clinical decision making and should therefore be performed at annual intervals following rhGH therapy as fasting glucose and HbA1C are poor predictors of abnormal glucose homeostasis in children with chronic disease treated with rhGH (Simon 2010). In CF, there may be a role of continuous glucose monitoring for monitoring of glucose homeostasis. In children with evidence of diabetes (eg CF diabetes) or impaired glucose tolerance at baseline, there needs to be careful discussion with the family regarding the risk and benefit of rhGH therapy. In our opinion, the detection of impaired glucose tolerance requires reconsideration of therapy. If oral GC dose can be reduced, we recommend close monitoring with earlier re-evaluation with OGTT. If this is not possible, or type 2 diabetes mellitus is diagnosed on OGTT, reduction of dose of rhGH is recommended, provided that growth response is favourable.

Annual assessment of IGF-1 level should be undertaken but interpretation of IGF-1 levels needs to take into account of delayed puberty in these children. Regular assessment of puberty and annual bone age is also important. Care must be taken in the interpretation of bone age in children with inflammatory arthritis. Ideally, this should be performed in the hand not affected by arthritis.

## **12. Conclusion**

The pathophysiology of growth failure in children with chronic inflammation is multi-factorial although the precise mechanism of the effects of cytokine, glucocorticoid and malnutrition on systemic and local growth factors is still unclear. The relative contribution of those factors on growth failure and the GH/IGF axis is unclear. Clinical studies in children with JIA, IBD and CF point to multiple levels of defect of the GH/IGF-1 axis although comprehensive evaluation of systemic growth factors in these children especially in relation to modern therapy is still limited. The interaction of the endocrine effects of the GH/IGF-1 axis with local growth plate regulating factors and the impact on linear growth in chronic disease is unclear and needs to be studied.

Although there is some preliminary evidence of the effects of rhGH on short term linear growth in children with chronic disease, catch-up growth maybe incomplete. Longer term treatment studies and its effects on adult height in these children should be performed. The impact of improvement in linear growth on quality of life in these children is unknown. The cost effectiveness and implication of treatment (burden of injections) needs careful consideration. Most children with chronic inflammatory disease will achieve their genetic potential with aggressive disease control and nutritional support. A small subgroup may have persistent growth failure leading to significant short stature and these children may benefit from adjuvant growth promoting therapy. Collaborative clinical trials and translational studies are needed and to be encouraged.

## **Disclosure**

SCW has received clinical and research fellowship grants from Novo Nordisk UK, Novo Nordisk Australia and has received speaker's honorarium from Sandoz. SFA has received consultation fees and research grants from Ipsen and Novo Nordisk UK. The other authors have no conflict of interest to declare pertaining to this submission.

## 12. References

1. Bechtold S, Roth J. Natural history of growth and body composition in juvenile idiopathic arthritis. *Hormone Research* 2009; 72 Suppl 1:13-19
2. Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? *Digestive Diseases* 2009; 27:404-411
3. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. *Gut* 1993; 34:939-943
4. Zhang Z, Lindstrom MJ, Lai HJ. Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis. *J Pediatr* 2013; 163:376-382
5. Umlawska W, Susanne C. Growth and nutritional status in children and adolescents with cystic fibrosis. *Annals of Human Biology* 2008; 35:145-153
6. Mason A, Malik S, Russell RK, Bishop J, McGrogan P, Ahmed SF. Impact of inflammatory bowel disease on pubertal growth. *Hormone research in pediatrics* 2011; 76:293-299
7. Simon D, Leger J, Fjellestad-Paulsen A, Crabbe R, Czernichow P, Group SGAS. Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens. *Hormone Research* 2006; 66:118-123
8. Sawczenko A, Ballinger AB, Croft NM, Sanderson IR, Savage MO. Adult height in patients with early onset of Crohn's disease. *Gut* 2003; 52:454-455; author reply 455

- | 1812 9. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features  
| 1813 affecting final adult height in patients with pediatric-onset Crohn's disease.  
| 1814 Pediatrics 2006; 118:124-129
- | 1815 10. Mason A, Malik S, McMillan M, McNeilly JD, Bishop J, McGrogan P, Russell  
| 1816 RK, Ahmed SF. A Prospective Longitudinal Study of Growth and Pubertal  
| 1817 Progress in Adolescents with Inflammatory Bowel Disease. Horm Res  
| 1818 Paediatr 2014;
- | 1819 11. MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth  
| 1820 disorders associated with pediatric chronic inflammatory diseases (review).  
| 1821 International Journal of Molecular Medicine 2006; 18:1011-1018
- | 1822 12. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol  
| 1823 Hepatol 2014; 11:601-610
- | 1824 13. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory  
| 1825 cytokines in inflammatory bowel disease growth retardation. Journal of  
| 1826 Pediatric Gastroenterology & Nutrition 2006; 43:144-155
- | 1827 14. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. J Adolesc Health  
| 1828 2002; 31:192-200
- | 1829 15. Tanner JM, Davies PS. Clinical longitudinal standards for height and height  
| 1830 velocity for North American children. Journal of Pediatrics 1985; 107:317-  
| 1831 329
- | 1832 16. Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth  
| 1833 spurt of boys and girls of the Harpenden growth study. Ann Hum Biol 1976;  
| 1834 3:109-126
- | 1835 17. Borzutzky A, Martinez-Aguayo A. Accelerated carpal bone maturation in  
| 1836 juvenile idiopathic arthritis: pitfall for bone age measurement. J Pediatr  
| 1837 Endocrinol Metab 2011; 24:551

18. Malik S, Mason A, Bakhshi A, Young D, Bishop J, Garrick V, McGrogan P, Russell RK, Ahmed SF. Growth in children receiving contemporary disease specific therapy for Crohn's disease. Archives of Disease in Childhood 2012; 97:698-703
19. Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M. Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy. European Journal of Pediatrics 2007; 166:775-784
20. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. Journal of Pediatric Gastroenterology & Nutrition 2011; 53:11-25
21. Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR, on behalf of the British Society for P, Adolescent Rheumatology Etanercept Cohort S. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) 2015;
22. Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR, British Society for P, Adolescent Rheumatology Etanercept Cohort S. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) 2015; 54:1279-1285
23. Cheung MS, Bridges NA, Prasad SA, Francis J, Carr SB, Suri R, Balfour-Lynn IM. Growth in children with cystic fibrosis-related diabetes. Pediatr Pulmonol 2009; 44:1223-1225
24. Hameed S, Morton JR, Field PI, Belessis Y, Yoong T, Katz T, Woodhead HJ, Walker JL, Neville KA, Campbell TA, Jaffe A, Verge CF. Once daily insulin

| 1865 detemir in cystic fibrosis with insulin deficiency. Arch Dis Child 2012;  
| 1866 97:464-467

| 1867 25. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in  
| 1868 childhood. Horm Res Paediatr 2010; 73:15-24

| 1869 26. Wong SC, Catto-Smith AG, Zacharin M. Pathological fractures in paediatric  
| 1870 patients with inflammatory bowel disease. Eur J Pediatr 2014; 173:141-151

| 1871 27. Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a  
| 1872 growing problem. Current Opinion in Endocrinology Diabetes and Obesity  
| 1873 2013; 20:547-552

| 1874 28. Brabnikova Maresova K. Secondary osteoporosis in patients with juvenile  
| 1875 idiopathic arthritis. J Osteoporos 2011; 2011:569417

| 1876 29. Franklin SL, Geffner ME. Growth hormone: the expansion of available  
| 1877 products and indications. Pediatr Clin North Am 2011; 58:1141-1165, x

| 1878 30. Hughes IP, Choong CS, Harris M, Ambler GR, Cutfield WS, Hofman PL, Cowell  
| 1879 CT, Werther G, Cotterill A, Davies PS, Australasian Paediatric Endocrine G.  
| 1880 Growth hormone treatment for Turner syndrome in Australia reveals that  
| 1881 younger age and increased dose interact to improve response. Clinical  
| 1882 Endocrinology 2011; 74:473-480

| 1883 31. Wasniewska M, Aversa T, Mazzanti L, Guarneri MP, Matarazzo P, De Luca F,  
| 1884 Lombardo F, Messina MF, Valenzise M. Adult height of girls with Turner  
| 1885 syndrome treated from before six years of age with a fixed per kg growth  
| 1886 hormone dose. Eur J Endocrinol 2013;

| 1887 32. Wasniewska M, De Luca F, Bergamaschi R, Guarneri MP, Mazzanti L,  
| 1888 Matarazzo P, Petri A, Crisafulli G, Salzano G, Lombardo F. Early treatment  
| 1889 with GH alone in Turner syndrome: prepubertal catch-up growth and waning  
| 1890 effect. Eur J Endocrinol 2004; 151:567-572

- 1891 33. Lem AJ, van der Kaay DC, de Ridder MA, Bakker-van Waarde WM, van der  
1892 Hulst FJ, Mulder JC, Noordam C, Odink RJ, Oostdijk W, Schroor EJ, Sulkers  
1893 EJ, Westerlaken C, Hokken-Koelega AC. Adult height in short children born  
1894 SGA treated with growth hormone and gonadotropin releasing hormone  
1895 analog: results of a randomized, dose-response GH trial. *Journal of Clinical*  
1896 *Endocrinology & Metabolism* 2012; 97:4096-4105
- 1897 34. Ranke MB, Martin DD, Eehalt S, Schwarze CP, Serra F, Wollmann HA,  
1898 Schweizer R. Short children with low birth weight born either small for  
1899 gestational age or average for gestational age show similar growth response  
1900 and changes in insulin-like growth factor-1 to growth hormone treatment  
1901 during the first prepubertal year. *Hormone research in pdiatrics* 2011;  
1902 76:104-112
- 1903 35. Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, Cowell  
1904 CT, Werther G, Cotterill A, Davies PS, Australasian Paediatric Endocrine G.  
1905 Growth hormone regimens in Australia: analysis of the first 3 years of  
1906 treatment for idiopathic growth hormone deficiency and idiopathic short  
1907 stature. *Clinical Endocrinology* 2012; 77:62-71
- 1908 36. Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G, Deal C,  
1909 Drop SL, Rappold G, Cutler GB, Jr. GH treatment to final height produces  
1910 similar height gains in patients with SHOX deficiency and Turner syndrome:  
1911 results of a multicenter trial. *J Clin Endocrinol Metab* 2013; 98:E1383-1392
- 1912 37. Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden  
1913 RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman  
1914 JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J,  
1915 Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van  
1916 Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-  
1917 Koelega AC. Eight years of growth hormone treatment in children with

| 1918 Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol  
| 1919 Metab 2013; 98:4013-4022

| 1920 38. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic  
| 1921 kidney disease. Cochrane Database of Systematic Reviews 2012; 2:CD003264

| 1922 39. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H,  
| 1923 Schwarz HP. Growth hormone increases final height in patients with  
| 1924 juvenile idiopathic arthritis: data from a randomized controlled study.  
| 1925 Journal of Clinical Endocrinology & Metabolism 2007; 92:3013-3018

| 1926 40. Lui JC, Nilsson O, Baron J. Recent research on the growth plate: Recent  
| 1927 insights into the regulation of the growth plate. J Mol Endocrinol 2014;  
| 1928 53:T1-9

| 1929 41. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later.  
| 1930 Journal of Clinical Endocrinology & Metabolism 2007; 92:4529-4535

| 1931 42. Rosello-Diez A, Joyner AL. Regulation of long bone growth in vertebrates; it  
| 1932 is time to catch-up. Endocr Rev 2015:er20151048

| 1933 43. Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that  
| 1934 the direct growth-promoting effect of growth hormone on cartilage in vivo  
| 1935 is mediated by local production of somatomedin. Proc Natl Acad Sci U S A  
| 1936 1986; 83:7932-7934

| 1937 44. Salmon WD, Jr., Burkhalter VJ. Stimulation of sulfate and thymidine  
| 1938 incorporation into hypophysectomized rat cartilage by growth hormone and  
| 1939 insulin-like growth factor-I in vitro: the somatomedin hypothesis revisited. J  
| 1940 Lab Clin Med 1997; 129:430-438

| 1941 45. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth  
| 1942 hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev  
| 1943 Biol 2001; 229:141-162



- 1944 46. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting  
1945 dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting  
1946 longitudinal bone growth. *Journal of Endocrinology* 2004; 180:247-255
- 1947 47. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R,  
1948 Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA.  
1949 Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I  
1950 but independent of Stat5. *Journal of Clinical Investigation* 2000; 106:1095-  
1951 1103
- 1952 48. Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ.  
1953 Insulin-like growth factor regulates peak bone mineral density in mice by  
1954 both growth hormone-dependent and -independent mechanisms.  
1955 *Endocrinology* 2003; 144:929-936
- 1956 49. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and  
1957 fibroblast growth factor, but not growth hormone, affect growth plate  
1958 chondrocyte proliferation. *Endocrinology* 2007; 148:3122-3130
- 1959 50. Wang Y, Nishida S, Sakata T, Elalieh HZ, Chang W, Halloran BP, Doty SB,  
1960 Bikle DD. Insulin-like growth factor-I is essential for embryonic bone  
1961 development. *Endocrinology* 2006; 147:4753-4761
- 1962 51. Yakar S, Isaksson O. Regulation of skeletal growth and mineral acquisition  
1963 by the GH/IGF-1 axis: Lessons from mouse models. *Growth Horm IGF Res*  
1964 2015;
- 1965 52. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal  
1966 growth and development in the absence of hepatic insulin-like growth  
1967 factor I. *Proceedings of the National Academy of Sciences of the United*  
1968 *States of America* 1999; 96:7324-7329
- 1969 53. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y,  
1970 Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O,

| 1971 Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H,  
| 1972 Domene H, Cohen P, Clemmons D, LeRoith D. Serum complexes of insulin-  
| 1973 like growth factor-1 modulate skeletal integrity and carbohydrate  
| 1974 metabolism. FASEB J 2009; 23:709-719

| 1975 **54.** Govoni KE, Lee SK, Chung YS, Behringer RR, Wergedal JE, Baylink DJ, Mohan  
| 1976 S. Disruption of insulin-like growth factor-I expression in type IIalpha  
| 1977 collagen-expressing cells reduces bone length and width in mice. Physiol  
| 1978 Genomics 2007; 30:354-362

| 1979 **55.** Wu Y, Sun H, Yakar S, LeRoith D. Elevated levels of insulin-like growth  
| 1980 factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null  
| 1981 mice. Endocrinology 2009; 150:4395-4403

| 1982 **56.** Wu S, Yang W, De Luca F. Insulin-Like Growth Factor-Independent Effects of  
| 1983 Growth Hormone on Growth Plate Chondrogenesis and Longitudinal Bone  
| 1984 Growth. Endocrinology 2015; 156:2541-2551

| 1985 **57.** Sundström K1 CT, Ohlsson C, Camacho-Hübner C, Sävendahl L. Combined  
| 1986 treatment with GH and IGF-I: additive effect on cortical bone mass but not  
| 1987 on linear bone growth in female rats. Endocrinology 2014; 155(12):4798-  
| 1988 4807

| 1989 **58.** Elis S, Wu Y, Courtland HW, Cannata D, Sun H, Beth-On M, Liu C, Jasper H,  
| 1990 Domene H, Karabatas L, Guida C, Basta-Pljakic J, Cardoso L, Rosen CJ,  
| 1991 Frystyk J, Yakar S. Unbound (bioavailable) IGF1 enhances somatic growth.  
| 1992 Dis Model Mech 2011; 4:649-658

| 1993 **59.** Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of  
| 1994 the growth plate. Hormone Research 2005; 64:157-165

| 1995 **60.** Kember NF. Cell population kinetics of bone growth: the first ten years of  
| 1996 autoradiographic studies with tritiated thymidine. Clin Orthop Relat Res  
| 1997 1971; 76:213-230

- 1998 61. Abad V, Meyers JL, Weise M, Gafni RI, Barnes KM, Nilsson O, Bacher JD,  
1999 Baron J. The role of the resting zone in growth plate chondrogenesis.  
2000 Endocrinology 2002; 143:1851-1857
- 2001 62. Kember NF, Walker KV. Control of bone growth in rats. Nature 1971;  
2002 229:428-429
- 2003 63. Hunziker EB. Mechanism of longitudinal bone growth and its regulation by  
2004 growth plate chondrocytes. Microsc Res Tech 1994; 28:505-519
- 2005 64. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples  
2006 hypertrophic cartilage remodeling, ossification and angiogenesis during  
2007 endochondral bone formation. Nat Med 1999; 5:623-628
- 2008 65. Farnum CE, Wilsman NJ. Cellular turnover at the chondro-osseous junction  
2009 of growth plate cartilage: analysis by serial sections at the light  
2010 microscopical level. J Orthop Res 1989; 7:654-666
- 2011 66. Hunziker EB, Wagner J, Zapf J. Differential effects of insulin-like growth  
2012 factor I and growth hormone on developmental stages of rat growth plate  
2013 chondrocytes in vivo. Journal of Clinical Investigation 1994; 93:1078-1086
- 2014 67. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J. Effect of  
2015 growth hormone and insulin-like growth factor I (IGF-I) on the expression of  
2016 IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and  
2017 articular chondrocytes in vivo. Endocrinology 2000; 141:2847-2853
- 2018 68. Farquharson C, Ahmed SF. Inflammation and linear bone growth: the  
2019 inhibitory role of SOCS2 on GH/IGF-1 signaling. Pediatric Nephrology 2013;  
2020 28:547-556
- 2021 69. Macrae VE, Horvat S, Pells SC, Dale H, Collinson RS, Pitsillides AA, Ahmed  
2022 SF, Farquharson C. Increased bone mass, altered trabecular architecture  
2023 and modified growth plate organization in the growing skeleton of SOCS2  
2024 deficient mice. Journal of Cellular Physiology 2009; 218:276-284

- 2025 70. Dobie R, Ahmed SF, Staines KA, Pass C, Jasim S, MacRae VE, Farquharson C.  
2026 Increased linear bone growth by GH in the absence of SOCS2 is independent  
2027 of IGF-1. J Cell Physiol 2015; 230:2796-2806
- 2028 71. MacRae VE, Farquharson C, Ahmed SF. The restricted potential for recovery  
2029 of growth plate chondrogenesis and longitudinal bone growth following  
2030 exposure to pro-inflammatory cytokines. Journal of Endocrinology 2006;  
2031 189:319-328
- 2032 72. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in  
2033 chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001; 19:785-796
- 2034 73. Martensson K, Chrysis D, Savendahl L. Interleukin-1beta and TNF-alpha act  
2035 in synergy to inhibit longitudinal growth in fetal rat metatarsal bones.  
2036 Journal of Bone & Mineral Research 2004; 19:1805-1812
- 2037 74. Choukair D, Hugel U, Sander A, Uhlmann L, Tonshoff B. Inhibition of IGF-I-  
2038 related intracellular signaling pathways by proinflammatory cytokines in  
2039 growth plate chondrocytes. Pediatr Res 2014; 76:245-251
- 2040 75. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin 1  
2041 suppresses expression of cartilage-specific types II and IX collagens and  
2042 increases types I and III collagens in human chondrocytes. J Clin Invest 1988;  
2043 82:2026-2037
- 2044 76. Horiguchi M, Akiyama H, Ito H, Shigeno C, Nakamura T. Tumour necrosis  
2045 factor-alpha up-regulates the expression of BMP-4 mRNA but inhibits  
2046 chondrogenesis in mouse clonal chondrogenic EC cells, ATDC5. Cytokine  
2047 2000; 12:526-530
- 2048 77. Ye W, Ma RF, Ding Y, Huang DS, Chen WJ, Peng Y, Liu SL. [Effect of  
2049 interleukin-6 on the chondrocytes in the cartilage endplate of rabbits in  
2050 vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27:1187-1189

- 2051     **78.**     Horan J, Dean D, Kieswetter K, Schwartz Z, Boyan B. Evidence that  
2052             interleukin-1, but not interleukin-6, affects costochondral chondrocyte  
2053             proliferation, differentiation, and matrix synthesis through an autocrine  
2054             pathway. *Journal of Bone and Mineral Research* 1996; 11:1119-1129
- 2055     **79.**     Nakajima S, Naruto T, Miyamae T, Imagawa T, Mori M, Nishimaki S, Yokota  
2056             S. Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic  
2057             progenitor cells. *Cytokine* 2009; 47:91-97
- 2058     **80.**     Legendre F, Dudhia J, Pujol J, P., Bogdanowicz P. JAK/STAT but not  
2059             ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-  
2060             regulation of type II collagen, aggrecan core, and link protein transcription  
2061             in articular chondrocytes. Association with a down-regulation of Sox9  
2062             expression. *Journal of Biological Chemistry* 2003; 278:2903-2912
- 2063     **81.**     Fernandez-Vojvodich P, Zaman F, Savendahl L. Interleukin-6 acts locally on  
2064             the growth plate to impair bone growth. *Annals of the Rheumatic Diseases*  
2065             2013;
- 2066     **82.**     Fernandez-Vojvodich P, Karimian E, Savendahl L. The biologics anakinra and  
2067             etanercept prevent cytokine-induced growth retardation in cultured fetal  
2068             rat metatarsal bones. *Hormone research in pdiatrics* 2011; 76:278-285
- 2069     **83.**     Fernandez-Vojvodich P, Palmblad K, Karimian E, Andersson U, Savendahl L.  
2070             Pro-inflammatory cytokines produced by growth plate chondrocytes may act  
2071             locally to modulate longitudinal bone growth. *Hormone research in pdiatrics*  
2072             2012; 77:180-187
- 2073     **84.**     Simsa-Maziel S, Zaretsky J, Reich A, Koren Y, Shahar R, Monsonego-Ornan E.  
2074             IL-1RI participates in normal growth plate development and bone modeling.  
2075             *American Journal of Physiology - Endocrinology and Metabolism* 2013;  
2076             305:E15-E21

- | 2077   **85.**    Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel  
| 2078           disease in Great Britain and Ireland. Archives of Disease in Childhood 2003;  
| 2079           88:995-1000
- | 2080   **86.**    MacRae VE, Wong SC, Smith W, Gracie A, McInnes I, Galea P, Gardner-  
| 2081           Medwin J, Farquharson C, Ahmed SF. Cytokine profiling and in vitro studies  
| 2082           of murine bone growth using biological fluids from children with juvenile  
| 2083           idiopathic arthritis. Clinical Endocrinology 2007; 67:442-448
- | 2084   **87.**    Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW,  
| 2085           Dantzer R, Kelley KW. IL-1beta impairs insulin-like growth factor i-induced  
| 2086           differentiation and downstream activation signals of the insulin-like growth  
| 2087           factor i receptor in myoblasts. J Immunol 2004; 172:7713-7720
- | 2088   **88.**    Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue of TNF  
| 2089           alpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal  
| 2090           kinases. Journal of Neuroscience Research 2004; 76:466-474
- | 2091   **89.**    Matsumoto T, Tsukazaki T, Enomoto H, Iwasaki K, Yamashita S. Effects of  
| 2092           interleukin-1 beta on insulin-like growth factor-I autocrine/paracrine axis in  
| 2093           cultured rat articular chondrocytes. Ann Rheum Dis 1994; 53:128-133
- | 2094   **90.**    Shen W, H., Zhou J, H., Broussard S, Freund G, Dantzer R, Kelley K.  
| 2095           Proinflammatory cytokines block growth of breast cancer cells by impairing  
| 2096           signals from a growth factor receptor. Cancer Research 2002; 62:4746-4756
- | 2097   **91.**    Strle K, Broussard S, McCusker R, Shen W, H., Johnson R, Freund G, Dantzer  
| 2098           R, Kelley K. Proinflammatory cytokine impairment of insulin-like growth  
| 2099           factor I-induced protein synthesis in skeletal muscle myoblasts requires  
| 2100           ceramide. Endocrinology 2004; 145:4592-4602
- | 2101   **92.**    Macrae VE, Ahmed SF, Mushtaq T, Farquharson C. IGF-I signalling in bone  
| 2102           growth: inhibitory actions of dexamethasone and IL-1beta. Growth Hormone  
| 2103           & Igf Research 2007; 17:435-439

- 2104 **93.** Li W, Dehnade F, Zafarullah M. Oncostatin M-induced matrix  
2105 metalloproteinase and tissue inhibitor of metalloproteinase-3 genes  
2106 expression in chondrocytes requires Janus kinase/STAT signaling pathway.  
2107 Journal of Immunology 2001; 166:3491-3498
- 2108 **94.** Boisclair Y, Wang J, Shi J, Hurst K, Ooi G. Role of the suppressor of cytokine  
2109 signaling-3 in mediating the inhibitory effects of interleukin-1beta on the  
2110 growth hormone-dependent transcription of the acid-labile subunit gene in  
2111 liver cells. Journal of Biological Chemistry 2000; 275:3841-3847
- 2112 **95.** Liu X, Shi Q, Sigmund C. Interleukin-1beta attenuates renin gene expression  
2113 via a mitogen-activated protein kinase kinase-extracellular signal-regulated  
2114 kinase and signal transducer and activator of transcription 3-dependent  
2115 mechanism in As4.1 cells. Endocrinology 2006; 147:6011-6018
- 2116 **96.** Shi H, Tzameli I, Bjorbaek C, Flier J. Suppressor of cytokine signaling 3 is a  
2117 physiological regulator of adipocyte insulin signaling. Journal of Biological  
2118 Chemistry 2004; 279:34733-34740
- 2119 **97.** Macrae VE, Horvat S, Pells SC, Dale H, Collinson RS, Pitsillides AA, Ahmed  
2120 SF, Farquharson C. Increased bone mass, altered trabecular architecture  
2121 and modified growth plate organization in the growing skeleton of SOCS2  
2122 deficient mice. J Cell Physiol 2009; 218:276-284
- 2123 **98.** Denson L, Held M, Menon R, Frank S, Parlow A, Arnold D. Interleukin-6  
2124 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-  
2125 3. American Journal of Physiology - Gastrointestinal and Liver Physiology  
2126 2003; 284:G646-G654
- 2127 **99.** Pass C, MacRae VE, Ahmed SF, Farquharson C. Inflammatory cytokines and  
2128 the GH/IGF-I axis: novel actions on bone growth. Cell Biochemistry &  
2129 Function 2009; 27:119-127

- 2130 100. Pass C, MacRae VE, Huesa C, Faisal Ahmed S, Farquharson C. SOCS2 is the  
2131 critical regulator of GH action in murine growth plate chondrogenesis.  
2132 Journal of Bone & Mineral Research 2012; 27:1055-1066
- 2133 101. Ahmed SF, Farquharson C. The effect of GH and IGF1 on linear growth and  
2134 skeletal development and their modulation by SOCS proteins. Journal of  
2135 Endocrinology 2010; 206:249-259
- 2136 102. Jantzen HM, Strahle U, Gloss B, Stewart F, Schmid W, Boshart M, Miksicek R,  
2137 Schutz G. Cooperativity of glucocorticoid response elements located far  
2138 upstream of the tyrosine aminotransferase gene. Cell 1987; 49:29-38
- 2139 103. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with  
2140 the transcription initiation complex. Endocrine Reviews 1996; 17:587-609
- 2141 104. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory  
2142 responses: Interactions between nuclear factor-kappa B and steroid  
2143 receptor-signaling pathways. Endocrine Reviews 1999; 20:435-459
- 2144 105. Chrysis D, Zaman F, Chagin AS, Takigawa M, Savendahl L. Dexamethasone  
2145 induces apoptosis in proliferative chondrocytes through activation of  
2146 caspases and suppression of the Akt-phosphatidylinositol 3'-kinase signaling  
2147 pathway. Endocrinology 2005; 146:1391-1397
- 2148 106. Luo J, Murphy L. Dexamethasone inhibits growth hormone induction of  
2149 insulin-like growth factor-I (IGF-I) messenger ribonucleic acid (mRNA) in  
2150 hypophysectomized rats and reduces IGF-I mRNA abundance in the intact  
2151 rat. Endocrinology 1989; 125:165-171
- 2152 107. Klaus G, Jux C, Fernandez P, Rodriguez J, Himmele R, Mehls O. Suppression  
2153 of growth plate chondrocyte proliferation by corticosteroids. Pediatric  
2154 Nephrology 2000; 14:612-615
- 2155 108. Giustina A, Grazia Buffoli M, Rosa Bussi A, Doga M, Girelli A, Pizzocolo G,  
2156 Pozzi A, Wehrenberg W. Comparative effect of clonidine and growth



- 2157 hormone (GH)-releasing hormone on GH secretion in adult patients on  
2158 chronic glucocorticoid therapy. *Hormone and Metabolic Research* 1992;  
2159 24:240-243
- 2160 **109.** Giustina A, Veldhuis J. Pathophysiology of the neuroregulation of growth  
2161 hormone secretion in experimental animals and the human. *Endocrine*  
2162 *reviews* 1998; 19:717-797
- 2163 **110.** Fujita T, Fukuyama R, Enomoto H, Komori T. Dexamethasone inhibits  
2164 insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt  
2165 signaling and DNA binding of Runx2. *Journal of Cellular Biochemistry* 2004;  
2166 93:374-383
- 2167 **111.** Mushtaq T, Bijman P, Ahmed SF, Farquharson C. Insulin-like growth factor-I  
2168 augments chondrocyte hypertrophy and reverses glucocorticoid-mediated  
2169 growth retardation in fetal mice metatarsal cultures. *Endocrinology* 2004;  
2170 145:2478-2486
- 2171 **112.** Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB, Jr. Dexamethasone acts  
2172 locally to inhibit longitudinal bone growth in rabbits. *Am J Physiol* 1992;  
2173 263:E489-492
- 2174 **113.** Silvestrini G, Mocetti P, Ballanti P, Di Grezia R, Bonucci E. Cytochemical  
2175 demonstration of the glucocorticoid receptor in skeletal cells of the rat.  
2176 *Endocrine Research* 1999; 25:117-128
- 2177 **114.** Abu E, Horner A, Kusec V, Triffitt J, Compston J. The localization of the  
2178 functional glucocorticoid receptor alpha in human bone. *Journal of Clinical*  
2179 *Endocrinology and Metabolism* 2000; 85:883-889
- 2180 **115.** Owen HC, Miner JN, Ahmed SF, Farquharson C. The growth plate sparing  
2181 effects of the selective glucocorticoid receptor modulator, AL-438. *Mol Cell*  
2182 *Endocrinol* 2007; 264:164-170

- 2183 116. Chrysis D, Ritzen EM, Savendahl L. Growth retardation induced by  
2184 dexamethasone is associated with increased apoptosis of the growth plate  
2185 chondrocytes. *Journal of Endocrinology* 2003; 176:331-337
- 2186 117. Zhao Y, Zuo Y, Huo H, Xiao Y, Yang X, Xin D. Dexamethasone reduces ATDC5  
2187 chondrocyte cell viability by inducing autophagy. *Molecular Medicine*  
2188 *Reports* 2014; 9:923-927
- 2189 118. Siebler T, Robson H, Shalet SM, Williams GR. Dexamethasone inhibits and  
2190 thyroid hormone promotes differentiation of mouse chondrogenic ATDC5  
2191 cells. *Bone* 2002; 31:457-464
- 2192 119. Mushtaq T, Farquharson C, Seawright E, Ahmed SF. Glucocorticoid effects  
2193 on chondrogenesis, differentiation and apoptosis in the murine ATDC5  
2194 chondrocyte cell line. *Journal of Endocrinology* 2002; 175:705-713
- 2195 120. Negishi Y, Ui N, Nakajima M, Kawashima K, Maruyama K, Takizawa T, Endo  
2196 H. p21cip-1/SDI-1/WAF-1 Gene Is Involved in Chondrogenic Differentiation  
2197 of ATDC5 Cells in Vitro. *Journal of Biological Chemistry* 2001; 276:33249-  
2198 33256
- 2199 121. Owen HC1 AS, Farquharson C. Chondrocyte p21(WAF1/CIP1) expression is  
2200 increased by dexamethasone but does not contribute to dexamethasone-  
2201 induced growth retardation in vivo. *Calcif Tissue Int* 2009:326-334
- 2202 122. Emons JA, Marino R, Nilsson O, Barnes KM, Even-Zohar N, Andrade AC,  
2203 Chatterjee NA, Wit JM, Karperien M, Baron J. The role of p27Kip1 in the  
2204 regulation of growth plate chondrocyte proliferation in mice. *Pediatric*  
2205 *Research* 2006; 60:288-293
- 2206 123. Zaman F, Chrysis D, Huntjens K, Fadeel B, Savendahl L. Ablation of the pro-  
2207 apoptotic protein Bax protects mice from glucocorticoid-induced bone  
2208 growth impairment. *PLoS ONE [Electronic Resource]* 2012; 7:e33168

124. Zaman F, Chrysis D, Huntjens K, Chagin A, Takigawa M, Fadeel B, Savendahl L. Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic Bid. *Toxicol Lett* 2014; 224:196-200
125. James CG, Ulici V, Tuckermann J, Underhill TM, Beier F. Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. *BMC Genomics* 2007; 8:205
126. Owen HC, Roberts SJ, Ahmed SF, Farquharson C. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. *Am J Physiol Endocrinol Metab* 2008; 294:E1023-1034
127. Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, Larson DP, Elmore SW, Pratt JK, Stashko MA, Falls HD, Lin CW, Nakane M, Miller L, Tyree CM, Miner JN, Jacobson PB, Wilcox DM, Nguyen P, Lane BC. Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. *J Med Chem* 2003; 46:1016-1030
128. Ayroldi E, Macchiarulo A, Riccardi C. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective. *FASEB J* 2014; 28:5055-5070
129. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. *Mol Endocrinol* 2003; 17:860-869
130. Boersma B, Wit JM. Catch-up growth. *Endocr Rev* 1997; 18:646-661

- 2235 131. Lui JC, Baron J. Effects of glucocorticoids on the growth plate. *Endocrine*  
2236 *Development* 2011; 20:187-193
- 2237 132. Prader A, Tanner JM, von HG. Catch-up growth following illness or  
2238 starvation. An example of developmental canalization in man. *J Pediatr*  
2239 1963; 62:646-659
- 2240 133. Boersma B, Rikken B, Wit JM. Catch-up growth in early treated patients  
2241 with growth hormone deficiency. Dutch Growth Hormone Working Group.  
2242 *Arch Dis Child* 1995; 72:427-431
- 2243 134. Damen GM, Boersma B, Wit JM, Heymans HS. Catch-up growth in 60 children  
2244 with celiac disease. *J Pediatr Gastroenterol Nutr* 1994; 19:394-400
- 2245 135. Baron J, Klein KO, Yanovski JA, Novosad JA, Bacher JD, Bolander ME, Cutler  
2246 GB, Jr. Induction of growth plate cartilage ossification by basic fibroblast  
2247 growth factor. *Endocrinology* 1994; 135:2790-2793
- 2248 136. Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, Cutler GB,  
2249 Jr. Catch-up growth after glucocorticoid excess: a mechanism intrinsic to  
2250 the growth plate. *Endocrinology* 1994; 135:1367-1371
- 2251 137. Gafni RI, Weise M, Robrecht DT, Meyers JL, Barnes KM, De-Levi S, Baron J.  
2252 Catch-up growth is associated with delayed senescence of the growth plate  
2253 in rabbits. *Pediatric Research* 2001; 50:618-623
- 2254 138. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs  
2255 through a decrease in insulin-like growth factor 1 which is independent of  
2256 undernutrition in a rat model of colitis. *Gut* 2000; 46:694-700
- 2257 139. Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of  
2258 pediatric Crohn's disease. *Expert Rev Clin Immunol* 2010; 6:667-676
- 2259 140. Tannenbaum GS, Rorstad O, Brazeau P. Effects of prolonged food  
2260 deprivation on the ultradian growth hormone rhythm and immunoreactive  
2261 somatostatin tissue levels in the rat. *Endocrinology* 1979; 104:1733-1738

- 2262 141. Straus DS, Takemoto CD. Effect of fasting on insulin-like growth factor-I  
2263 (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene  
2264 transcription in rat liver. *Mol Endocrinol* 1990; 4:91-100
- 2265 142. Bornfeldt KE, Arnqvist HJ, Enberg B, Mathews LS, Norstedt G. Regulation of  
2266 insulin-like growth factor-I and growth hormone receptor gene expression  
2267 by diabetes and nutritional state in rat tissues. *J Endocrinol* 1989; 122:651-  
2268 656
- 2269 143. Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects serum insulin-like  
2270 growth factors (IGFs) and IGF-binding proteins differently in patients with  
2271 noninsulin-dependent diabetes mellitus versus healthy nonobese and obese  
2272 subjects. *J Clin Endocrinol Metab* 1994; 78:960-967
- 2273 144. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB, Jr. The effect of  
2274 anorexia nervosa and refeeding on growth hormone-binding protein, the  
2275 insulin-like growth factors (IGFs), and the IGF-binding proteins. *J Clin*  
2276 *Endocrinol Metab* 1992; 75:762-767
- 2277 145. Kubicky RA, Wu S, Kharitonov A, De Luca F. Role of fibroblast growth  
2278 factor 21 (FGF21) in undernutrition-related attenuation of growth in mice.  
2279 *Endocrinology* 2012; 153:2287-2295
- 2280 146. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y,  
2281 Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC,  
2282 Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting  
2283 response by PPARalpha-mediated induction of fibroblast growth factor 21.  
2284 *Cell Metab* 2007; 5:415-425
- 2285 147. Reitman ML. FGF21: a missing link in the biology of fasting. *Cell Metab*  
2286 2007; 5:405-407

- 2287   **148.**   Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA.  
2288           Inhibition of growth hormone signaling by the fasting-induced hormone  
2289           FGF21. *Cell Metab* 2008; 8:77-83
- 2290   **149.**   Wu S, Grunwald T, Kharitonov A, Dam J, Jockers R, De Luca F. Increased  
2291           expression of fibroblast growth factor 21 (FGF21) during chronic  
2292           undernutrition causes growth hormone insensitivity in chondrocytes by  
2293           inducing leptin receptor overlapping transcript (LEPROT) and leptin  
2294           receptor overlapping transcript-like 1 (LEPROTL1) expression. *J Biol Chem*  
2295           2013; 288:27375-27383
- 2296   **150.**   Pando R, Shtaif B, Phillip M, Gat-Yablonski G. A serum component mediates  
2297           food restriction-induced growth attenuation. *Endocrinology* 2014; 155:932-  
2298           940
- 2299   **151.**   De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A,  
2300           Ciliberto G, Fattori E. Interleukin 6 causes growth impairment in transgenic  
2301           mice through a decrease in insulin-like growth factor-I. A model for stunted  
2302           growth in children with chronic inflammation. *Journal of Clinical*  
2303           Investigation 1997; 99:643-650
- 2304   **152.**   De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T,  
2305           Fattori E, Garrone S, Barreca A, Martini A. Effect of IL-6 on IGF binding  
2306           protein-3: a study in IL-6 transgenic mice and in patients with systemic  
2307           juvenile idiopathic arthritis. *Endocrinology* 2001; 142:4818-4826
- 2308   **153.**   De Benedetti F, Pignatti P, Vivarelli M, Meazza C, Ciliberto G, Savino R,  
2309           Martini A. In vivo neutralization of human IL-6 (hIL-6) achieved by  
2310           immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. *J*  
2311           Immunol 2001; 166:4334-4340

- 2312 154. Lopez-Calderon A, Soto L, Martin AI. Chronic inflammation inhibits GH  
2313 secretion and alters the serum insulin-like growth factor system in rats. Life  
2314 Sci 1999; 65:2049-2060
- 2315 155. Ibanez De Caceres I, Holly JM, Priego T, Martin AI, Lopez-Calderon A,  
2316 Villanua MA. Arthritis-induced increase in serum levels of IGF-binding  
2317 protein-3 in rats is secondary to the decrease in its proteolytic activity.  
2318 Journal of Endocrinology 2002; 173:357-364
- 2319 156. Ibanez De Caceres I, Villanua MA, Soto L, Martin AI, Lopez-Calderon A. IGF-I  
2320 and IGF-I-binding proteins in rats with adjuvant-induced arthritis given  
2321 recombinant human growth hormone. Journal of Endocrinology 2000;  
2322 165:537-544
- 2323 157. Granado M, Martin AI, Villanua MA, Lopez-Calderon A. Experimental arthritis  
2324 inhibits the insulin-like growth factor-I axis and induces muscle wasting  
2325 through cyclooxygenase-2 activation. American Journal of Physiology -  
2326 Endocrinology & Metabolism 2007; 292:E1656-1665
- 2327 158. Crist DM, Peake GT, Mackinnon LT, Sibbitt WL, Jr., Kraner JC. Exogenous  
2328 growth hormone treatment alters body composition and increases natural  
2329 killer cell activity in women with impaired endogenous growth hormone  
2330 secretion. Metabolism 1987; 36:1115-1117
- 2331 159. Ballinger A. Fundamental mechanisms of growth failure in inflammatory  
2332 bowel disease. Hormone Research 2002; 58 Suppl 1:7-10
- 2333 160. Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental colitis impairs  
2334 linear bone growth independent of nutritional factors. Journal of Pediatric  
2335 Gastroenterology & Nutrition 1997; 25:137-141
- 2336 161. Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO,  
2337 Ballinger AB, Sanderson IR. Intestinal inflammation-induced growth  
2338 retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C

| 2339 polymorphism in children. Proceedings of the National Academy of Sciences  
| 2340 of the United States of America 2005; 102:13260-13265

| 2341 **162.** Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and  
| 2342 response to testosterone in a rat model of colitis. American Journal of  
| 2343 Physiology - Regulatory Integrative & Comparative Physiology 2001;  
| 2344 281:R1483-1491

| 2345 **163.** Deboer MD, Li Y. Puberty is delayed in male mice with dextran sodium  
| 2346 sulfate colitis out of proportion to changes in food intake, body weight, and  
| 2347 serum levels of leptin. Pediatric Research 2011; 69:34-39

| 2348 **164.** DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out  
| 2349 of proportion to changes in leptin and corticosterone. Journal of  
| 2350 Gastroenterology 2010; 45:277-284

| 2351 **165.** Kalra PS, Fuentes M, Sahu A, Kalra SP. Endogenous opioid peptides mediate  
| 2352 the interleukin-1-induced inhibition of the release of luteinizing hormone  
| 2353 (LH)-releasing hormone and LH. Endocrinology 1990; 127:2381-2386

| 2354 **166.** Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing  
| 2355 hormone secretion and ovulation in the rat. Endocrinology 1990; 127:849-  
| 2356 856

| 2357 **167.** Nappi RE, Rivest S. Effect of immune and metabolic challenges on the  
| 2358 luteinizing hormone-releasing hormone neuronal system in cycling female  
| 2359 rats: an evaluation at the transcriptional level. Endocrinology 1997;  
| 2360 138:1374-1384

| 2361 **168.** Morales V, Santana P, Diaz R, Tabraue C, Gallardo G, Lopez Blanco F,  
| 2362 Hernandez I, Fanjul LF, Ruiz de Galarreta CM. Intratesticular delivery of  
| 2363 tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic  
| 2364 acute regulatory protein expression and Leydig cell steroidogenesis in adult  
| 2365 rats. Endocrinology 2003; 144:4763-4772



- 2366 169. Rosenberg LA, Schluchter MD, Parlow AF, Drumm ML. Mouse as a model of  
2367 growth retardation in cystic fibrosis. *Pediatr Res* 2006; 59:191-195
- 2368 170. Hodges CA, Grady BR, Mishra K, Cotton CU, Drumm ML. Cystic fibrosis  
2369 growth retardation is not correlated with loss of Cftr in the intestinal  
2370 epithelium. *Am J Physiol Gastrointest Liver Physiol* 2011; 301:G528-536
- 2371 171. Rogan MP, Reznikov LR, Pezzulo AA, Gansemer ND, Samuel M, Prather RS,  
2372 Zabner J, Fredericks DC, McCray PB, Jr., Welsh MJ, Stoltz DA. Pigs and  
2373 humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1)  
2374 levels at birth. *Proc Natl Acad Sci U S A* 2010; 107:20571-20575
- 2375 172. Lopez-Menduina M, Martin AI, Castellero E, Villanua MA, Lopez-Calderon A.  
2376 Short-term growth hormone or IGF-I administration improves the IGF-IGFBP  
2377 system in arthritic rats. *Growth Hormone & Igf Research* 2012; 22:22-29
- 2378 173. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB,  
2379 Lund PK. Enhanced survival and mucosal repair after dextran sodium  
2380 sulfate-induced colitis in transgenic mice that overexpress growth hormone.  
2381 *Gastroenterology* 2001; 120:925-937
- 2382 174. Han X, Sosnowska D, Bonkowski EL, Denson LA. Growth hormone inhibits  
2383 signal transducer and activator of transcription 3 activation and reduces  
2384 disease activity in murine colitis. *Gastroenterology* 2005; 129:185-203
- 2385 175. Christensen H, Flyvbjerg A, Orskov H, Laurberg S. Effect of growth hormone  
2386 on the inflammatory activity of experimental colitis in rats. *Scand J*  
2387 *Gastroenterol* 1993; 28:503-511
- 2388 176. DiFedele LM, He J, Bonkowski EL, Han X, Held MA, Bohan A, Menon RK,  
2389 Denson LA. Tumor necrosis factor alpha blockade restores growth hormone  
2390 signaling in murine colitis. *Gastroenterology* 2005; 128:1278-1291
- 2391 177. D'Mello S, Trauernicht A, Ryan A, Bonkowski E, Willson T, Trapnell BC, Frank  
2392 SJ, Kugasathan S, Denson LA. Innate dysfunction promotes linear growth

2393 failure in pediatric Crohn's disease and growth hormone resistance in murine  
2394 ileitis. *Inflammatory Bowel Diseases* 2012; 18:236-245

2395 **178.** Petty RE, Southwood TR, Baum J, Bhattay E, Glass DN, Manners P,  
2396 Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM. Revision  
2397 of the proposed classification criteria for juvenile idiopathic arthritis:  
2398 Durban, 1997. *Journal of Rheumatology* 1998; 25:1991-1994

2399 **179.** Prakken BJ, Albani S. Using biology of disease to understand and guide  
2400 therapy of JIA. *Best Pract Res Clin Rheumatol* 2009; 23:599-608

2401 **180.** Berkun Y, Padeh S. Environmental factors and the geoepidemiology of  
2402 juvenile idiopathic arthritis. *Autoimmun Rev* 2010; 9:A319-324

2403 **181.** Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria  
2404 for juvenile idiopathic arthritis. *International League of Associations for*  
2405 *Rheumatology. Journal of Rheumatology* 2000; 27:1069-1072

2406 **182.** Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X,  
2407 Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P,  
2408 International League of Associations for R. International League of  
2409 Associations for Rheumatology classification of juvenile idiopathic arthritis:  
2410 second revision, Edmonton, 2001. *Journal of Rheumatology* 2004; 31:390-  
2411 392

2412 **183.** Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt  
2413 EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE,  
2414 Ruperto N. 2011 American College of Rheumatology recommendations for  
2415 the treatment of juvenile idiopathic arthritis: initiation and safety  
2416 monitoring of therapeutic agents for the treatment of arthritis and systemic  
2417 features. *Arthritis care & research* 2011; 63:465-482

2418 **184.** Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the  
2419 intraarticular effectiveness of triamcinolone hexacetonide and

| 2420 triamcinolone acetonide in treatment of juvenile rheumatoid arthritis.  
 | 2421 Journal of Rheumatology 2004; 31:2507-2512

| 2422 **185.** Eberhard BA, Ilowite NT, Sison C. A dose schedule for intraarticular steroids  
 | 2423 in juvenile arthritis. Journal of Rheumatology 2012; 39:374-376

| 2424 **186.** Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, Bohm M, Nieto-Gonzalez  
 | 2425 JC, Pistorio A, Lanni S, Consolaro A, Martini A, Ravelli A. Delineating the  
 | 2426 role of multiple intraarticular corticosteroid injections in the management  
 | 2427 of juvenile idiopathic arthritis in the biologic era. Arthritis care & research  
 | 2428 2013; 65:1112-1120

| 2429 **187.** Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg  
 | 2430 length discrepancy in young children with pauciarticular juvenile  
 | 2431 rheumatoid arthritis by treatment with intraarticular steroids. Arthritis &  
 | 2432 Rheumatism 1999; 42:2330-2334

| 2433 **188.** Habib GS. Systemic effects of intra-articular corticosteroids. Clinical  
 | 2434 Rheumatology 2009; 28:749-756

| 2435 **189.** Hameed R, Zacharin MR. Cushing syndrome, adrenal suppression and local  
 | 2436 corticosteroid use. J Paediatr Child Health 2006; 42:392-394

| 2437 **190.** Gondwe JS, Davidson JE, Deeley S, Sills J, Cleary AG. Secondary Cushing's  
 | 2438 syndrome in children with juvenile idiopathic arthritis following intra-  
 | 2439 articular triamcinolone acetonide administration. Rheumatology 2005;  
 | 2440 44:1457-1458

| 2441 **191.** Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing's syndrome after intra-  
 | 2442 articular and intradermal administration of triamcinolone acetonide in three  
 | 2443 pediatric patients. Pediatrics 2004; 113:1820-1824

| 2444 **192.** Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular  
 | 2445 corticosteroids for chronic arthritis in children: efficacy and effects on  
 | 2446 cartilage and growth. Journal of Pediatrics 1995; 127:317-321

- 2447 193. Heuck C, Wolthers OD, Herlin T. Growth-suppressive effect of intra-articular  
2448 glucocorticoids detected by knemometry. *Hormone Research* 1999; 52:95-96
- 2449 194. Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular  
2450 and pauciarticular juvenile rheumatoid arthritis. *J Bone Joint Surg Am* 1981;  
2451 63:209-215
- 2452 195. Wahezi DM, Ilowite NT. Juvenile idiopathic arthritis: an update on current  
2453 pharmacotherapy and future perspectives. *Expert Opin Pharmacother* 2013;  
2454 14:975-989
- 2455 196. Dannecker GE, Quartier P. Juvenile idiopathic arthritis: classification,  
2456 clinical presentation and current treatments. *Hormone Research* 2009; 72  
2457 Suppl 1:4-12
- 2458 197. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ, Jr., Fink CW, Hanson  
2459 V, Jacobs JC, Masi AT, Schaller JG, et al. A study of classification criteria  
2460 for a diagnosis of juvenile rheumatoid arthritis. *Arthritis & Rheumatism*  
2461 1986; 29:274-281
- 2462 198. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M,  
2463 Zink A. Long-term outcome in patients with juvenile idiopathic arthritis.  
2464 *Arthritis & Rheumatism* 2002; 46:2392-2401
- 2465 199. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. *Rheum Dis Clin North Am*  
2466 2007; 33:441-470, vi
- 2467 200. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P,  
2468 Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V, Leflunomide in  
2469 Juvenile Rheumatoid Arthritis Investigator G. Leflunomide or methotrexate  
2470 for juvenile rheumatoid arthritis. *New England Journal of Medicine* 2005;  
2471 352:1655-1666
- 2472 201. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink  
2473 CW, Newman AJ, Cassidy JT, Zemel LS. Methotrexate in resistant juvenile

- | 2474           rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-  
| 2475           controlled trial. The Pediatric Rheumatology Collaborative Study Group and  
| 2476           The Cooperative Children's Study Group. New England Journal of Medicine  
| 2477           1992; 326:1043-1049
- | 2478   **202.**   Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ,  
| 2479           Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK.  
| 2480           Etanercept in children with polyarticular juvenile rheumatoid arthritis.  
| 2481           Pediatric Rheumatology Collaborative Study Group. New England Journal of  
| 2482           Medicine 2000; 342:763-769
- | 2483   **203.**   Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ,  
| 2484           Hospach T, Huppertz HI, Keitzer R, Kuster RM, Michels H, Moebius D,  
| 2485           Rogalski B, Thon A, Paediatric Rheumatology Collaborative G. The German  
| 2486           etanercept registry for treatment of juvenile idiopathic arthritis. Annals of  
| 2487           the Rheumatic Diseases 2004; 63:1638-1644
- | 2488   **204.**   Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D,  
| 2489           Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V,  
| 2490           Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz H-I, Olson  
| 2491           NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A,  
| 2492           Pediatric Rheumatology Collaborative Study G, Pediatric Rheumatology  
| 2493           International Trials O. Adalimumab with or without methotrexate in  
| 2494           juvenile rheumatoid arthritis. New England Journal of Medicine 2008;  
| 2495           359:810-820
- | 2496   **205.**   Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S.  
| 2497           Etanercept treatment improves longitudinal growth in prepubertal children  
| 2498           with juvenile idiopathic arthritis. Journal of Rheumatology 2007; 34:2481-  
| 2499           2485

- 2500   **206.** Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of  
2501           anti-TNF treatment on growth in severe juvenile idiopathic arthritis. *Annals*  
2502           of the Rheumatic Diseases 2006; 65:1044-1049
- 2503   **207.** Simon D, Fernando C, Czernichow P, Prieur A-M. Linear growth and final  
2504           height in patients with systemic juvenile idiopathic arthritis treated with  
2505           longterm glucocorticoids. *Journal of Rheumatology* 2002; 29:1296-1300
- 2506   **208.** Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, Stephens  
2507           D, Feldman BM. Early predictors of poor functional outcome in systemic-  
2508           onset juvenile rheumatoid arthritis: a multicenter cohort study. *Arthritis &*  
2509           *Rheumatism* 2000; 43:2402-2409
- 2510   **209.** Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, Henrickson M,  
2511           Watcher S, Reiff A. Etanercept treatment in patients with refractory  
2512           systemic onset juvenile rheumatoid arthritis. *Journal of Rheumatology* 2005;  
2513           32:935-942
- 2514   **210.** de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new  
2515           treatment for systemic juvenile idiopathic arthritis? *Arthritis & Rheumatism*  
2516           2005; 52:687-693
- 2517   **211.** Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1  
2518           (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and  
2519           clinical response to IL-1 blockade. *J Exp Med* 2005; 201:1479-1486
- 2520   **212.** Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, Delfino L,  
2521           Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M,  
2522           Vecchi A, Ravelli A, Martini A, Rubartelli A. The pattern of response to anti-  
2523           interleukin-1 treatment distinguishes two subsets of patients with systemic-  
2524           onset juvenile idiopathic arthritis. *Arthritis & Rheumatism* 2008; 58:1505-  
2525           1515

213. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. *J Clin Rheumatol* 2009; 15:161-164
214. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. *Arthritis & Rheumatism* 2011; 63:545-555
215. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). *Annals of the Rheumatic Diseases* 2011; 70:747-754
216. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. *Arthritis & Rheumatism* 1991; 34:1158-1163
217. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. *Arthritis Research & Therapy* 2005; 7:R1281-1288

218. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008; 371:998-1006
219. De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R, Brown D, Chaitow J, Pardeo M, Espada G, Gerloni V, Myones B, Frane J, Wang J, Lipman TH, Bharucha KN, Martini A, Lovell D, the Paediatric Rheumatology International Trials O, Pediatric Rheumatology Collaborative Study G. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial. *Arthritis Rheumatol* 2014;
220. Arvidsson LZ, Fjeld MG, Smith HJ, Flato B, Ogaard B, Larheim TA. Craniofacial growth disturbance is related to temporomandibular joint abnormality in patients with juvenile idiopathic arthritis, but normal facial profile was also found at the 27-year follow-up. *Scandinavian Journal of Rheumatology* 2010; 39:373-379
221. Carvalho RT, Braga FS, Brito F, Capelli Junior J, Figueredo CM, Sztajnbok FR. Temporomandibular joint alterations and their orofacial complications in patients with juvenile idiopathic arthritis. *Rev Bras Reumatol* 2012; 52:907-911
222. Demant S, Hermann NV, Darvann TA, Zak M, Schatz H, Larsen P, Kreiborg S. 3D analysis of facial asymmetry in subjects with juvenile idiopathic arthritis. *Rheumatology* 2011; 50:586-592
223. Liem JJ, Rosenberg AM. Growth patterns in juvenile rheumatoid arthritis. *Clinical & Experimental Rheumatology* 2003; 21:663-668



- 2578 224. Saha MT, Verronen P, Laippala P, Lenko HL. Growth of prepubertal children  
2579 with juvenile chronic arthritis. *Acta Paediatrica* 1999; 88:724-728
- 2580 225. Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children  
2581 with oligoarticular juvenile idiopathic arthritis are at considerable risk for  
2582 growth retardation. *Journal of Pediatrics* 2011; 159:832-837 e831-832
- 2583 226. Gardner-Medwin JM, Killeen OG, Ryder CA, Bradshaw K, Johnson K.  
2584 Magnetic resonance imaging identifies features in clinically unaffected  
2585 knees predicting extension of arthritis in children with monoarthritis.  
2586 *Journal of Rheumatology* 2006; 33:2337-2343
- 2587 227. Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N,  
2588 Papale MR. Growth retardation in non-steroid treated juvenile rheumatoid  
2589 arthritis. *Scandinavian Journal of Rheumatology* 1997; 26:99-103
- 2590 228. Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile  
2591 idiopathic arthritis exhibit more inflammatory features and a worse  
2592 outcome. *Journal of Rheumatology* 2013; 40:329-334
- 2593 229. Aggarwal B, Bhalla AK, Singh S. Sexual maturation in boys with juvenile  
2594 rheumatoid arthritis. *Rheumatol Int* 2011; 31:1419-1421
- 2595 230. Maher SE, Ali FI. Sexual maturation in Egyptian boys and girls with juvenile  
2596 rheumatoid arthritis. *Rheumatol Int* 2013; 33:2123-2126
- 2597 231. Aggarwal B, Bhalla AK, Singh S. Longitudinal growth attainments of Indian  
2598 boys with juvenile rheumatoid arthritis. *Rheumatol Int* 2011; 31:635-640
- 2599 232. Rusconi R, Corona F, Grassi A, Carnelli V. Age at menarche in juvenile  
2600 rheumatoid arthritis. *J Pediatr Endocrinol Metab* 2003; 16 Suppl 2:285-288
- 2601 233. Umlawska W, Krzyzanowska M. Growth and menarche during remission in  
2602 children with juvenile idiopathic arthritis. *Med Wieku Rozwoj* 2009; 13:194-  
2603 200

234. Ostensen M, Almborg K, Koksvik HS. Sex, reproduction, and gynecological disease in young adults with a history of juvenile chronic arthritis. *Journal of Rheumatology* 2000; 27:1783-1787
235. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. *Journal of Rheumatology* 1995; 22:308-319
236. Zak M, Muller J, Karup Pedersen F. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. *Hormone Research* 1999; 52:80-85
237. Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL. Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. *Clinical Rheumatology* 2002; 21:363-368
238. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. *Hormone Research* 2009; 72 Suppl 1:20-25
239. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. *Rheumatology* 2002; 41:1440-1443
240. Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, Martini A, Ravelli A. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. *Arthritis & Rheumatism* 2006; 54:2989-2996
241. Rygg M, Pistorio A, Ravelli A, Maghnie M, Di Iorgi N, Bader-Meunier B, Da Silva C, Roldan-Molina R, Barash J, Dracou C, Laloum SG, Jarosova K, Deslandre CJ, Kone-Paut I, Garofalo F, Press J, Sengler C, Tauber T, Martini A, Ruperto N, Paediatric Rheumatology International Trials O. A longitudinal

| 2631 PRINTO study on growth and puberty in juvenile systemic lupus  
| 2632 erythematosus. *Annals of the Rheumatic Diseases* 2012; 71:511-517

| 2633 242. Haugen MA, Hoyeraal HM, Larsen S, Gilboe IM, Trygg K. Nutrient intake and  
| 2634 nutritional status in children with juvenile chronic arthritis. *Scandinavian*  
| 2635 *Journal of Rheumatology* 1992; 21:165-170

| 2636 243. Saha MT, Ruuska T, Laippala P, Lenko HL. Growth of prepubertal children  
| 2637 with inflammatory bowel disease. *Journal of Pediatric Gastroenterology &*  
| 2638 *Nutrition* 1998; 26:310-314

| 2639 244. Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM. Growth velocity  
| 2640 and interleukin 6 concentrations in juvenile idiopathic arthritis. *Journal of*  
| 2641 *Rheumatology* 2008; 35:2265-2271

| 2642 245. Tsatsoulis A, Siamopoulou A, Petsoukis C, Challa A, Bairaktari E, Seferiadis  
| 2643 K. Study of growth hormone secretion and action in growth-retarded  
| 2644 children with juvenile chronic arthritis (JCA). *Growth Hormone & Igf*  
| 2645 *Research* 1999; 9:143-149

| 2646 246. Allen RC, Jimenez M, Cowell CT. Insulin-like growth factor and growth  
| 2647 hormone secretion in juvenile chronic arthritis. *Annals of the Rheumatic*  
| 2648 *Diseases* 1991; 50:602-606

| 2649 247. Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM,  
| 2650 Preece MA, Woo PM. Juvenile rheumatoid arthritis. Effects of disease  
| 2651 activity and recombinant human growth hormone on insulin-like growth  
| 2652 factor 1, insulin-like growth factor binding proteins 1 and 3, and  
| 2653 osteocalcin. *Arthritis & Rheumatism* 1997; 40:332-340

| 2654 248. Bozzola E, Pagani S, Meazza C, Cortis E, Lisini D, Laarej K, Bozzola M.  
| 2655 Changes in growth hormone receptor gene expression during therapy in  
| 2656 children with juvenile idiopathic arthritis. *Hormone research in pdiatrics*  
| 2657 2012; 77:52-58

249. Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla Pozza R, Hafner R, Haas JP, Schmidt H. Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. *Growth Hormone & Igf Research* 2012; 22:180-185
250. Saha MT, Haapasaari J, Hannula S, Sarna S, Lenko HL. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. *Journal of Rheumatology* 2004; 31:1413-1417
251. Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. *Arch Dis Child* 2015;
252. Growth Hormone Research S. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. *GH Research Society. J Clin Endocrinol Metab* 2000; 85:3990-3993
253. Soto L, Martin AI, Millan S, Vara E, Lopez-Calderon A. Effects of endotoxin lipopolysaccharide administration on the somatotrophic axis. *Journal of Endocrinology* 1998; 159:239-246
254. Wong SC, MacRae VE, Gracie JA, McInnes IB, Galea P, Gardner-Medwin J, Ahmed SF. Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. *Growth Hormone & Igf Research* 2008; 18:369-378
255. Grote FK, Van Suijlekom-Smit LW, Mul D, Hop WC, Ten Cate R, Oostdijk W, Van Luijk W, Jansen-van Wijngaarden CJ, De Muinck Keizer-Schrama SM. Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. *Archives of Disease in Childhood* 2006; 91:56-60

256. Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. *Annals of the Rheumatic Diseases* 2006; 65:301-305
257. Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A. Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. *Journal of Pediatric Endocrinology* 2000; 13:899-905
258. Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, Schwarz HP. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. *Journal of Rheumatology* 2004; 31:1407-1412
259. Butenandt O. Rheumatoid arthritis and growth retardation in children: treatment with human growth hormone. *European Journal of Pediatrics* 1979; 130:15-28
260. Davies UM, Rooney M, Preece MA, Ansell BM, Woo P. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. *Journal of Rheumatology* 1994; 21:153-158
261. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. *Journal of Rheumatology* 2003; 30:2492-2499
262. Svantesson H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis. A pilot study. *Clinical & Experimental Rheumatology* 1991; 9 Suppl 6:47-50
263. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body

- | 2712 composition.[Erratum appears in J Clin Endocrinol Metab 1998  
 | 2713 May;83(5):1547]. Journal of Clinical Endocrinology & Metabolism 1998;  
 | 2714 83:403-409
- | 2715 **264.** Simon D, Touati G, Prieur AM, Ruiz JC, Czernichow P. Growth hormone  
 | 2716 treatment of short stature and metabolic dysfunction in juvenile chronic  
 | 2717 arthritis. Acta Paediatrica Supplement 1999; 88:100-105
- | 2718 **265.** Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP. Growth hormone  
 | 2719 improves height in patients with juvenile idiopathic arthritis: 4-year data of  
 | 2720 a controlled study. Journal of Pediatrics 2003; 143:512-519
- | 2721 **266.** Bechtold S, Ripperger P, Muhlbayer D, Truckenbrodt H, Hafner R, Butenandt  
 | 2722 O, Schwarz HP. GH therapy in juvenile chronic arthritis: results of a two-  
 | 2723 year controlled study on growth and bone. Journal of Clinical Endocrinology  
 | 2724 & Metabolism 2001; 86:5737-5744
- | 2725 **267.** Grote FK, Van Suijlekom-Smit LWA, Mul D, Hop WCJ, Ten Cate R, Oostdijk  
 | 2726 W, Van Luijk W, Jansen-van Wijngaarden CJA, De Muinck Keizer-Schrama  
 | 2727 SMPF. Growth hormone treatment in children with rheumatic disease,  
 | 2728 corticosteroid induced growth retardation, and osteopenia. Archives of  
 | 2729 Disease in Childhood 2006; 91:56-60
- | 2730 **268.** Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P. Early  
 | 2731 recombinant human growth hormone treatment in glucocorticoid-treated  
 | 2732 children with juvenile idiopathic arthritis: a 3-year randomized study.  
 | 2733 Journal of Clinical Endocrinology & Metabolism 2007; 92:2567-2573
- | 2734 **269.** Mehls O, Wuhl E, Tonshoff B, Schaefer F, Nissel R, Haffner D. Growth  
 | 2735 hormone treatment in short children with chronic kidney disease. Acta  
 | 2736 Paediatrica 2008; 97:1159-1164

- | 2737   **270.** Mahan JD, Warady BA. Assessment and treatment of short stature in  
| 2738           pediatric patients with chronic kidney disease: a consensus statement.  
| 2739           Pediatric Nephrology 2006; 21:917-930
- | 2740   **271.** Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children  
| 2741           from birth to 20 years of age. First Zurich longitudinal study of growth and  
| 2742           development. Helv Paediatr Acta Suppl 1989; 52:1-125
- | 2743   **272.** Ranke MB, Lindberg A. Observed and predicted total pubertal growth during  
| 2744           treatment with growth hormone in adolescents with idiopathic growth  
| 2745           hormone deficiency, Turner syndrome, short stature, born small for  
| 2746           gestational age and idiopathic short stature: KIGS analysis and review.  
| 2747           Hormone research in pdiatrics 2011; 75:423-432
- | 2748   **273.** Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis.  
| 2749           Gastroenterology 1998; 115:182-205
- | 2750   **274.** Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel  
| 2751           disease. Nature 2007; 448:427-434
- | 2752   **275.** Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn's  
| 2753           disease in Stockholm, Sweden. Lancet 1999; 354:1179
- | 2754   **276.** Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, Winter  
| 2755           HS, Fain P, King C, Smith T, El-Serag HB. Children with early-onset  
| 2756           inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium  
| 2757           registry. Journal of Pediatrics 2005; 146:35-40
- | 2758   **277.** Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J.  
| 2759           Changing pattern of paediatric inflammatory bowel disease in northern  
| 2760           Stockholm 1990-2001. Gut 2003; 52:1432-1434
- | 2761   **278.** Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F,  
| 2762           Weisdorf-Schindele S, San Pablo W, Jr., Perrault J, Park R, Yaffe M, Brown  
| 2763           C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph CD,

- Binion DG, Wisconsin Pediatric Inflammatory Bowel Disease A. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. *Journal of Pediatrics* 2003; 143:525-531
279. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Jr., Fellermann K, Ganz T, Stange EF, Bevins CL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102:18129-18134
280. Hampton T. Scientists explore pathogenesis of IBD. *JAMA* 2004; 292:2708-2713
281. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE, Cortot A, Colombel JF, Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature* 1996; 379:821-823
282. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? *Lancet* 2006; 367:1271-1284
283. Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J. Novel susceptibility genes in inflammatory bowel disease. *World Journal of Gastroenterology* 2006; 12:1991-1999
284. Russell RK, Wilson DC, Satsangi J. Unravelling the complex genetics of inflammatory bowel disease. *Archives of Disease in Childhood* 2004; 89:598-603
285. Russell RK, Drummond HE, Nimmo ER, Anderson NH, Noble CL, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT, Bisset WM, Mahdi G, Satsangi J. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on



- | 2791 disease susceptibility and growth indices in early onset inflammatory bowel  
| 2792 disease. Gut 2006; 55:1114-1123
- | 2793 **286.** Levine A, Shamir R, Wine E, Weiss B, Karban A, Shaoul RR, Reif SS, Yakir B,  
| 2794 Friedlander M, Kaniel Y, Leshinsky-Silver E. TNF promoter polymorphisms  
| 2795 and modulation of growth retardation and disease severity in pediatric  
| 2796 Crohn's disease. American Journal of Gastroenterology 2005; 100:1598-1604
- | 2797 **287.** Lee JJ, Essers JB, Kugathasan S, Escher JC, Lettre G, Butler JL, Stephens  
| 2798 MC, Ramoni MF, Grand RJ, Hirschhorn J. Association of linear growth  
| 2799 impairment in pediatric Crohn's disease and a known height locus: a pilot  
| 2800 study. Ann Hum Genet 2010; 74:489-497
- | 2801 **288.** Regan BP, Bousvaros A. Pediatric ulcerative colitis: a practical guide to  
| 2802 management. Paediatr Drugs 2014; 16:189-198
- | 2803 **289.** Stenke E, Hussey S. Ulcerative colitis: management in adults, children and  
| 2804 young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed  
| 2805 2014; 99:194-197
- | 2806 **290.** Heuschkel R. Enteral nutrition should be used to induce remission in  
| 2807 childhood Crohn's disease. Digestive Diseases 2009; 27:297-305
- | 2808 **291.** Sylvester FA. Effects of exclusive enteral nutrition on bone mass, linear  
| 2809 growth and body composition in children with Crohn's disease. Nestle Nutr  
| 2810 Inst Workshop Ser 2014; 79:125-130
- | 2811 **292.** Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC,  
| 2812 Mearin ML, de Meij T, Hendriks D, George E, Hummel T, Norbruis O, van  
| 2813 Rheenen P. Methotrexate for maintaining remission in paediatric Crohn's  
| 2814 patients with prior failure or intolerance to thiopurines: a multicenter  
| 2815 cohort study. J Crohns Colitis 2015; 9:305-311
- | 2816 **293.** Yang LS, Alex G, Catto-Smith AG. The use of biologic agents in pediatric  
| 2817 inflammatory bowel disease. Curr Opin Pediatr 2012; 24:609-614

- 2818 294. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in Children and  
2819 Adolescents With Juvenile Idiopathic Arthritis and Inflammatory Bowel  
2820 Disease Treated With Tumor Necrosis Factor-alpha Inhibitors: Systematic  
2821 Review of the Literature. Clin Infect Dis 2013;
- 2822 295. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma  
2823 associated with infliximab use in young patients treated for inflammatory  
2824 bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48:386-388
- 2825 296. Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK.  
2826 Improvement in growth of children with Crohn disease following anti-TNF-  
2827 alpha therapy can be independent of pubertal progress and glucocorticoid  
2828 reduction. Journal of Pediatric Gastroenterology & Nutrition 2011; 52:31-37
- 2829 297. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, Bourke B,  
2830 Thomas A, Akobeng AK, Fagbemi A, Wilson DC, Russell RK. The effects of  
2831 anti-TNF-alpha treatment with adalimumab on growth in children with  
2832 Crohn's disease (CD). Journal of Crohn's & colitis 2012; 6:337-344
- 2833 298. Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, Griffiths AM.  
2834 Infliximab maintains durable response and facilitates catch-up growth in  
2835 luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014; 20:1177-1186
- 2836 299. Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth  
2837 retardation in paediatric inflammatory bowel disease. Paediatr Drugs 2014;  
2838 16:29-42
- 2839 300. Romano C, Famiani A, Gallizzi R, Comito D, Ferrau V, Rossi P. Indeterminate  
2840 colitis: a distinctive clinical pattern of inflammatory bowel disease in  
2841 children. Pediatrics 2008; 122:e1278-1281
- 2842 301. Ahmed SF, Russell S, Rashid R, Beattie TJ, Murphy AV, Ramage IJ, Maxwell  
2843 H. Bone mineral content, corrected for height or bone area, measured by

- | 2844 DXA is not reduced in children with chronic renal disease or in  
| 2845 hypoparathyroidism. *Pediatric Nephrology* 2005; 20:1466-1472
- | 2846 **302.** Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset  
| 2847 inflammatory bowel disease: a systematic review. *J Clin Gastroenterol*  
| 2848 2012; 46:581-589
- | 2849 **303.** Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children  
| 2850 and adolescents with inflammatory bowel disease. *Journal of Pediatric*  
| 2851 *Gastroenterology & Nutrition* 1994; 18:165-173
- | 2852 **304.** Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in  
| 2853 children with inflammatory bowel disease: a prospective study.  
| 2854 *Gastroenterology* 1993; 105:681-691
- | 2855 **305.** Newby EA, Croft NM, Green M, Hassan K, Heuschkel RB, Jenkins H, Casson  
| 2856 DH. Natural history of paediatric inflammatory bowel diseases over a 5-year  
| 2857 follow-up: a retrospective review of data from the register of paediatric  
| 2858 inflammatory bowel diseases. *Journal of Pediatric Gastroenterology &*  
| 2859 *Nutrition* 2008; 46:539-545
- | 2860 **306.** Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A,  
| 2861 Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M,  
| 2862 Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth  
| 2863 abnormalities persist in newly diagnosed children with crohn disease despite  
| 2864 current treatment paradigms. *Journal of Pediatric Gastroenterology &*  
| 2865 *Nutrition* 2009; 48:168-174
- | 2866 **307.** Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V,  
| 2867 Merlin B, Lerebours E, Savoye G, Salomez JL, Cortot A, Colombel JF, Turck  
| 2868 D. Nutritional status and growth in pediatric Crohn's disease: a population-  
| 2869 based study. *American Journal of Gastroenterology* 2010; 105:1893-1900

- | 2870   **308.**   Trauernicht AK, Steiner SJ. Serum antibodies and anthropometric data at  
| 2871           diagnosis in pediatric Crohn's disease. *Digestive Diseases & Sciences* 2012;  
| 2872           57:1020-1025
- | 2873   **309.**   Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and  
| 2874           adolescents before the diagnosis of Crohn's disease. *Gastroenterology* 1988;  
| 2875           95:1523-1527
- | 2876   **310.**   DeBoer MD, Denson LA. Delays in puberty, growth, and accrual of bone  
| 2877           mineral density in pediatric Crohn's disease: despite temporal changes in  
| 2878           disease severity, the need for monitoring remains. *Journal of Pediatrics*  
| 2879           2013; 163:17-22
- | 2880   **311.**   Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel  
| 2881           disease. *Baillieres Clinical Gastroenterology* 1994; 8:83-100
- | 2882   **312.**   Hood HC, Cohen LE, Lee JJ. Late adolescent linear growth pattern in  
| 2883           pediatric-onset inflammatory bowel disease. *Journal of Pediatric*  
| 2884           *Gastroenterology & Nutrition* 2011; 53:246-249
- | 2885   **313.**   Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric patients  
| 2886           with Crohn's disease. *Digestive Diseases & Sciences* 2012; 57:2975-2981
- | 2887   **314.**   Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease:  
| 2888           height and body mass index in adult life. *BMJ* 1994; 308:1259-1263
- | 2889   **315.**   Gupta N, Lustig RH, Kohn MA, McCracken M, Vittinghoff E. Sex differences in  
| 2890           statural growth impairment in Crohn's disease: role of IGF-1. *Inflammatory*  
| 2891           *Bowel Diseases* 2011; 17:2318-2325
- | 2892   **316.**   Castile RG, Telander RL, Cooney DR, Ilstrup DM, Perrault J, van Heerden J,  
| 2893           Stickler GB. Crohn's disease in children: assessment of the progression of  
| 2894           disease, growth, and prognosis. *Journal of Pediatric Surgery* 1980; 15:462-  
| 2895           469

- 2896 317. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in  
2897 pediatric inflammatory bowel disease. *Journal of Pediatric Gastroenterology*  
2898 & *Nutrition* 1993; 16:373-380
- 2899 318. Alemzadeh N, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CB, van  
2900 Hogezaand RA. Adult height in patients with early onset of Crohn's disease.  
2901 *Gut* 2002; 51:26-29
- 2902 319. Lee JJ, Escher JC, Shuman MJ, Forbes PW, Delemarre LC, Harr BW, Kruijer  
2903 M, Moret M, Allende-Richter S, Grand RJ. Final adult height of children with  
2904 inflammatory bowel disease is predicted by parental height and patient  
2905 minimum height Z-score. *Inflammatory Bowel Diseases* 2010; 16:1669-1677
- 2906 320. Herzog D, Buehr P, Koller R, Rueger V, Heyland K, Nydegger A, Spalinger J,  
2907 Schibli S, Braegger CP, Swiss IBDCSG. Gender differences in paediatric  
2908 patients of the swiss inflammatory bowel disease cohort study. *Pediatr*  
2909 *Gastroenterol Hepatol Nutr* 2014; 17:147-154
- 2910 321. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in  
2911 childhood Crohn's disease. *Journal of Pediatric Gastroenterology & Nutrition*  
2912 1993; 17:75-81
- 2913 322. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth  
2914 failure in childhood Crohn's disease. *Cochrane Database of Systematic*  
2915 *Reviews* 2005:CD003873
- 2916 323. Cameron FL, Gerasimidis K, Papangelou A, Missiou D, Garrick V, Cardigan T,  
2917 Buchanan E, Barclay AR, McGrogan P, Russell RK. Clinical progress in the  
2918 two years following a course of exclusive enteral nutrition in 109 paediatric  
2919 patients with Crohn's disease. *Alimentary Pharmacology & Therapeutics*  
2920 2013; 37:622-629

- 2921 324. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab  
 2922 dependency in a national cohort of children with Crohn's disease. Journal of  
 2923 Pediatric Gastroenterology & Nutrition 2006; 42:40-45
- 2924 325. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.  
 2925 Infliximab improves inflammation and anthropometric measures in pediatric  
 2926 Crohn's disease. J Gastroenterol Hepatol 2010; 25:810-816
- 2927 326. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of  
 2928 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's  
 2929 disease. Gastroenterology 2000; 119:895-902
- 2930 327. Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose  
 2931 prednisone on height velocity and disease activity in pediatric and  
 2932 adolescent patients with Crohn disease. Journal of Pediatric  
 2933 Gastroenterology & Nutrition 2007; 45:312-318
- 2934 328. Street ME, de'Angelis G, Camacho-Hubner C, Giovannelli G, Ziveri MA,  
 2935 Bacchini PL, Bernasconi S, Sansebastiano G, Savage MO. Relationships  
 2936 between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in  
 2937 inflammatory bowel disease. Hormone Research 2004; 61:159-164
- 2938 329. Pasternak BA, D'Mello S, Jurickova, II, Han X, Willson T, Flick L, Petiniot L,  
 2939 Uozumi N, Divanovic S, Traurnicht A, Bonkowski E, Kugathasan S, Karp CL,  
 2940 Denson LA. Lipopolysaccharide exposure is linked to activation of the acute  
 2941 phase response and growth failure in pediatric Crohn's disease and murine  
 2942 colitis. Inflammatory Bowel Diseases 2010; 16:856-869
- 2943 330. Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated  
 2944 serum growth hormone concentrations in inflammatory bowel disease.  
 2945 Journal of Clinical Endocrinology & Metabolism 1977; 44:622-628

- 2946 331. Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children  
2947 and adolescents with chronic inflammatory bowel disease. *Gastroenterology*  
2948 1986; 91:830-836
- 2949 332. Chong SK, Grossman A, Walker-Smith JA, Rees LH. Endocrine dysfunction in  
2950 children with Crohn's disease. *Journal of Pediatric Gastroenterology &*  
2951 *Nutrition* 1984; 3:529-534
- 2952 333. Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson  
2953 AM. Nocturnal growth hormone and gonadotrophin secretion in growth  
2954 retarded children with Crohn's disease. *Gut* 1981; 22:933-938
- 2955 334. Gronbek H, Thogersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF.  
2956 Low free and total insulinlike growth factor I (IGF-I) and IGF binding  
2957 protein-3 levels in chronic inflammatory bowel disease: partial  
2958 normalization during prednisolone treatment. *American Journal of*  
2959 *Gastroenterology* 2002; 97:673-678
- 2960 335. Bannerjee K, Camacho-Hubner C, Babinska K, Dryhurst KM, Edwards R,  
2961 Savage MO, Sanderson IR, Croft NM. Anti-inflammatory and growth-  
2962 stimulating effects precede nutritional restitution during enteral feeding in  
2963 Crohn disease. *Journal of Pediatric Gastroenterology & Nutrition* 2004;  
2964 38:270-275
- 2965 336. Beattie RM, Camacho-Hubner C, Wacharasindhu S, Cotterill AM, Walker-  
2966 Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic  
2967 intervention in children and adolescents with Crohn's disease. *Clinical*  
2968 *Endocrinology* 1998; 49:483-489
- 2969 337. Eivindson M, Gronbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A,  
2970 Dahlerup JF. The insulin-like growth factor (IGF) system and its relation to  
2971 infliximab treatment in adult patients with Crohn's disease. *Scand J*  
2972 *Gastroenterol* 2007; 42:464-470

- 2973 338. Wong SC, Smyth A, McNeill E, Galloway PJ, Hassan K, McGrogan P, Ahmed  
2974 SF. The growth hormone insulin-like growth factor 1 axis in children and  
2975 adolescents with inflammatory bowel disease and growth retardation.  
2976 Clinical Endocrinology 2010; 73:220-228
- 2977 339. Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Winter HS, Baldassano RN,  
2978 Gold BD, Abramson O, Smith T, Cohen SA, Heyman MB. Gender differences  
2979 in presentation and course of disease in pediatric patients with Crohn  
2980 disease. Pediatrics 2007; 120:e1418-1425
- 2981 340. Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, Tonshoff B. Differential  
2982 effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on  
2983 cultured growth plate chondrocytes. Kidney Int 2002; 62:1591-1600
- 2984 341. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T, Arnold GJ, Lahm  
2985 H, Kolb HJ, Wolf E. Overexpression of insulin-like growth factor-binding  
2986 protein-2 in transgenic mice reduces postnatal body weight gain.  
2987 Endocrinology 1999; 140:5488-5496
- 2988 342. McCaffery TD, Jr., Nasr K, Lawrence AM, Kirsner JB. Effect of administered  
2989 human growth hormone on growth retardation in inflammatory bowel  
2990 disease. American Journal of Digestive Diseases 1974; 19:411-416
- 2991 343. Henker J. Therapy with recombinant growth hormone in children with Crohn  
2992 disease and growth failure. European Journal of Pediatrics 1996; 155:1066-  
2993 1067
- 2994 344. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch S, Haymond  
2995 MW. Growth hormone has anabolic effects in glucocorticosteroid-dependent  
2996 children with inflammatory bowel disease: a pilot study. Metabolism:  
2997 Clinical & Experimental 2002; 51:127-135
- 2998 345. Wong SC, Hassan K, McGrogan P, Weaver LT, Ahmed SF. The effects of  
2999 recombinant human growth hormone on linear growth in children with



3000 Crohn's disease and short stature. *Journal of Pediatric Endocrinology* 2007;  
3001 20:1315-1324

3002 **346.** Heyman MB, Garnett EA, Wojcicki J, Gupta N, Davis C, Cohen SA, Gold BD,  
3003 Kirschner BS, Baldassano RN, Ferry GD, Winter HS, Kaplan S. Growth  
3004 hormone treatment for growth failure in pediatric patients with Crohn's  
3005 disease. *Journal of Pediatrics* 2008; 153:651-658, 658 e651-653

3006 **347.** Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley  
3007 MJ. A preliminary study of growth hormone therapy for Crohn's disease. *New*  
3008 *England Journal of Medicine* 2000; 342:1633-1637

3009 **348.** Slonim AE, Grovit M, Bulone L. Effect of exclusion diet with nutraceutical  
3010 therapy in juvenile Crohn's disease. *Journal of the American College of*  
3011 *Nutrition* 2009; 28:277-285

3012 **349.** Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of  
3013 recombinant growth hormone treatment on children with Crohn's disease  
3014 and short stature: a pilot study. *Inflammatory Bowel Diseases* 2005; 11:435-  
3015 441

3016 **350.** Denson LA, Kim M-O, Bezold R, Carey R, Osuntokun B, Nylund C, Willson T,  
3017 Bonkowski E, Li D, Ballard E, Collins M, Moyer MS, Klein DJ. A randomized  
3018 controlled trial of growth hormone in active pediatric Crohn disease.  
3019 *Journal of Pediatric Gastroenterology & Nutrition* 2010; 51:130-139

3020 **351.** Wong SC, Kumar P, Galloway PJ, Blair JC, Didi M, Dalzell AM, Hassan K,  
3021 McGrogan P, Ahmed SF. A preliminary trial of the effect of recombinant  
3022 human growth hormone on short-term linear growth and glucose  
3023 homeostasis in children with Crohn's disease. *Clinical Endocrinology* 2011;  
3024 74:599-607

3025 **352.** SC Wong AMD, P.M .Mcgrogan,M.DIDI,P.Laing and S.F.Ahmed. The  
3026 *Inflammatory Milieu and the Insulin Like Growth Factor Axis in Children*

3027 with Inflammatory Bowel Disease Following Recombinant Human Growth  
3028 Hormone Treatment J Biol Regul Homeost Agents 2015; 29

3029 **353.** Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O. The effect of  
3030 recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic  
3031 acid-induced colitis in rats: an experimental study. Inflammatory Bowel  
3032 Diseases 2004; 10:112-115

3033 **354.** Andiran N, Yordam N. TNF-alpha levels in children with growth hormone  
3034 deficiency and the effect of long-term growth hormone replacement  
3035 therapy. Growth Hormone & Igf Research 2007; 17:149-153

3036 **355.** Bozzola M, De Amici M, Zecca M, Schimpff RM, Rapaport R. Modulating  
3037 effect of human growth hormone on tumour necrosis factor-alpha and  
3038 interleukin-1beta. Eur J Endocrinol 1998; 138:640-643

3039 **356.** Bozzola M, De Benedetti F, De Amici M, Jouret B, Travaglino P, Pagani S,  
3040 Conte F, Tauber M. Stimulating effect of growth hormone on cytokine  
3041 release in children. Eur J Endocrinol 2003; 149:397-401

3042 **357.** Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M.  
3043 Serum cytokine levels in GH-deficient children during substitutive GH  
3044 therapy. Eur J Endocrinol 2005; 152:207-210

3045 **358.** Pagani S, Meazza C, Travaglino P, Moretta A, Bozzola M. Effect of growth  
3046 hormone therapy on the proinflammatory cytokine profile in growth  
3047 hormone-deficient children. Eur Cytokine Netw 2005; 16:65-69

3048 **359.** Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS,  
3049 Griffiths AM, Katz AJ, Grand RJ, Boyle JT, et al. Development and validation  
3050 of a pediatric Crohn's disease activity index. Journal of Pediatric  
3051 Gastroenterology & Nutrition 1991; 12:439-447

360. Levy E, Gurbindo C, Lacaille F, Paradis K, Thibault L, Seidman E. Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis. *Pediatr Res* 1993; 34:162-166
361. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. *Am J Respir Crit Care Med* 1998; 157:1764-1769
362. Coutinho CA, Marson FA, Marcelino AR, Bonadia LC, Carlin MP, Ribeiro AF, Ribeiro JD, Bertuzzo CS. TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis. *Int J Mol Epidemiol Genet* 2014; 5:87-99
363. Shmarina G, Pukhalsky A, Petrova N, Zakharova E, Avakian L, Kapranov N, Alioshkin V. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. *J Transl Med* 2013; 11:19
364. de Vries L, Griffiths A, Armstrong D, Robinson PJ. Cytokine gene polymorphisms and severity of CF lung disease. *J Cyst Fibros* 2014;
365. Street ME, Ziveri MA, Spaggiari C, Viani I, Volta C, Grzincich GL, Viridis R, Bernasconi S. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. *Eur J Endocrinol* 2006; 154:47-52
366. Street ME, Spaggiari C, Volta C, Ziveri MA, Viani I, Rossi M, Pisi G, Grzincich G, Bernasconi S. The IGF system and cytokine interactions and relationships with longitudinal growth in prepubertal patients with cystic fibrosis. *Clin Endocrinol (Oxf)* 2009; 70:593-598
367. Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, Strachan R, Day AS, Jaffe A, Ooi CY. Intestinal Inflammation and Impact on Growth in Children With Cystic Fibrosis. *J Pediatr Gastroenterol Nutr* 2014;

368. Walicka-Serzysko K, Sands D. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report. *Dev Period Med* 2015; 19:66-79
369. Fillaux J, Bremont F, Murris M, Cassaing S, Tetu L, Segonds C, Pipy B, Magnaval JF. Aspergillus sensitization or carriage in cystic fibrosis patients. *Pediatr Infect Dis J* 2014; 33:680-686
370. Mahdavinia M, Grammer LC. Management of allergic bronchopulmonary aspergillosis: a review and update. *Ther Adv Respir Dis* 2012; 6:173-187
371. Lebecque P, Leonard A, De Boeck K, De Baets F, Malfroot A, Casimir G, Desager K, Godding V, Leal T. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. *J Cyst Fibros* 2009; 8:26-30
372. Woestenenk JW, Hoekstra T, Hesseling C, van der Doef HPJ, van der Ent CK. Comparison of height for age and height for bone age with and without adjustment for target height in pediatric patients with CF. *Journal of Cystic Fibrosis* 2011; 10:272-277
373. Collins CE, MacDonald-Wicks L, Rowe S, O'Loughlin EV, Henry RL. Normal growth in cystic fibrosis associated with a specialised centre. *Arch Dis Child* 1999; 81:241-246
374. Mahadeva R, Webb K, Westerbeek RC, Carroll NR, Dodd ME, Bilton D, Lomas DA. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. *BMJ* 1998; 316:1771-1775
375. Lucidi V, Alghisi F, Raia V, Russo B, Valmarana L, Valmarana R, Coruzzo A, Beschi S, Dester S, Rinaldi D, Maglieri M, Guidotti ML, Ravaioli E, Pesola M, De Alessandri A, Padoan R, Grynzech L, Ratclif L, Repetto T, Ambroni M, Provenzano E, Tozzi AE, Colombo C. Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study. *J Pediatr Gastroenterol Nutr* 2009; 49:335-342

- 3104     **376.**    Woestenenk JW, Stellato RK, Terheggen-Lagro SW, van der Ent CK, Houwen  
3105                RHJ. The relationship between body growth and pulmonary function in  
3106                children with cystic fibrosis. *Acta Paediatrica* 2014; 103:162-167
- 3107     **377.**    Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship  
3108                among growth, nutritional status, and pulmonary function in children with  
3109                cystic fibrosis: Analysis of the Cystic Fibrosis Foundation National CF Patient  
3110                registry. *Journal of Pediatrics* 2000; 137:374-380
- 3111     **378.**    Haeusler G, Frisch H, Waldhor T, Gotz M. Perspectives of Longitudinal  
3112                Growth in Cystic-Fibrosis from Birth to Adult Age. *European Journal of*  
3113                *Pediatrics* 1994; 153:158-163
- 3114     **379.**    Bournez M, Bellis G, Huet F. Growth during puberty in cystic fibrosis: a  
3115                retrospective evaluation of a French cohort. *Arch Dis Child* 2012; 97:714-720
- 3116     **380.**    Levy LD, Durie PR, Pencharz PB, Corey ML. Effects of Long-Term Nutritional  
3117                Rehabilitation on Body-Composition and Clinical Status in Malnourished  
3118                Children and Adolescents with Cystic-Fibrosis. *Journal of Pediatrics* 1985;  
3119                107:225-230
- 3120     **381.**    Shepherd RW, Holt TL, Thomas BJ, Kay L, Isles A, Francis PJ, Ward LC.  
3121                Nutritional Rehabilitation in Cystic-Fibrosis - Controlled-Studies of Effects  
3122                on Nutritional Growth-Retardation, Body Protein-Turnover, and Course of  
3123                Pulmonary-Disease. *Journal of Pediatrics* 1986; 109:788-794
- 3124     **382.**    Dalzell AM, Shepherd RW, Dean B, Cleghorn GJ, Holt TL, Francis PJ.  
3125                Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. *J*  
3126                *Pediatr Gastroenterol Nutr* 1992; 15:141-145
- 3127     **383.**    Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term  
3128                gastrostomy feedings in children with cystic fibrosis. *Journal of the*  
3129                *American Dietetic Association* 1999; 99:191-194

- 3130 384. Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic  
3131 fibrosis: a center-based analysis. *Pediatr Pulmonol* 2015; 50:35-41
- 3132 385. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G,  
3133 Laessig RH, Splaingard ML. Early diagnosis of cystic fibrosis through neonatal  
3134 screening prevents severe malnutrition and improves long-term growth.  
3135 Wisconsin Cystic Fibrosis Neonatal Screening Study Group. *Pediatrics* 2001;  
3136 107:1-13
- 3137 386. Pederzini F, D'Orazio C, Tamiazzo G, Faraguna D, Giglio L, Mastella G.  
3138 Growth evaluation at one year of life in infants with cystic fibrosis  
3139 diagnosed by neonatal screening. *Pediatr Pulmonol Suppl* 1991; 7:64-68
- 3140 387. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, Shen  
3141 G, Walker S, Farrell PM. Growth status in children with cystic fibrosis based  
3142 on the National Cystic Fibrosis Patient Registry data: evaluation of various  
3143 criteria used to identify malnutrition. *J Pediatr* 1998; 132:478-485
- 3144 388. Haeusler G, Frisch H, Waldhor T, Gotz M. Perspectives of longitudinal  
3145 growth in cystic fibrosis from birth to adult age. *Eur J Pediatr* 1994;  
3146 153:158-163
- 3147 389. Ghosal S, Taylor CJ, Pickering M, McGaw J. Head growth in cystic fibrosis  
3148 following early diagnosis by neonatal screening. *Arch Dis Child* 1996; 75:191-  
3149 193
- 3150 390. Ghosal S, Taylor CJ, Pickering M, McGaw J, Beckles-Willson N, Wales JK.  
3151 Disproportionate head growth retardation in cystic fibrosis. *Arch Dis Child*  
3152 1995; 72:150-152
- 3153 391. Festini F, Taccetti G, Repetto T, Reali MF, Campana S, Mergni G, Marianelli  
3154 L, de Martino M. Gestational and neonatal characteristics of children with  
3155 cystic fibrosis: a cohort study. *J Pediatr* 2005; 147:316-320

- 3156   **392.** Keller BM, Aebischer CC, Kraemer R, Schoni MH. Growth in prepubertal  
3157           children with cystic fibrosis, homozygous for the Delta F508 mutation. J  
3158           Cyst Fibros 2003; 2:76-83
- 3159   **393.** Bizzarri C, Montemitro E, Pedicelli S, Ciccone S, Majo F, Cappa M, Lucidi V.  
3160           Glucose tolerance affects pubertal growth and final height of children with  
3161           cystic fibrosis. Pediatr Pulmonol 2015; 50:144-149
- 3162   **394.** Vieni G, Faraci S, Collura M, Lombardo M, Traverso G, Cristadoro S, Termini  
3163           L, Lucanto MC, Furnari ML, Trimarchi G, Triglia MR, Costa S, Pellegrino S,  
3164           Magazzu G. Stunting is an independent predictor of mortality in patients  
3165           with cystic fibrosis. Clinical Nutrition 2013; 32:382-385
- 3166   **395.** Umlawska W, Sands D, Zielinska A. Age of menarche in girls with cystic  
3167           fibrosis. Folia Histochemica Et Cytobiologica 2010; 48:185-190
- 3168   **396.** Johannesson M, Gottlieb C, Hjelte L. Delayed puberty in girls with cystic  
3169           fibrosis despite good clinical status. Pediatrics 1997; 99:29-34
- 3170   **397.** Landon C, Rosenfeld RG. Short stature and pubertal delay in cystic fibrosis.  
3171           Pediatrician 1987; 14:253-260
- 3172   **398.** Sinnema G, Vanderlaag H, Stoop JW. Psychological-Development as Related  
3173           to Puberty, Body Height and Severity of Illness in Adolescents with Cystic-  
3174           Fibrosis. Israel Journal of Medical Sciences 1991; 27:186-191
- 3175   **399.** Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM. Comparison of  
3176           growth status of patients with cystic fibrosis between the United States and  
3177           Canada. American Journal of Clinical Nutrition 1999; 69:531-538
- 3178   **400.** Aswani N, Taylor CJ, McGaw J, Pickering M, Rigby AS. Pubertal growth and  
3179           development in cystic fibrosis: a retrospective review. Acta Paediatr 2003;  
3180           92:1029-1032

- 3181 401. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and long-term lung  
3182 function in cystic fibrosis: a longitudinal study of patients diagnosed by  
3183 neonatal screening. *Pediatr Pulmonol* 2009; 44:209-215
- 3184 402. Dijk FN, McKay K, Barzi F, Gaskin KJ, Fitzgerald DA. Improved survival in  
3185 cystic fibrosis patients diagnosed by newborn screening compared to a  
3186 historical cohort from the same centre. *Arch Dis Child* 2011; 96:1118-1123
- 3187 403. Morison S, Dodge JA, Cole TJ, Lewis PA, Coles EC, Geddes D, Russell G,  
3188 Littlewood JM, Scott MT. Height and weight in cystic fibrosis: a cross  
3189 sectional study. UK Cystic Fibrosis Survey Management Committee. *Arch Dis*  
3190 *Child* 1997; 77:497-500
- 3191 404. Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A,  
3192 Meyerovitch J, Sher D, Assael BM. Growth retardation and reduced growth  
3193 hormone secretion in cystic fibrosis. Clinical observations from three CF  
3194 centers. *Journal of Cystic Fibrosis* 2013; 12:165-169
- 3195 405. Lebl J, Zahradnikova M, Bartosova J, Zemkova D, Pechova M, Vavrova V.  
3196 Insulin-like growth factor-I and insulin-like growth factor-binding protein-3  
3197 in cystic fibrosis: a positive effect of antibiotic therapy and  
3198 hyperalimentation. *Acta Paediatr* 2001; 90:868-872
- 3199 406. Ozen M, Cokugras H, Ozen N, Camcioglu Y, Akcakaya N. Relation between  
3200 serum Insulin-like growth factor-I and insulin-like growth factor-binding  
3201 protein-3 levels, clinical status and growth parameters in prepubertal cystic  
3202 fibrosis patients. *Pediatrics International* 2004; 46:429-435
- 3203 407. Laursen EM, Juul A, Lanng S, Hoiby N, Koch C, Muller J, Skakkebaek NE.  
3204 Diminished Concentrations of Insulin-Like Growth-Factor-I in Cystic-Fibrosis.  
3205 *Archives of Disease in Childhood* 1995; 72:494-497
- 3206 408. Switzer M, Rice J, Rice M, Hardin DS. Insulin-like Growth Factor-I Levels  
3207 Predict Weight, Height and Protein Catabolism in Children and Adolescents



3208 with Cystic Fibrosis. Journal of Pediatric Endocrinology & Metabolism 2009;  
3209 22:417-424

3210 409. Sermet-Gaudelus I, Souberbielle JC, Azhar I, Ruiz JC, Magnine P, Colomb V,  
3211 Le Bihan C, Folio D, Lenoir G. Insulin-like growth factor I correlates with  
3212 lean body mass in cystic fibrosis patients. Archives of Disease in Childhood  
3213 2003; 88:956-961

3214 410. Gifford AH, Nymon AB, Ashare A. Serum Insulin- Like Growth Factor-1 ( IGF-  
3215 1) During CF Pulmonary Exacerbation: Trends and Biomarker Correlations.  
3216 Pediatric Pulmonology 2014; 49:335-341

3217 411. Street ME, Spaggiari C, Volta C, Ziveri MA, Viani I, Rossi M, Pisi G, Grzincich  
3218 G, Bernasconi S. The IGF system and cytokine interactions and relationships  
3219 with longitudinal growth in prepubertal patients with cystic fibrosis. Clinical  
3220 Endocrinology 2009; 70:593-598

3221 412. Taylor AM, Thomson A, Bruce-Morgan C, Ahmed ML, Watts A, Harris D, Holly  
3222 JMP, Dunger DB. The relationship between insulin, IGF-I and weight gain in  
3223 cystic fibrosis. Clinical Endocrinology 1999; 51:659-665

3224 413. Smerieri A, Montanini L, Maiuri L, Bernasconi S, Street ME. FOXO1 Content Is  
3225 Reduced in Cystic Fibrosis and Increases with IGF-I Treatment. International  
3226 Journal of Molecular Sciences 2014; 15:18000-18022

3227 414. Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, Chen  
3228 WT, Talati R, Kluger J, White CM. Recombinant Human Growth Hormone in  
3229 the Treatment of Patients With Cystic Fibrosis. Pediatrics 2010; 126:E1211-  
3230 E1226

3231 415. Thaker V, Haagensen AL, Carter B, Fedorowicz Z, Houston BW. Recombinant  
3232 growth hormone therapy for cystic fibrosis in children and young adults.  
3233 Cochrane Database of Systematic Reviews 2013;

- | 3234 416. Hardin DS, Ferkol T, Ahn C, Dreimane D, Dyson M, Morse M, Prestidge C,  
| 3235 Rice J, Seilheimer DK. A retrospective study of growth hormone use in  
| 3236 adolescents with cystic fibrosis. *Clinical Endocrinology* 2005; 62:560-566
- | 3237 417. Hardin DS, Sy JP. Effects of growth hormone treatment in children with  
| 3238 cystic fibrosis: The National Cooperative Growth Study experience. *Journal*  
| 3239 *of Pediatrics* 1997; 131:S65-S69
- | 3240 418. Hardin DS, Stratton R, Kramer JC, de la Rocha SR, Govaerts K, Wilson DP.  
| 3241 Growth hormone improves weight velocity and height velocity in  
| 3242 prepubertal children with cystic fibrosis. *Hormone and Metabolic Research*  
| 3243 1998; 30:636-641
- | 3244 419. Alemzadeh R, Upchurch L, McCarthy V. Anabolic effects of growth hormone  
| 3245 treatment in young children with cystic fibrosis. *Journal of the American*  
| 3246 *College of Nutrition* 1998; 17:419-424
- | 3247 420. Huseman CA, Colombo JL, Brooks MA, Smay JR, Greger NG, Sammut PH,  
| 3248 Bier DM. Anabolic effect of biosynthetic growth hormone in cystic fibrosis  
| 3249 patients. *Pediatric Pulmonology* 1996; 22:90-95
- | 3250 421. Sackey AH, Taylor CJ, Barraclough M, Wales JKH, Pickering M. Growth-  
| 3251 Hormone as a Nutritional Adjunct in Cystic-Fibrosis - Results of a Pilot-  
| 3252 Study. *Journal of Human Nutrition and Dietetics* 1995; 8:185-191
- | 3253 422. Stalvey MS, Anbar RD, Konstan MW, Jacobs JR, Bakker B, Lippe B, Geller DE.  
| 3254 A Multi-Center Controlled Trial of Growth Hormone Treatment in Children  
| 3255 With Cystic Fibrosis. *Pediatric Pulmonology* 2012; 47:252-263
- | 3256 423. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth  
| 3257 hormone improves clinical status in prepubertal children with cystic fibrosis:  
| 3258 Results of a randomized controlled trial. *Journal of Pediatrics* 2001;  
| 3259 139:636-642

- 3260 424. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T,  
3261 Howenstine M, Prestidge C, Royce F, Rice J, Seilheimer DK, Steelman J,  
3262 Shepherds R. Growth hormone treatment improves growth and clinical  
3263 status in prepubertal children with cystic fibrosis: Results of a multicenter  
3264 randomized controlled trial. *Journal of Clinical Endocrinology & Metabolism*  
3265 2006; 91:4925-4929
- 3266 425. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter,  
3267 randomized, double-blind, placebo-controlled trial to evaluate the  
3268 metabolic and respiratory effects of growth hormone in children with cystic  
3269 fibrosis. *Pediatrics* 2007; 119:E1230-E1238
- 3270 426. Hutler M, Schnabel D, Staab D, Tacke A, Wahn U, Boning D, Beneke R.  
3271 Effect of growth hormone on exercise tolerance in children with cystic  
3272 fibrosis. *Medicine and Science in Sports and Exercise* 2002; 34:567-572
- 3273 427. Hardin DS, Rice J, Ahn C, Ferkol T, Howenstine M, Spears S, Prestidge C,  
3274 Seilheimer DK, Shepherd R. Growth hormone treatment enhances nutrition  
3275 and growth in children with cystic fibrosis receiving enteral nutrition.  
3276 *Journal of Pediatrics* 2005; 146:324-328
- 3277 428. Bessich JL, Nyman AB, Moulton LA, Dorman D, Ashare A. Low Levels of  
3278 Insulin-like Growth Factor-1 Contribute to Alveolar Macrophage Dysfunction  
3279 in Cystic Fibrosis. *Journal of Immunology* 2013; 191:378-385
- 3280 429. Lee HW, Cheng J, Kovbasnjuk O, Donowitz M, Guggino WB. Insulin-Like  
3281 Growth Factor 1 (IGF-1) Enhances the Protein Expression of CFTR. *Plos One*  
3282 2013; 8
- 3283 430. Schibler A, von der Heiden R, Birrer P, Mullis PE. Prospective randomised  
3284 treatment with recombinant human growth hormone in cystic fibrosis.  
3285 *Archives of Disease in Childhood* 2003; 88:1078-1081

- 3286 431. Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jorgensen JO,  
3287 Christiansen JS. Short-term growth hormone treatment in girls with Turner  
3288 syndrome decreases fat mass and insulin sensitivity: a randomized, double-  
3289 blind, placebo-controlled, crossover study. *Pediatrics* 2002; 110:889-896
- 3290 432. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL.  
3291 Carbohydrate metabolism during long-term growth hormone (GH) treatment  
3292 and after discontinuation of GH treatment in girls with Turner syndrome  
3293 participating in a randomized dose-response study. Dutch Advisory Group on  
3294 Growth Hormone. *Journal of Clinical Endocrinology & Metabolism* 2000;  
3295 85:769-775
- 3296 433. Colmenares A, Pinto G, Taupin P, Giuseppe A, Odent T, Trivin C, Laborde K,  
3297 Souberbielle JC, Polak M. Effects on growth and metabolism of growth  
3298 hormone treatment for 3 years in 36 children with Prader-Willi syndrome.  
3299 *Hormone research in pdiatrics* 2011; 75:123-130
- 3300 434. Crino A, Di Giorgio G, Manco M, Grugni G, Maggioni A. Effects of growth  
3301 hormone therapy on glucose metabolism and insulin sensitivity indices in  
3302 prepubertal children with Prader-Willi syndrome. *Hormone Research* 2007;  
3303 68:83-90
- 3304 435. Lebl J, Lebenthal Y, Kolouskova S, Steensberg A, Jons K, Kappelgaard AM,  
3305 Ibanez L, Phillip M. Metabolic impact of growth hormone treatment in short  
3306 children born small for gestational age. *Hormone research in pdiatrics* 2011;  
3307 76:254-261
- 3308 436. Allen DB. Safety of growth hormone treatment of children with idiopathic  
3309 short stature: the US experience. *Hormone research in pdiatrics* 2011; 76  
3310 Suppl 3:45-47
- 3311 437. Child CJ, Zimmermann AG, Scott RS, Cutler GB, Jr., Battelino T, Blum WF.  
3312 Prevalence and incidence of diabetes mellitus in GH-treated children and

- 3313 adolescents: analysis from the GeNeSIS observational research program.
- 3314 Journal of Clinical Endocrinology & Metabolism 2011; 96:E1025-1034
- 3315 **438.** Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP.
- 3316 Dose-dependent effects of recombinant human interleukin-6 on glucose
- 3317 regulation. Journal of Clinical Endocrinology & Metabolism 1997; 82:4167-
- 3318 4170
- 3319 **439.** Horber FF, Marsh HM, Haymond MW. Differential effects of prednisone and
- 3320 growth hormone on fuel metabolism and insulin antagonism in humans.
- 3321 Diabetes 1991; 40:141-149
- 3322 **440.** Bismuth E, Chevenne D, Czernichow P, Simon D. Moderate deterioration in
- 3323 glucose tolerance during high-dose growth hormone therapy in
- 3324 glucocorticoid-treated patients with juvenile idiopathic arthritis. Hormone
- 3325 research in pdiatrics 2010; 73:465-472
- 3326 **441.** Viner RM, White B, Barrett T, Candy DCA, Gibson P, Gregory JW, Matyka K,
- 3327 Ong K, Roche E, Rudolf MCJ, Shaikh G, Shield JP, Wales JK. Assessment of
- 3328 childhood obesity in secondary care: OSCA consensus statement. Archives of
- 3329 Disease in Childhood-Education and Practice Edition 2012; 97:98-105
- 3330 **442.** O'Riordan SM, Hindmarsh P, Hill NR, Matthews DR, George S, Grealley P,
- 3331 Canny G, Slattery D, Murphy N, Roche E, Costigan C, Hoey H. Validation of
- 3332 continuous glucose monitoring in children and adolescents with cystic
- 3333 fibrosis: a prospective cohort study. Diabetes Care 2009; 32:1020-1022
- 3334 **443.** Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term
- 3335 safety of recombinant human growth hormone in children. Journal of
- 3336 Clinical Endocrinology & Metabolism 2010; 95:167-177
- 3337 **444.** Smida M, Nouri H, Kandara H, Jalel C, Ben Ghachem M. Bone diseases in
- 3338 children receiving growth hormone. Acta Orthop Belg 2003; 69:458-462

- 3339 445. Bowlby DA, Rapaport R. Safety and efficacy of growth hormone therapy in  
3340 childhood. *Pediatr Endocrinol Rev* 2004; 2 Suppl 1:68-77
- 3341 446. Fidler MW, Brook CG. Slipped upper femoral epiphysis following treatment  
3342 with human growth hormone. *J Bone Joint Surg Am* 1974; 56:1719-1722
- 3343 447. Mostoufi-Moab S, Isaacoff EJ, Spiegel D, Gruccio D, Ginsberg JP, Hobbie W,  
3344 Shults J, Leonard MB. Childhood cancer survivors exposed to total body  
3345 irradiation are at significant risk for slipped capital femoral epiphysis during  
3346 recombinant growth hormone therapy. *Pediatr Blood Cancer* 2013;
- 3347 448. Hussain WM, Hussain HM, Hussain MS, Ho SS. Human growth hormone and  
3348 the development of osteochondritis dissecans lesions. *Knee Surg Sports*  
3349 *Traumatol Arthrosc* 2011; 19:2108-2110
- 3350 449. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S,  
3351 Gay R. Collagen content and types in the intestinal strictures of Crohn's  
3352 disease. *Gastroenterology* 1988; 94:257-265
- 3353 450. Matthes H, Herbst H, Schuppan D, Stallmach A, Milani S, Stein H, Riecken  
3354 EO. Cellular localization of procollagen gene transcripts in inflammatory  
3355 bowel diseases. *Gastroenterology* 1992; 102:431-442
- 3356 451. Fruchtman S, Simmons JG, Michaylira CZ, Miller ME, Greenhalgh CJ, Ney  
3357 DM, Lund PK. Suppressor of cytokine signaling-2 modulates the fibrogenic  
3358 actions of GH and IGF-I in intestinal mesenchymal cells. *American Journal of*  
3359 *Physiology - Gastrointestinal & Liver Physiology* 2005; 289:G342-350
- 3360 452. Theiss AL, Fuller CR, Simmons JG, Liu B, Sartor RB, Lund PK. Growth  
3361 hormone reduces the severity of fibrosis associated with chronic intestinal  
3362 inflammation. *Gastroenterology* 2005; 129:204-219
- 3363 453. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y,  
3364 Robison LL, Sklar CA. Growth hormone treatment and risk of second

- 3365 neoplasms in the childhood cancer survivor. *Journal of Clinical*  
3366 *Endocrinology & Metabolism* 2006; 91:3494-3498
- 3367 454. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y,  
3368 Robison LL. Risk of disease recurrence and second neoplasms in survivors of  
3369 childhood cancer treated with growth hormone: a report from the Childhood  
3370 Cancer Survivor Study. *Journal of Clinical Endocrinology & Metabolism* 2002;  
3371 87:3136-3141
- 3372 455. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G.  
3373 Long-term safety of growth hormone replacement after CNS irradiation.  
3374 *Journal of Clinical Endocrinology & Metabolism* 2011; 96:2756-2761
- 3375 456. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell  
3376 E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with  
3377 juvenile idiopathic arthritis and its treatment. *Arthritis & Rheumatism* 2012;  
3378 64:1263-1271
- 3379 457. Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on  
3380 malignancies in the German juvenile idiopathic arthritis registry.  
3381 *Rheumatology* 2011; 50:230-236
- 3382 458. Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of  
3383 malignancy in children with juvenile idiopathic arthritis not treated with  
3384 biologic agents. *Arthritis care & research* 2012; 64:1357-1364
- 3385 459. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and  
3386 mortality of colorectal adenocarcinoma in persons with inflammatory bowel  
3387 disease from 1998 to 2010. *Gastroenterology* 2012; 143:382-389
- 3388 460. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD.  
3389 Risk of melanoma and nonmelanoma skin cancer among patients with  
3390 inflammatory bowel disease. *Gastroenterology* 2012; 143:390-399 e391


- 3391 461. Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly.  
3392 Pituitary 2013;
- 3393 462. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most  
3394 common cancer associated with acromegaly. Pituitary 2010; 13:242-248
- 3395 463. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of  
3396 colorectal neoplasm in patients with acromegaly: a meta-analysis. World  
3397 Journal of Gastroenterology 2008; 14:3484-3489
- 3398 464. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer  
3399 protection against post-natal development of malignancies. Eur J Endocrinol  
3400 2011; 164:485-489
- 3401 465. Melmed GY, Devlin SM, Vlotides G, Dhall D, Ross S, Yu R, Melmed S. Anti-  
3402 aging therapy with human growth hormone associated with metastatic colon  
3403 cancer in a patient with Crohn's colitis. Clinical Gastroenterology &  
3404 Hepatology 2008; 6:360-363
- 3405 466. Miller ME, Michaylira CZ, Simmons JG, Ney DM, Dahly EM, Heath JK, Lund  
3406 PK. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor  
3407 of intestinal epithelial cell proliferation. Gastroenterology 2004; 127:570-  
3408 581
- 3409 467. Michaylira C, Simmons J, Ramocki N, Scull B, McNaughton K, Fuller C, Lund  
3410 P. Suppressor of cytokine signaling-2 limits intestinal growth and  
3411 enterotrophic actions of IGF-I in vivo. American Journal of Physiology -  
3412 Gastrointestinal and Liver Physiology 2006; 291:G472-G481
- 3413 468. Dobie R, MacRae V, Huesa C, van't Hof R, Ahmed S, Farquharson C. Direct  
3414 stimulation of bone mass by increased GH signalling in the osteoblasts of  
3415 Socs2-/- mice. Journal of Endocrinology 2014; 223:93-106
- 3416 469. Savage MO, Blair JC, Jorge AJ, Street ME, Ranke MB, Camacho-Hubner C.  
3417 IGFs and IGFBPs in GH insensitivity. Endocrine Development 2005; 9:100-106



- 3418 470. Besson A, Salemi S, Eble A, Joncourt F, Gallati S, Jorge AA, Mullis PE.  
3419 Primary GH insensitivity '(Laron syndrome) caused by a novel 4 kb deletion  
3420 encompassing exon 5 of the GH receptor gene: effect of intermittent long-  
3421 term treatment with recombinant human IGF-I. Eur J Endocrinol 2004;  
3422 150:635-642
- 3423 471. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-  
3424 term treatment with recombinant insulin-like growth factor (IGF)-I in  
3425 children with severe IGF-I deficiency due to growth hormone insensitivity.  
3426 Journal of Clinical Endocrinology & Metabolism 2007; 92:902-910
- 3427 472. Backeljauw P, Bang P, Clayton PE, Geffner M, Woods KA. Diagnosis and  
3428 management of primary insulin-like growth factor-I deficiency: current  
3429 perspectives and clinical update. Pediatr Endocrinol Rev 2010; 7 Suppl  
3430 1:154-171
- 3431 473. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM. Recombinant  
3432 insulin-like growth factor (IGF)-I treatment in short children with low IGF-I  
3433 levels: first-year results from a randomized clinical trial. Journal of Clinical  
3434 Endocrinology & Metabolism 2010; 95:611-619
- 3435 474. Ranke MB. Treatment of children and adolescents with idiopathic short  
3436 stature. Nature Reviews Endocrinology 2013; 9:325-334
- 3437 475. Vicari AP, Mocci S, Openshaw P, O'Garra A, Zlotnik A. Mouse gamma delta  
3438 TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major  
3439 histocompatibility complex class I independent, and are developmentally  
3440 related to alpha beta TCR+NK1.1+ thymocytes. Eur J Immunol 1996;  
3441 26:1424-1429
- 3442 476. Jensen RB, Thankamony A, O'Connell SM, Kirk J, Donaldson M, Ivarsson SA,  
3443 Soder O, Roche E, Hoey H, Dunger DB, Juul A. A randomised controlled trial  
3444 evaluating IGF1 titration in contrast to current GH dosing strategies in

| 3445 children born small for gestational age: the North European Small-for-  
 | 3446 Gestational-Age Study. European Journal of Endocrinology 2014; 171:509-  
 | 3447 518  
 | 3448 **477.** Edmondson SR, Baker NL, Oh J, Kovacs G, Werther GA, Mehls O. Growth  
 | 3449 hormone receptor abundance in tibial growth plates of uremic rats: GH/IGF-  
 | 3450 I treatment. Kidney International 2000; 58:62-70  
 | 3451 **478.** Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the  
 | 3452 anabolic effects of growth hormone and insulin-like growth factor I by use  
 | 3453 of both agents simultaneously. Journal of Clinical Investigation 1993;  
 | 3454 91:391-396  
 | 3455 **479.** Landon C, Rosenfeld RG. Short stature and pubertal delay in male  
 | 3456 adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child 1984;  
 | 3457 138:388-391  
 | 3458 **480.** Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy  
 | 3459 for delayed growth and puberty in boys with inflammatory bowel disease.  
 | 3460 Hormone research in pdiatrics 2011; 75:8-13  
 | 3461







**Figure 1: Age Of Presentation Of Chronic Disease In Childhood**

CF: cystic fibrosis, DMD: duchenne muscular dystrophy; JIA: juvenile idiopathic arthritis; CRI: chronic renal insufficiency; IBD: inflammatory bowel disease; SLE: systemic lupus erythematosus; CTD: connective tissue diseases


**Figure 2: Mechanism Of Growth Failure In Chronic Inflammatory Disease**




**Fig 3: Multiple Level Of Defect Of the GH/IGF-1 Axis In Children With Chronic Disease**




GH: growth hormone; IGF-1: insulin like growth factor-1; IGFBP: insulin growth factor binding protein



**Figure 4: Effects Of TNF $\alpha$  And IL1 $\beta$  On ATDC5 Cell Line Chondrogenesis**








**Figure 6a: Effects of addition of antibodies to metatarsals exposed to TNF $\alpha$  and IL1 $\beta$**


Martensson K et al J Bone MinerRes 2004; 19:1805-12<sup>73</sup>




**Figure 6b: Effects of addition of antibodies to metatarsals exposed to synovial fluid of a child with systemic JIA during acute relapse**

MacRae VE et al Clin Endocrinol 2007; 67:442-8<sup>86</sup>

PBS: phosphate buffered solution; SF-A: synovial fluid from child A; Ab: antibody




**Figure 7: Synchronized mean growth curves from baseline to adult height in 13 children with JIA treated with rhGH (solid lines) in comparison with 18 controls (dashed lines)**



**Figure 8: Height SDS In Children And Adolescent With IBD And Body Image Domain Score On IMPACT III Questionnaire**

(Mason A et al Horm Res Pediatr 2014; 83:45-54)



**Figure 9: Peak Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF1) To Insulin Tolerance Test (ITT) In Children With Inflammatory Bowel Disease (IBD).**


IGF1: insulin-like growth factor 1, GH: growth hormone, SDS: standard deviation score.

Grp A: Peak GH < 3 mcg/l, IGF1 SDS < 0 (Functional GH deficiency).

Grp B: Peak GH < 6 mcg/l but ≥ 3 mcg/l, IGF1 SDS < 0 (Functional GH insufficiency).

Grp C: Peak GH ≥ 6 mcg/l, IGF1 SDS < 0 (Functional GH resistance).

Grp D: IGF1 SDS ≥ 0 (Functional GH-IGF1 resistance).



**Figure 10: Height velocity (HV) and height SDS before and after 6 months of therapy with recombinant human growth hormone (rhGH) or no therapy (Ctrl) in inflammatory bowel disease.**

HV:  $P = 0.003$  (rhGH – baseline vs 6 months),  $P = 0.58$  (Ctrl – baseline vs 6 months) Ht SDS:  $P = 0.003$  (rhGH – baseline vs 6 months),  $P = 0.14$  (Ctrl – baseline vs 6 months).

	No patients	Age at assessment	Adult height result	Deviation from mid-parental height
Gare et al (1995) <sup>232</sup>	124 (33 oligo, 58 poly, 2 systemic, 30 others)	18 yrs	Females 165.9 cm, males 176.9 cm	ND
Zak et al (1999) <sup>233</sup>	65 (21 oligo, 39 poly, 5 systemic)	26 yr	Ht SDS -0.3 (11% Ht SDS < -2.0)	ND
Minden et al (2002) <sup>195</sup>	215 (85 oligo, 30 poly, 30 systemic, 30 others)	23 yrs	Females 166 cm, males 179 cm	ND
Packham et al (2002) <sup>236</sup>	259 (70 oligo, 78 poly, 52 systemic, 61 others)	28 yrs	Ht SDS females -1.1 Ht SDS males -0.7	ND
Wang et al (2002) <sup>234</sup>	33 (7 oligo, 18 poly, 8 systemic)	20 yrs	Infrequent GC 165.6 cm Intermittent GC 165.8 cm Prolonged GC 147.6 cm	Infrequent GC +3.0 cm above MPH Intermittent GC +1.0 cm above MPH Prolonged GC -12.0 cm from MPH
Simon D et al (2002) <sup>204</sup>	24 systemic	25 yrs	Ht SDS -2.0 41% Ht SDS < -2.0	-1.7 SD below MPH SDS (87% below MPH SDS)
Minden et al (2009) <sup>235</sup>	141 JIA	18 ys	Females 165 cm, males 176 cm Female poly Ht SDS -0.5 Males poly Ht SDS -0.6 Females systemic Ht SDS -0.5 Males systemic Ht SDS -2.1	ND

**Table 1: Published Studies Of Adult Height In Childhood Onset Juvenile Idiopathic Arthritis**

JIA: juvenile idiopathic arthritis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; GC: glucocorticoid; MPH: mid-parental height

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline (cm/yr)	HV follow-up (cm/yr)	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
Butenandt et al (1979) <sup>256</sup>	Retrospective	20	Variable	0.18	13.0	2.7	6.2 (1 <sup>st</sup> yr)	130%	-	-	-
Svantesson et al (1991) <sup>259</sup>	Retrospective	6	Variable	0.16-0.46	13.7	2.8	6.7 (1 <sup>st</sup> yr)	139%	-3.4	-	-
Davies et al (1994) <sup>257</sup> (1997) <sup>244</sup>	Prospective	10 low dose	1.0	0.15	9.2	2.4	4.5	88%	-3.0	-	-
		10 high dose		0.30	10.6	2.0	6.1	205%	-3.4		
Touati et al (1998) <sup>260</sup>	Prospective	14	1.0	0.46	10.8	1.9	5.4	184%	-4.3	-4.3	0
Al-Mutair et al (2000) <sup>254</sup>	Retrospective	10	Variable	0.16-0.30	11.9	2.5	4.8 (1 <sup>st</sup> yr) 5.4 (2 <sup>nd</sup> yr)	92% 116%	-	-	-
Simon et al (2003) <sup>258</sup>	Prospective	14	3.0	0.46	12.5	2.0	6.0 (1 <sup>st</sup> yr)	200%	-4.6	-4.5 (1 <sup>st</sup> yr)	+0.1
							5.0 (2 <sup>nd</sup> yr)	150%		-4.3 (2 <sup>nd</sup> yr)	+0.3
							4.1 (3 <sup>rd</sup> yr)	105%		-4.3 (3 <sup>rd</sup> yr)	+0.3
Bechtold et al (2004) <sup>255</sup>	Prospective	11	4.0	0.25-0.33	10.3	-	-	-	-3.9	-2.1	+1.8

**Table 2: Published Non Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With Juvenile Idiopathic Arthritis**

yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline	HV follow-up	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
Bechtold et al (2001) <sup>266</sup>	RCT	14 rhGH 5 rhGH (GHD) 16 Ctrl	2.0	0.33 0.16	9.7 10.5 7.8	-2.9 SD -3.1 SD -3.2 D	+0.3 SD -0.5 SD -1.2 SD	-	-3.7 -2.6 -2.9	-2.9 -2.4 -3.2	+0.8 +0.2 -0.3
Bechtold et al (2003) <sup>265</sup>	RCT	18 rhGH (9GHD) 20 Ctrl	4.0	0.33 (0.20 for GHD)	10.5 9.6	2.4 cm/yr 2.3 cm/yr	4.7 cm/yr 3.4 cm/yr	96% 48%	-3.3 -2.3	-2.3 -3.0	+1.0 -0.7
Saha et al (2004) <sup>250</sup>	RCT (Cross-over trial rhGH vs placebo)	24	0.5	0.23	9.0	-	+2.0 SD (rhGH) -0.1 SD (placebo)	-	-2.1 -2.2	-1.9 -2.0	+0.2 +0.2
Grote et al (2006) <sup>267</sup>	RCT	10 rhGH 7 Ctrl	2.0	0.32	8.0 8.1	-	-	-	-1.4 -1.9	-1.0 -2.1	+0.4 -0.2
Simon et al (2007) <sup>268</sup>	RCT	15 rhGH 15 Ctrl	3.0	0.47	5.6 5.7	2.7 cm/yr 2.6 cm/yr	6.5 cm/yr 5.0 cm/yr	141% 85%	-1.1 -1.0	-0.4 -1.8	+0.7 -0.8
Bechtold et al (2007) <sup>39</sup>	RCT	13 rhGH 18 Ctrl	13.7 14.4	0.33	4.8 4.0	-2.2 SD -2.6 SD	-	-	-2.7 -3.5	-1.6 -3.4	+1.1 +0.1

**Table 3: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Juvenile Idiopathic Arthritis**

RCT: randomized controlled trials; yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score



	No patients	Age at assessment	Adult height result	Deviation from mid-parental height
Castile et al (1980) <sup>316</sup>	177 CD	23 yrs	Medically managed Ht SDS -0.6 Surgically managed Ht SDS -0.3	ND
Griffiths et al (1993) <sup>3</sup>	67 CD	17 yrs and HV < 1 cm/yr	Females Ht SDS -0.5 Males Ht SDS -1.0	ND
Markowitz et al (1993) <sup>317</sup>	48 IBD (38 CD, 10 UC)	21 yrs	CD: 56% < 25 <sup>th</sup> centile UC: 25% < 5 <sup>th</sup> centile	ND
Hildebrand et al (1994) <sup>303</sup>	124 IBD (46 CD, 60 UC18 IBDU)	>16 yrs or HV < 0.5 cm/yr	CD Ht SDS +0.4 UC Ht SDS +0.2 IBDU Ht SDS -0.1	ND
Ferguson et al (1994) <sup>314</sup>	70 IBD (50 CD, 20 UC)	ND	CD males 175 cm, CD females 157 cm UC males 175 cm, UC females 159 cm	ND
Alemazadeh et al (2002) <sup>318</sup>	135 CD	≥ 18 yrs	Prepubertal onset Ht SDS -1.0 Pubertal onset -0.1 Adult onset +0.1	Prepubertal onset 2.1 cm below MPH Pubertal onset 0.6 cm above MPH Adult onset 0.9 cm above MPH
Sawczenko et al (2003) <sup>8</sup>	43 CD	> 16 yrs	Ht SDS -0.7	5.9 cm below MPH
Sawczenko et al (2006) <sup>9</sup>	123 CD	HV < 1 cm/yr	Ht SDS -0.3	3 cm below MPH but 20% were ≥ 8 cm below MPH
Lee et al (2010) <sup>319</sup>	141 IBD	≥ 18 yrs	“Growth impaired” Ht SDS -1.3 “Not growth impaired” Ht SDS -0.1	“Growth impaired” -0.7 SD lower than MPH SDS “Not growth impaired” -0.1 SD lower than MPH SDS

**Table 4: Published Studies Of Adult Height In Childhood Onset Inflammatory Bowel Disease**

IBD: inflammatory bowel disease; CD: crohn’s disease; UC: ulcerative colitis; IBDU: inflammatory bowel disease unclassified; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; MPH: mid-parental height

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline	HV follow-up	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
McCaffery et al (1974) <sup>342</sup>	Retrospective	2	0.5	10 mg for 5 days then 3 mg three times per week	-	6.5 cm/yr	9.2 cm/yr	42%	-	-	-
Henker et al (1996) <sup>343</sup>	Retrospective	3	2.0	0.9-1.0 mg daily	16.2	5.0 cm/yr	10.4 cm/yr	108%	-3.4	-1.6	+1.8
Mauras et al (2002) <sup>344</sup>	Prospective	10	0.5-1.0	0.35	11.9	4.0 cm/yr	7.4 cm/yr (1 <sup>st</sup> yr)	85%	-	-	-
Wong et al (2007) <sup>345</sup>	Retrospective	7	Variable	0.15-0.31	15.9	2.5 cm/yr	3.7 cm/yr (0.5 yrs)	48%	-2.2	-1.9	+0.3
Heyman et al (2008) <sup>346</sup>	Prospective	8 rhGH 24 historical Ctrl	1.0	0.30	12.6	3.0 cm/yr	8.3 cm/yr	177%	-2.0	-1.2	+0.8
					12.5	4.0 cm/yr	4.9 cm/yr	23%	-1.8	-1.6	+0.2
Slonim et al (2009) <sup>348</sup>	Retrospective	4	4.5-7.5	0.18-0.20	13.8	-	-	-	-3.5	-1.9	+1.6

**Table 5: Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With Inflammatory Bowel Disease**

yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline	HV follow-up	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
Calenda et al (2005) <sup>349</sup>	RCT (Placebo cross-over)	3 rhGH 4 Ctrl (placebo)	1.0	0.35	11.0	-	-	-	-	-	+0.1 SD +0.2 SD
Denson et al (2010) <sup>350</sup>	RCT	10 rhGH 10 Ctrl	0.25	0.53	12.0 13.0	-	+2.0 SD -2.1 SD	-	-	-	-
Wong et al (2011) <sup>351</sup>	RCT	11 rhGH 11 Ctrl	0.5	0.45	14.7 13.7	4.5 cm/yr 3.8 cm/yr	10.8 cm/yr 3.5 cm/yr	140% -7.9%	-2.8 -1.8	-2.5 -1.9	+0.3 -0.1

**Table 6: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Inflammatory Bowel Disease**

RCT: randomized controlled trial; yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score; SD: standard deviation

	No patients	Age at assessment	Adult height result	Deviation from mid-parental height
Hauesler et al (1994) <sup>388</sup>	139	19 yrs	Males 173 cm (25 <sup>th</sup> centile) Females 161.5 cm (25 <sup>th</sup> centile)	ND
Morrison et al (1997) <sup>403</sup>	1604 males 1452 females	20 yrs	Males Ht SDS -0.7 Females Ht SDS -0.9	ND
Lai et al (1999) <sup>399</sup>	30	Males 19 yrs Females 17 yrs	Males Ht SDS -1.2 Females Ht SDS -0.1	48% below MPH
Aswani et al (2003) <sup>400</sup>	US: 27349 males, 23797 females Canada: 4315 males, 3816 females	≥ 25 yrs	25 <sup>th</sup> centile	ND
Assael et al (2009) <sup>401</sup>	112 “mild disease” 112 “severe disease”	> 20 ys	“Mild disease “ males 172.4 cm “Mild disease” female 161.3 cm “Severe disease” males 171.1 cm “Severe disease” females 160.1 cm	ND
Boumez et al (2012) <sup>379</sup>	398 males 331 females	19 yrs	Males Ht SDS -0.7 Females Ht SDS -0.5	ND
Djik et al (2011) <sup>402</sup>	38 clinical diagnosis 41 neonatal screening	18 yrs	Clinical diagnosis -1.2 Neonatal screening -0.2	ND
Zhang et al (2013) <sup>4</sup>	1862 (269 with parental height)	21 yrs	160 cm (28 <sup>th</sup> centile)	MPH 53d centile

**Table 7: Published Studies Of Adult Height In Childhood Onset Cystic Fibrosis**

CF: cystic fibrosis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; MPH: mid-parental height

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline	HV follow-up	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
Huseman et al (1996) <sup>420</sup>	Prospective	9	1.0	0.30	7.0	5.7 cm/yr	7.8cm/yr	37%	-1.3	-0.8	+0.5
Hardin et al (1997) <sup>417</sup>	Retrospective	24	1.0-2.0	0.29	10.3	3.7 cm/yr	7.8 cm/yr (1 <sup>st</sup> yr) 6.5 cm/yr (2 <sup>nd</sup> yr)	111% 76%	-3.2	-	-
Alemzadeh et al (1998) <sup>419</sup>	Prospective	15	2.0	0.35	3.2	-	-	-	-2.8	-0.9	+1.9
Hardin et al (1998) <sup>419</sup>	Prospective	9	1.0	0.35	5.4-12.2	5.6 cm/yr	8.0 cm/yr	43%	-1.9	-1.3	+0.6
Sackey et al (1998) <sup>421</sup>	Prospective	7	1.0	0.16	7.9	0.3 cm/yr	4.1 cm/yr (0.5 yrs)	1141%	-	-	-
Hardin et al (2005) <sup>416</sup>	Retrospective	13 rhGH 12 historical Ctrl	1.0	0.30	13.8 14.3	5.1 cm/yr 5.0 cm/yr	8.0 cm/yr 5.0 cm/yr	57% 0%	-1.9 -1.9	-	-

**Table 8: Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With Cystic Fibrosis**

yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score

	Study design	No patients	Duration (yrs)	rhGH dose (mg/kg/wk)	Age baseline (yrs)	HV baseline	HV follow-up	% change HV	Ht SDS baseline	Ht SDS follow-up	Change Ht SDS
Hardin D et al (2001) <sup>423</sup>	RCT	10 rhGH 9 Ctrl	1.0	0.30	10.2 11.4	3.9 cm/yr 4.0 cm/yr	8.0 cm/yr 4.0cm/yr	105% 0%	-0.5 -0.6	-0.3 -0.9	+0.2 -0.3
Hutler et al (2002) <sup>426</sup>	RCT	6 rhGH 4 Ctrl	0.5	0.27-0.35	12.1	-	9. cm/yr 5.4 cm/yr	-	139 cm 139cm	141.1 cm 143.3 cm	-
Hardin et al (2005) <sup>427</sup>	RCT	9 rhGH 9 Ctrl	1.0	0.30	11.6 11.1	-	8.0 cm/yr 3.8 cm/yr	-	-1.7 -1.7	-1.1 -1.7	+0.6 0.0
Hardin et al (2006) <sup>424</sup>	RCT	32 rhGH 29 Ctrl	1.0	0.30	10.3 9.7	-	8.0 cm/yr 5.0 cm/yr	-	-1.8 -1.9	-	-
Schnabel et al (2007) <sup>425</sup>	RCT	20 high dose 22 low dose 21 Ctrl (placebo)	0.5	0.49 0.27	14.3 13.8 14.6	-	6.8 cm/yr 5.6 cm/yr 3.8 cm/yr	-	-2.1 -1.8 -2.5	-	-
Stalvey et al (2012) <sup>422</sup>	RCT	36 rhGH 32 Ctrl	1.0	0.30	9.4 9.4	-	8.2 cm/yr 5.3 cm/yr	-	-1.8 -1.9	-1.4 -1.9	+0.4 0.0

**Table 9: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Cystic Fibrosis**

yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation score